var title_f22_61_23504="Laryngeal cleft type 4";
var content_f22_61_23504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of type 4 laryngeal cleft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type 4 laryngeal clefts involve a major portion of the intrathoracic tracheoesophageal wall. In the image above, the endotracheal tube is displaced into the laryngeal cleft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23504=[""].join("\n");
var outline_f22_61_23504=null;
var title_f22_61_23505="Hypertrophic scar";
var content_f22_61_23505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Injection of kenalog in a hypertrophic scar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The appearance of the hypertrophic scar is similar to that of keloids, but does not extend beyond the margin of the scar. The scar is being injected with kenalog.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23505=[""].join("\n");
var outline_f22_61_23505=null;
var title_f22_61_23506="Dyclonine: Pediatric drug information";
var content_f22_61_23506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dyclonine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/46/26338?source=see_link\">",
"    see \"Dyclonine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/45/32467?source=see_link\">",
"    see \"Dyclonine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sucrets&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Sucrets&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Sucrets&reg; Regular Strength [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/46/26338?source=see_link\">",
"      see \"Dyclonine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;3 years: Topical: Slowly dissolve 1 lozenge (1.2 mg) in mouth every 2 hours, if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults: Topical: Slowly dissolve 1 lozenge (3 mg) in mouth every 2 hours, if necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sucrets&reg; Children's: 1.2 mg (18s) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sucrets&reg; Maximum Strength: 3 mg (18s) [black-cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sucrets&reg; Maximum Strength: 3 mg (18s) [wintergreen flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sucrets&reg; Regular Strength: 2 mg (18s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sucrets&reg; Regular Strength: 2 mg (18s [DSC]) [wild cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply to mucous membranes of the mouth or throat area: food should not be ingested for 60 minutes following application in the mouth or throat area",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in tight, light-resistant container; avoid freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used topically for temporary relief of pain associated with oral mucosa",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dyclonine may be confused with dicyclomine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F163944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Irritation, numbness, pain, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Allergic reactions, cold/heat sensation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorobutanol (preservative used in dyclonine), dyclonine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13831148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When used for self-medication (OTC), patients should contact healthcare provider if symptoms worsen or last for &gt;7 days. When treating a severe sore throat, patients should contact healthcare provider if symptoms lasts &gt;2 days, occur with fever, headache, rash, nausea, or vomiting. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/45/32467?source=see_link\">",
"      see \"Dyclonine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not chew lozenge; numbness of the tongue and buccal mucosa may result in increased risk of biting trauma; may impair swallowing",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carnel SB, Blakeslee DB, Oswald SG, et al, &ldquo;Treatment of Radiation- and Chemotherapy-Induced Stomatitis,&rdquo;",
"      <i>",
"       Otolaryngol Head Neck Surg",
"      </i>",
"      , 1990, 102(4):326-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/61/23506/abstract-text/2113258/pubmed\" id=\"2113258\" target=\"_blank\">",
"        2113258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13262 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23506=[""].join("\n");
var outline_f22_61_23506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163927\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047147\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047141\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163914\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163899\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047150\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047143\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047149\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163946\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163944\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047153\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831148\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299244\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163908\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047145\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13262|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/46/26338?source=related_link\">",
"      Dyclonine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/45/32467?source=related_link\">",
"      Dyclonine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_61_23507="Classifying ebola marburg";
var content_f22_61_23507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Classifying ebola marburg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mike Bray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23507=[""].join("\n");
var outline_f22_61_23507=null;
var title_f22_61_23508="Ocular cicatricial pemphigoid stage 4";
var content_f22_61_23508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Stage 4 ocular cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    End stage disease, with complete dry eye and \"leatherization\" of the ocular surface with corneal scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23508=[""].join("\n");
var outline_f22_61_23508=null;
var title_f22_61_23509="Extramammary Paget disease2";
var content_f22_61_23509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extramammary Paget disease of the vulva-2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 300px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEsAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDiV0LwzpsZe6tpp7mT7qStzTGiS0lkljs0tIyfkIPTFRW0l+LmR77TJyG4EuznNWDd+dDFaahhLZWG8HBkbHb2r1o0ox1bv8z2nO7tGNvkC3IWVZpfOuI+DFAAefc4q1Homqa5qK3GrP8AYrFf9Wg6kfStrSdSt47Zpo7dIIV4Ve7/AF9qqXeoS6jcLDAD8zYbHU1EU3LRWNJqPL7zudRoem2FlZMLa22Q9WYj5+O+axL7UNH1C9uI7iWRcgCJMYA+tbyano+maFJZ6rfRx3MqmNFPXB6VT0zwOuoTw3l5C24NuRkOAfSqhGMW5T0MqlRySUCey8D2WhaLd+Kob7LW1u00cYH3uOhrI8EeJr3xgZYnsLcJyDKw616D8QbMWvwu1W2iQbo7bACD3FZXwS0dNO8G20rIpkuh5hPt6VipKUJzlrrZEx5o1Eo7HnHiy1u7CSVW4gik2eWowKq/AvX9O8P+O3udXjKiRCgcjO0nvXsHj/w1HqFs8kI8pWPzfWvJNQ0bTLe6ZZUZ5k6lDjFaUZxcHFrfQqvRdVppnvPxX1jSNR8MKsRWWeQZgO3vXz7rc+o28KRQSJJ6ZUjBPvVy6vLqaJEijcRoMKSf8ateHdMlvb1ZLxhBbwHcWJxu9hU0afslpsV7JRhynGiz1aCSI6n5sIdwgA7VtWemXkkN1cQtN9ntxkvnpz616reXGkXmmC0McV3ION5blPpmua1PUprDSTZafbRt5nysuAcDOa19q5K3LZkRpcmvMclqtubqwijgWViV5OM5rkLJZdF8T2txd2xMcMofyyOGxXS3Fp4vuGeRXZRnAiiXGB7VduSRpStrgV7leEzwR9auF4baozqWrO70aO28Uz6Zqvh2W50GOO2+0qC8SnaGIrnbHxnqljClu1jugjj2eW6hkLdmwe9cxarqCMGsYZBDncPlODWqdP8AETqJntZVQHJGyoUXBOOlvMp8s7XWo/T75pr25urqLbJMSc44BrRit3ugQshUgZwnNO07+05FOz57dQAym3QtnNbl9pOpywRtp0aWuBiUPCE3flWct+x1waSsjlLgX8ChoxvjTozKARVT+2FlfFyjLJ/eU/0qt4qfVdO2Q3A3Rgn7vesHSEmvrwQIxJJ6/wB2t4Uk43uc88RJT5Ujr1mjmUNbyDI6joacjQS4SdVLfkaR9MuLK5kt7ZEmkQAlj2+lT2OnXOplhJAsMgPdCBWcoacy2N4Vbvl6lC705YpPNtWyhH76A8eYPp61zs0z+HLsrA5uNJuB88bDJX2Irs59K1C3k8owuwHQ9R+Brn9asN6YMEhj/wCWkeMlfce1RHfV3Qq0PdvFWaLPhSfwxYSSz6tpqalp90u11dcyW49V9xXF+JrKx03WpZfDV1LNpT/OnnIVI/2TVt9Nu7H9/pLCeL+KMDJ/LtUltqVpeiSG4jMM54IIwf8A69KVKLv1ON6tP4WY+leIntbpJbSaSGdT95TjFeiWnj5L7Tzaa5plpf5XAnC7ZR6cjr+Neean4diUGexyYycHZz+naseR7rTsEHfDnqK8ytg04+7oddLH1KTtWV13R213pV5JC17p9s/2X0U79lTaN4v8QaLsS3u5kjT/AJZMdw/KuY0jxLc2DrJazSwyfd46GtObxFPqTZuDFM/QkoM1yclWno0d0a9Gq7wkdyvxBe7JfU7OzvHb7xmgBP51mnxXJYX32rw75mmOfvJC5CN/wGuXEM5hLxwuQPQVZstN1S7XdDZSDHXK4qYynHWKN5JT92SX3Hb2/wAQPEd5GY7/AMS3Vsh6+UpLfypLvU9CmVH1TVdd1d16xySbFJ/EmvPb+SSylaO7bY47ZFVftcDRqz3MaD61sq1d6RRzuGHg7uyOilvrH+0/tMVgkcS/6uInI/Gk1nxTeXMeJJ2WBRwgOFFULEaY2nTXEly0kiN8hHyoB+Nc5q+qrfKYLS3cHpgc5pfU6tSX7wdTMadGn+73Z0Vu9tNpM2oXEkjBOETH3mrnGee81FZ7b5IVYbA3QGrWn2sqwJFq9yLezBz5K/fNX5b0mW2g0Ww8yMD93v65zXqYbDRh8KPIr1510nN/LqWhbXD7hLCjT7Gdwn+C07wt4ea7D6jqTnyIySsX9+uls7aS1DXeqeRBdSps8tDk/wDfIqa8aztNLRiswjj+YoP4q7Wla0QhR+3PZGTDveMxabbxxQ95GPCfWtKK2N2kUt7Ks+OI8JgD3qPTc6jCZCmyxj6ADG8+gp2o6vujEKokQiPCJxiq5JfDE0Tgven8iW522RC26gueFAFWbO1nuEcoytKTg7Rwv0qDRVN1bSXMhOScRkjt611+h6lonhyDOoFi4+faBnNS1b3Urs15klzy2K+g+AtZl1COYbVh+8TKcACvULOw1OGRLW3u7TeqDEe04rL8LePbbXne2t7WSMOpEZYYyMVc1LxZpvh/U7cTXttHOhwwduSOM1z1Y1pPkktTONWKTlEzNd8ax6Lc3Wn39jBd3MfyS+SAcce9eT+NvG02oxbLCBLWzUEBEUD860Pjh4evLHxDB4h0Sdriy1IeaCOcHPINYWpabNdWaGGEo80PmSJjoacKNL2XtOvUyhWnOVkjQvbbUp1L3lzsA5GDz9Ko2kEUJPlxPI+fvHvRbRTXcybLiSYEc8H8sV39t4QufsEUivweqjqK1b9mrNnSkqnvWMe2S2+yiG5kRW65Hap7LSWt71LqxlikI/hJrbt9D07R2imvXVGYcB+d59MVmeIdLuJJ2/s3EKKcDZWbm4vR6M1io1FqtUcz4m8N393qtxcQWj3rTt8oTkqfpXqnwvv76zsItF13T7izu4l/d+YvDj2rxyW+1HT7loYzKkyn/WbyCfpXRaL4p8SK0Us148iQnOJMHFbTcpQ5ZWsckaUee8GfQWp2CXGmSwzR7o5Bjk9sVgaFbw2OlfZrTJS3BjVR2pll4ttNW0xY47lIbkgDa7YBOKmhmsbCza4ub+2jwDuzIPmrgUZRTTNvh+I5TV/EzXP2m3UBEtSN4HU155capBJcXP2SDIUlmbGccf41p69qcOt3F5NpalLVHEZlzgyn/wDVWRBf2OmRvYkrmX/WHH6V2citZLUmMmle5d8JSxpay6xq2Hi8zyoYc8n8O9dnp9zpmuH7PCjRNtz5OwJ171zXhTSra68wXAV7aAmWNc9D61u2scGl6np100lrEER98ucHb9KtqD1W5nzSi+VnHeMNKuLDxJaxWKOpYhWx09q63WdHuLC6tDZiFYsf64nhzjJGfaug8Na3o3inXja2UJvRA3mO4XqR710HjDw5Lq2nfZGCQhBuiUcD6VnUqtOMZqxMbK/KzhNGury2vVZHtJ88FoxzVv4keFIdV0uzv4AEka4HnBQAD2zXI6Xoz6DdTpPK0LBifLLk4A7it/wt4r1PXNWuNPuxGNORd0eVwS2cDmtJ07NTh0/IlTv7szstFtIoLaIi2CxQ4CrsweOlZ1zLceJJNWsbK7NkLGPfKSnJPoPauf8AiP45Gla0mlBpkdFDOIW6596xvD3xDuNM05rjTdMbVNQuppBM4HPldsnt1rONCUo+0tq9ialZfChfDs66ZqdvbrctdGaLzPnBHlnuPpXcWXiC2+dCyEIMFV5IrzLx7fm6udMnntRYwNF8wB55603w9prXut21v4XuDN56AyLHn92uOSxPvXS6MZLmkKOIkrRO8+IWiWl5pyX0aEMpAPHr3ry7Vo08NPuJie5lYbADwBXscus6PBaX+j3N1DNdLAw2A5AYDjB9c182+IHuLvVd25jtOAprDCpuXK9jSvVSheO56neJJDYQXlvDI7XaA/uj8wPcVueArSe21GGW5jYPOCrxuc4960PD+mQz6BZx3X7spGuByD+ddhpmmwx4uipcr/H120TrWThYqNPXmMvxZpdzb2Ms9gUAPIUrxXl93fl7kymMQSKcMo7eufY19ATzwG2jWTayscY9q85+K/g17S0PiLw8MxrxLFt6L3rkpz5XyyOr2qaszyu+CNcFrNY4ZOoIGP1rJml0/WYnjuYIvtkRxuHBP4irlreQah+7j2LcKcNF/UUy602NLhljjEO479w713KMZfFozmldaw1RieQktxssZTBdpw9tNx5mPem6jocd1A8ys9tdp/rYXHB966kWSTfZ5JYY47hP9VJJ/H7Grl5e6NqcgtcfZtTQYIH8vesaifRGsKUZJqTPMxpJmfyLSRVni5Kjhj9K5u7tpLe+Jmco+/nzEIr0jUPDbXxlCMBLn/R54z0Poa4+/wD7X0m5W21u1eWNTgCRcg/7prHlV0kcWJptbq3maHhrxJqWiFntNQjkZ+iccfnV268X6nfoLa4+0geqIM1jTS6ddsl1p9mkVxH/AMsADsP1rFS01Q3RkSCdZGO75Bj8qcoRVnKOoo4irTVou6Og/wCEem1cPPBdCOPuZEIqvFp/h/T5QL67luGXqIl4NXdXnnbQ7CLTluhO/FwuDkvWx4auLCz0+T+2vDksz+TiNyuFD9jWiop31FNrm0jr33KOnzaJqjOgt54rW3T8B+HvVKaa2L+TYI1tA54bZ85+tLeA2MEzxwCIzHJwcYq94V0GbUXa8kPlQKcmVxgVr7OK1fQcXObUbalvQtBtorr7VcxNMmdyKe/pXR3FukkJktUiheL74j4KVl6vqaaftisITPnpIT1/4DWh4b0m4mje41N0ggl5eKP+L61aUbc8joSd/Z00VdDha2tXu7nM1y/+rR+T9auR6a13J52ps2PveQp4/GtO4uYzJ5enIAg48zH8qg+0pYofMILuM7mPSi8tZLQ25YRST6Dr9C1osMH7raPkx2rmm0SHS0ea/uXeRzu8sdTWnBrET3Aw43A+nWs7xCZLtxIATgYOKqCkmo7GVbklHnWrGQeJ9jfZrfZsHAXH3a6bTvEFhrnl2mowm2ulIKzxDIOPUVgeDPDlrLFc3F7FkHiMnsfWu70PwrA9wv2O0YxDAZ5O1OThBuy1IhGpOK53oLpl3YaHqRuYNQkmk8v/AJbAKq+yAV57Pp51XXWu9Uv/ACYTJ5kkmck89hXTfEzRntrmBLRGJAKMFHernw7+HhZ11PxBFIbJBuEUpI3H0+lTCbjH2rkZ1IxcuRR0Lmq/EjTI7aG1g3m1tkEcUezgeprBg8RabqCzNDqCLez5J8wFOfSu5fUfD0k8kEPhnTXgjU4aReeOvT+VclqFr4Z1eeeKPSY7aVYTKskUbRr9OtYSpXi24taPqi6deUJJRsbfhzRms/D15qg8vdGgOWHA9hVvw34nu7y9htjIhtR/CPSu+vtLEfw4k05IwhlTazD17CvnJbrUfB+vSC5iIXd8y9Ay1VBKrzJ79C61V05J9DofiT4na4v40tUw1s2ABwMV12i+Jra40eK4eIncMFB1H0rj4NG0zxxrbXWlXklrKFDvDMuPrjHWu/PgY2unWtvpN24mQ5l6DzBVydNJQmrEQdS7nFkWp22mazpcd3YgLeQkghhg/jXCy3Fy6syxHHQmvUrfRvsNgZ7/ABGAr4yckk9684sNUMd4kKKGEny47VinGLfLqdUbySu7EFnPJFblVU8/xAd6x59J1C9/dKsqxA53ZP61q+INXi0h/s8BXzCCzjPQmuUn8Q3ssplNwyr2UcCtafO/ejoY1p017sjtLOCPT7VbOL5m6ls9TWTqWjxzXXnm9SPccYxXS+B54dTtGS+2rMp+V/bFcj450a5tL+aRIy0fYDpilFv2lm7MupyqknFXOq02RtN0e7F1IkYRd4b147fWs/T9ZtfEmk3NlGiJqCoQAx6j2qDQDJe+GLiCZeqFdrj8eK5/RPBuvCT7fp6BmViR5bYIqopXkpPUyqTknFxWjR6B8Fpp/C/iQRXsTrbPlXz+mDX0FrmoWN5YCWG5iKleMOMn2NeCeGNT85ZhqFlJDLaqZJihHzYrkPEvxLtprhrSztAsYk64wR+NZVKcq8/NEuNOlaVz0nV9YgEN1KkdqVgJCicZ3evPauKTxfNfa1o1iILLTrW6mUvJDwcehNa8mjHUdIhlvG3W80YkCZx1rnNQ8P2N2rWIcQS2zDZKOM/St6fJ1WxNRTv7rOt8ceCZbrxZBcSXkflzhQJiMEjpn8K6fQtL8K+FGmigvJIZCuXaUbkbH8qj0Pwyl74ReDUL8XCx2xwXbDIeua8vPg+01qwnlXUZQwJA3T46exrnU+aLg5Oy8ipw1vFanfyWfhzx9NfWVnqBbUIADEI14OOpHr1rr/hr4StPB+nalevOXmeJhmTCtkDjAry34Vabp/hnVYLj7bC8wO0sT09jXpPijW4L+8jt0h2AMN7q+dy98VNVu/s4t8rNI0HKOu55ZEskuqy7IowkpMskx6g/3KhtrqzsrCWBNNim1qSc7JZPuxDg8/nXf6j4f0+BoprebyYGG4gdD3rhVjs9a1qYWFwI5I3JiHQcdifeumNSNRrTRGc6TgnrqdX8N/ErXZ+z3UduZHchgrH5SPQGvW9BsmnaeB5NsI+ZR65ryDwZDpdrrs1xqd3aC8dgyxxtv2Ee9esNdpbBZEfl+FNc+IST91blQ5pRt1ItZtFsVU5zGOcZ6Y9Ks6FfWmsaPfaU0qMzQnCk84I9KqeILNtQ0G5kswzXQRmTHrivCvCNze6Z4nmyksM6tiR3JHH09amnQ+sQkm9UKrO1o2PO9XsptI8YXCxFlEUpwfoa9cj0YavoEN5An7+RN3A4U1z3jK1hu/E1xO/Kq26TA9a9G8M6hbWmkQWpcIgHDelbVZ3hG26N8PTcJO+zOAtJhOpt7qMCeM4IIxg1V8Q6L/aFo1/YxRrd2+Tt6ZrtfEWkWeoXElxYOi3iruZQeGFcjDMttdGGSQxzHoSevsazi23eOjOuajKNmcl4v1Ca2tLTUtPk8sygJJF/tjrU+m+LV1po7LWrZLefHySlMoT/ALVdPq0dhM1s9za5KSbJQvy5HrVtbzw5qennR20iOHUJYXEd05VNjdmwPpWvLGcfhvb8Dz6rqUpv3tGcFrM1z4cvNkmn2S2shx9phj3b63LfRb5rZZlOxHAcDGM1T8PusFy+hXLJqMUinMQ+cIwzk5rSvtL1A2pgjvruK0XhYyA5T8afuR0l94ownJc0dV+RziareQamNNgkRjvwQBkx/N610evx6ndwwW1mYwdgaQ4+5Vb+yWsojHpNqIZiP313cMM/gKu3ERtNMjiE8Y3DJIPJPrmlLklZxRrShKMXzmDb6Bp1tcyTX1x/aN6g3vHnZGPb3p1/cy6iViLJDaR9I4/lRae+lzkK8xt5IJfv7vmIqK5aF50W3i81c8LGOlawSvfdmMk0rWsizp9wlvBGvl98F/vflW9dMI4xHnAxytYRhezP2i9AVuFWLrg1kX+ptPdeXJPsL/wr1p+z55XiX7f2MbS3O608RPCwXA2jLYHauX8QQm8uJgikxZxheorZ8MpDa6exvZCXk4VTkkitC70yyjt2lMu12GUwf51nzKnM3lD2tPsc34d0F3O66/dJGu5cjlq6iPQ7J4t4LyYXLDsPaqBlNyY4rLChzsyO/wCNbtnP9iE+maTb/aLpAfPllGAv0qZzlJ3uTGEYQsh/hM213qkFrc262FuxCr6AevPrXrF3ZRwFktpClqoGCuMGvnmefUhqYiuomedWBQRnPXvXqfgXXDcEaXqpaJ9v32PQjsaK9K6Uoswp1He0jN1TWJdL19itnbvGp6zck5716Boh/tXSo7ieHZvOAoztFbOl+FtIVFvLwRzDJYM+MLWrqF3YTRGOx8tjGOQowK5Z1YyioqOq6kuVqmmp5VrXg21nuTcqzROMnEBxyfUHrXN+J5LqDSpdIUW0ltj5pdu1wOuD2r1wvJLb7XhC4+98vSuI8eaY6WFw5YmGdSGCtgg45FUpvl5ZbFyinZ21Ov1y4LaI0Vv5Zmh4C++MjNeI3Eun67a3FtdKJNYacRqsg5A7kD86634hXEt7qel2rGS2tLmJ5Q0XO+QDgH864nQdBOoXBvLUpJe2OC0TPy3bitsNCMYczM6sm5WR1fgrTNI02bLo0F8hI83d8pHqK7axv9Ma7EcdwN/8XqfeuM0XQNRP77U42gBJIBIzk+grY0vw0lpqH2r7Q0kkfAVhwR3oquDu3I2pp2SSML4s659ito41O2dtyImedp7muA0a7tbZILq4YLITgL1x71c+JVtc+JvFosrchXh/dk54bHNc14x06PRdMRElVp06nPQ4opQi4JdWRUqyg3K2iDSoY9c8bS/ay0luG24H5Cum8X+E7LR7looJmlVgNo28jPJrA+DU0P8AbslxdfcEe/BHU16D4oiW/v49QtWQiIeWyZx+NXKXJOMeiQqNL2lJz6s4KCzeC+8u2SdohhWLA7s/4V3Hh6GfUY7mzuogY4Ou/sMVkRG4026HmTfZraNd7tgvnPap9ee5v4Jf7LkeCeUAFl48we1ay99GavSdjpdNgs7WWAzRwkOpiUEYwcVy9reyW19dRQArCpO4ZKc+n1rZ8DWmo65eWcc8TeRZYeWSUYLEVt+KvDFibr7SrywsSSyoflP4Vi3CnOz1NVzzV0VyukRxRyKShliw3zfeBFeb6x4V0qK/h1F5d1l5n7xU6rz3qWczz6pGxiRbCUM8Uhf5tq8YPp0/WpfEF9ZQQQRQIJZ57bNyG/hz0x78Zp+y5HzRbM3XVRcslsda3/Ex0SG5tQN9lmKSANjMfUEVzyag9zqotpIg25T80jgiMe/vXITDWrnw09tC8kVqGGX3YDjsKk0FtW8PRG60mFLu7X/Wuf3m0fSnB8t43M6kuaXNY6vXl1GbT742U00AiQHBztljzgn8zXS/DDwhZ67oCw3VxcQTljiQDgnvxXEXni7xVq8seoX8UUVtaKcp5YG7PbGK3PBPxJWTKy25i8g5kSIAceoFTL2nJZfgbU5RlK70bOjvPhadI1VpJ57i4ss8PHwPxq+1hFDBGIyy7eFPWvTND8X6Zq+m/wCjhbpCo4TqPrXN+IDbzWxtoIzG6uCT6VwyqVJO0+h6OF005bHKaxDetpMluCTKFPlqPpXjOnPdWty0CDEkoKuec5z0Fe+T3B0/XBJLH5kQjGfpXH69o9j/AMJhHe6bFmF28xZYzgKcc5H1rfB1mrp63Mcxo6xktDA8PWN5qFu6Q2wkum/dgIhQKQcZzXtU0l6YbGz+60UYbzPLyCe9cno3iKzN81tNPgqeHUdfrXUa3qUOm6Gbuyc/aWOPMY5AHrW1WrKbScTmhTUI3TOostRFjBEt0yqXA3EDAzXE+OdU0GxtrnUZUhaVPuOuME+me9ePNr2uX+vOstxczO0hAEHOT24q74n8B+MPF95Da21p5NlEAxycIpPUn3qHhlTacpWuR7TRuKuynoWrwa7d3kjEfaJX3hTwH+ldRfxu2njYqIVPKSZGa0PBfwh/4R6KO41C/iedGxtUfKT7GsP4uXl/p89vNAqGBSY1/wBqnzQlUUaTOiFVqleoZdgbqC9guIGd1ztJUcD1Bpvim1lttQkUJvyQeO3vTfAfipJrsafeQ+XDe/IxxwG9a6fxDYXNjIkjqJRb5iZl5wvY1vObhNXQqcVUp+6znrNRcxy2NwcSKMRSno3saxb7QLbUZZLe4e5tb8ZIA+4R7GunjghnSN7dt2PQY596tsz21jGL8FCSUBzyPSspNp3ibqCnG1TocBoVnb6ALmK2nYTsN0kki7Sg9BWrd6dP9jM6SzErlkbPBHY1Lr/D+RqOGjbmGcdj71jPHf4kfUb2KS1cgCOInn0ram1a7OScHF8kdi94a8OXl5Gbi7uyRjiMnp9a0GsLG3nXzp/NkH8IPApZNTitIfssLv5hHzbPp3rDubl43IjCl88FO+alKc3dmzlCmkkrl7U4raS6SKKR0Vu27pWhptoNN064uUjwBwrYzXdfDLwHazWkWua9Iq26nGJP4j6Cum8ax6KbnTNJs4T9muXLyMhA4QdB9ay9onJUlr3YnVjFuVtTwQztqBFu+7YTnfjp+NaLeHra2tvtUQ+0XBwFJGcflXaQa5bwa7bNp8MNrCrSRSRzIB5gHqa66LQNM8VWkkuihrG627iB9w1rWcqaTtoZUpwm3z7ni+mRXX292uFL5GBnjnPYVkeOL64854oWIIfZsFeleIrebwyGN6mb9ThCen1Fcbrlgtze2msWw2+diTa3TeOtFOopyUuhdam40+WL1ZLaaHrWg6DaXzrhpT5ix4OcU3RfiMLDUJxqNntaXKs6LgjPt3rr9d8QNqkVlGsYhESgk1x+o6Ta6vNP+5/e9UI4pfFd1ERZpJU3qZWpm9l1VtR0m4yh5Xb/AAj3r0H4SXB1LUCdZikdl6uB1qx8PPAsUAM1xL5rL8xjU9K9TnESIJYBFalUwSFAzUVa6S5Er+Yo0mnduxo6jqeiw2KxTzLHGAEA3flWYuo2FooawKyzN0DZI/GuI+IVxFHZ2jSzRyQRMS4VgGGTwT9DWbp1zLc3DjTbqKSNQDuJz25rGlRvG9xuSjLlPTtW8R2lnphvLrEaIMSAHr74rmLnxJ4Y8WeGr+Cxvtt1sPlKx2ktisDxbdJf+D7uBTGZwpPDcE55rzv4d+B76+km1KVmhtYQW3DoxHSl7KHs5yk7WE3LnjGB0kl/BruiTWlzI0co5T5sFT3waw7G7v8AQ7C4aFtj28ZjWQ5O8E8flWZqKSC3a4DsNvI296ZoV3dy3cVo/wByXpXVSXLB2ZVa0qm1mVJ/HPiC4OI7qZdnbdnFd74C8XagdOu11DeyDGCw/i7im2ukWN2rqLGB2HVguPxq3c+Hbw2yW1vH9nVhvPY8dhROrGceXlSCFGVJ8zlczYby0GvLexfPKXzKq+/vXHeP9LmF448zfDI2dzckV3lh/YWlJNALppLrp5p5QH615t4q1e81FJLecRmSN/ldBgsP60oJ83u7IjESi4Wlub/wz0aK4hvIbSVFvio8sdzjqBW/4eWSLVRb353RsTHJmrPwz0KGHwdd6vdeZGYkHksg+8w65/Gk0bUhqJvL+WFEe2Adkx17ZqamspW6GuHfLFI19U8P29tHFqFxC0+mucN3UHtk9qp2hlk1WHTLCw81XYMkg4aIev0r2fwdPpOsaGEiSFUuF+7gYJxggiqtjoOnaHfTzRxRxb/lLKOT6VnCvyXhJarYyqLnncpR2L6ageFv3bHYVX1qG50S6vY/+JnIAGGCF9PrXUraNcxkSkxKBlVHXmqchcXYicqyxqT83U1hFmvMzmrT4aeF7rT7iFYRb3zAncznb7Ec14t4t+EviPw9qrXMcEl1aMCwkVtygD1r6CjuQ1wV2EAnAx/Srms6ssfg7UDLJl4YjgMMkCr9pVpv3Xe/c550k/ePk+4h1nX7Wy0e1R2TzfkRB1J4ya958DfCnTtA0uJry4M9/IB548zCKO/HeuQ0K1fS/hvca/a7UvWuWWFsYwuetWvBHxKma1UavDO0Mr+X9oJBGfQ5repTqVIyjT0Sf3ijKEZJ9T0jUPDHh4RvmBhCBtKsev0rxjxPomi6frouNHgkRYm2ygfxe3vXuVrcQ30STQSGZGHcVxHirw8JNU+3W90ogBy0CkD5u+TWFCKjK0mzepeyaOH+H/23TNRvbq0v4oNLDZcs2MDPTHrWx4q8RanaJLd2scdxaOP3cqHIb/69cbDDLZeNX0meT/QdY3RMo6K/8JH4102i6JcJ4YubHUbsQBJT5W89PWta6Sak9f6/MvDVXKLitGiDw14xOqyPNLlriIBZIX9Pao/F+ofY7eO6smMa4529GrhIFl0zWYprUlj5mCAOMd67XXdPltY4ra9UC3vF8yLuFz2olRVOanHZmkK8qtN057oo+HdXN3ZXBVjBKvClRnNdb4Emvr6Z7K9cXNqRyWHH5CuV03Tdc0vTLn+x7FLqFzk7eWT14rsvg7pmqalqzRXkVxZgNuZgMA+orpk4yi3dWOO/s3qeyeDvCWm2UYu4LSKNpCDlk5/+tXVaq8FnptxI+2NFQkkcdqtwosMKoOAgxXlXxl8bQafp506zcS3TglgD90e9eQoutOxyqTqTv0OJ8XeL7CGwW0tZHnleQxsYyehbjmk8b6Pu8LafHqKg4kZVLDBUdRXB+EbafxB4khKnybVfnnULx1zgV3XxR1Vbi2sbKCQqYWLsvUHjGa9GrTVNxjHfdnfRk53bWhw9v4YSwvFmkkxDnKsSMCum1LURFdRl5hLbyIAxHIJxXIXmoTXNi0Bl5AAFM0aeW6Rrcsgb+6eRV8rkrzZtzxh7sEbOo2v2ZFvLIkQMedv8FYniG7kmu7eONiZHGASeD/8AXrsNNl/4l93DtBAZeOowa5TxRaJH5TxnDKQ6gcY5oh8S5gqtuD5TPttTWQS2V8wuIgdhI6qaoanp95b6hBDOpaB5Rhh0Iq/bxNMhWOEBnYF9gxzXQXuoW9tbR2xUSYwORk5qpvll7i3M6cOaF6j2Ma702SC8uZnify2GEatHw1pkF/q9jGRuWL52XHU+lJbasbi5IkImt24K+1aXg7WbWLxTYBgiKJSpJqVKSXLYtxh8Seh0fjjxLfyT2+k6faOtlE45Hy4PoB3rpodHTVdMsUuMrPH+8R84ZD2qr4g8Pi9udR1DRrmJLqRA67jkFvb06V4TYaj4mvPFqWsk9x9s83ywuT8p6VlS5ay5Ivla1Zyzm6T1V7ntqeBBqF9BHqN0rw28nmH5MFz712vlwaFpkr2/Dop2kevv7VfbSymlwebJmZEDSvj7zY5rmta1q00vSne/ZhAEyyhc7vasHUlVVm7m0Yxs5WOP+Il+1x4azq0cUzjlZcc+xBri7SeGHQDBcDdCsm8E9Vz3FZd540mv9Tl07S0Z7K5fmGQZI+laeqWElhoi20mDO0YaQdxzx+ldsqfJFLa5FCrzN+QXFhOlqt7bTBrYjGcZx7V6R4I8GK9r9r1OUtOygLF0CivMfAF9MNWgsJgGs5pRuVvbmvftItLlXklmuQ0cr5CBeFHbBrHESlBctzSLT95FSDQ2tp4kssqGz5kaZrR1TSjFapEYllSQ4YyOQV/Kta0kFrI+0b2YZy3UVBqc32mNoX2oASQ47etcbk2wcm2fKXxNjR/FN9bxNcBIhtyH46elZPgnTta8xvsE7KrZP39uQOte8+MfBulapdxvEWSR1xJMoyCPp3rEtNN0nwpd2b3GosZY8+VbiMAke4zXo0665OVb2OOVF8/O9jxbxBDrVlMZHuJY4DwSr4z9RXo3wl8YWlhplxY6kZbuSVGRI927GR6Ve+I2jWet6HBdaLGskhl2FMFSTXm2gafp9lrf2TWILqxv1GY8HIY1nKXtaMoz7P1NIxVOsuXZncaLHaBG/tNlEWRtXPQ1et2tIDcRWEXmSOcQlRyAetYviKIWsNstihmkmX5FHOT7U3wAurnx1o9lcwyAvJkxMuCB3pxp8y5rnXOsoS5LfM9g8IeHri1s01G/Hl7vlSJR8q/Wq/xBupxp13JYRsGK+WpA5ArtfFJmgs7OxsUzlixwCcYrCA/0bOoRAgkjbIT8x5rm5+d87CMfdPCNFhe70SXTr9lFqXMu9P8AWk56Vu6J8MrbURBcx6l9jvnbfFDKhIKV3WsS+H9NliVNNiMs+cMIuc1weueILmW9t2gvEhmR/wCADOK6vaSrX5NDlVONP49Tv5fCXiDwp4bdLK5t7mwlO5osYKMevXqK89sjcrr2zygsUsRjfHGK6DTvEV/rKG2vZppFjOAVP64rVn02GcRG3aM3cI+8Dy49x61jaVJvm1Z10kqiSZlaRE+l21tcxuY7R2wxzgqa6rSvFFs93DazktNC+Dv7jsQe9ZulWa3kMlpdO2zBIQL3rnZvC1xptvbXMeqmB71mITqFUHpUUpKppI1xMfZs9hTxVpUqsr3SKwOAA+cVh614v0Wy1jy5pUMjR4UKcspryswRabqtpZalB5cNxkrcRNvya5fxlp3la/MLe6WXeAo2NlyfTAreOGp82+h58qrSukfRGkX9nqUX2myLuoYAnI4PrWb4ut7iSwlhiVlkuBhT61U+DHh2/i8Jz2t2m12k8z5+CB2rt7iyWKPyDcW7Sg8IZRn+dYSlGFS0XexqpJqzOZ0DwcniTwJbaZJK8BjB3lRtO7kHivK7nwePC5urG9imvQJCYADtCSe/rXqI1vWtJ8W2llb25W0Z/wB6yDcvPU1f+K8kOp6eo0Uwi7Vy0szkIMY6DPU1rCrOM/KRhVp2d2ebaN40Xwvpfk6oitOrBVEZ9ua43V9Zv9V1C9ltb65tzzJCu7CkdunvSXHhmXWLyG3u/MzKxjTknac/1r0vwp8LLTw/Fv1jGoNtwgK8JW85U6bcnuyV7SfurY8wks73VbfT7ppzJc2RE28Rbc4xnnHNPa6vNc0+9trmctPBKXi55YGvR9c8T+H9Cu5NOj01W+Xy5PKU5HsKytM0qyme81Sxje3hjGfKYc5wfWsZzlbmasuh0UoRTtf1PO/DdveuWLwnykODKT0NetI1lfaXbw6y8HCYjlDZ2/l0ry3xyLyO/bT0mMVnaxJJKIRjLNzzUHgy+RbmP7UvmWu7aQxOR6fWtZUnVjzv8BQrKnLkR3i+LBoU0TabOn2lCQSBlSPcV6HpXxftbTSIZtRsFaZuN1tyCfXHauWm8PaDdQG4hsAZ5sAbH/kK8p8bPd+H9SmsInhkjXkRc5H/ANesIU4VXytF4m1uaZ6R47+O2oaoGsPDkX2JmXDTOfmx7VzehJo01rI/iPU/LuG/eeY77i59/wDCvM7I6hesvlW6w5P38dPxqPU7CCyugbyZrmTP3UfrXUqcILkhp6bnFCXKrpHtXgvxHo1l9vs9JDXErAhZiuAR7elcxfeJ7ay1CWC6iE7SPiWVhyPpUHw+iEkb316I9P0e2G5yeN3sPWsdfsniTxhcajKDFp6yDykJwWA6VPLF1G5dtTpVVqKjDc0vEVgGkaOBikbAOCPQ0/wjFImpEDlVUgZH3q6m4gh1GF7hGjVI+CVHQdKRdW0/SVtVSARqG4mYY3mpVR8vLbU6JUkpc97FuK5g0uw86TmW4lwAegA/+vVGSWK6nzcIhQj0xWP4qu43v7WKFyUC7wD2zVnWnm0uxW9SHcqgRx5HGT396UY81r9S5VeSLfY3NE02FLzzInVgv8OeRVK78OyQ6gbsqpgyclj0rS8M6d5GnTanLLuvY9rrvOAQeqYrr57N2lkBQmCQblGMDBNFRezle5nGarRtax4fBDdW3iGSO5IIkbKbRjjvxTPsd/NPIdOKkRMZGjPVPfNdn/ZCLr8jcBk+6pOfyrN1jTZp5DqGjO0UgfE8I71qq0eZPyM3h5xh8yvdeItSngjgspo7cFN5LOUZnHUA11Hw+8Q6XP4kifULKN9QC7VYEMZMe471x1tZRX9ldx3SP8sglIHVSeDitDwyfDnhOaS9eO4urpUPl+Y23YcVMlTacWtfIzdOpdSex9BT6q2qn7PACHbG2JXH+RXn3xR8LeI761MdlbGNVySRyGyPUV5ynivVZ5v7QtcxDIwQDxXaWPxa13R7CGXVfKuoZOBGUwSB1Oa5nRnSadO3obSs42Wx5x4V8NX3h+W61iaNZ7u2XAhxnac459K3Yr6/vdfK31uYztAaM9FH1rodf8R6VrcyatozG1eZfLuIcZw2c5xWA99qmo36tdSRGW8fyxsTGI/U49hXZ71Rc01Z/kclN+zfLHYedKFvqyzi4tVAkDhVlGePSvXo7ye30yKZJ90bplDjn6fWvnX4oaLPp+t2VtpMkkheLeFB963vBPifWtO06Oz1pWe1gbcFl4K/Q1hKHPBSubqo3NxUT1PU/HkNjYYME32g9UCncfWuVt/i1BcagbO8s54IiNocfMR9a6jSLnwn4wiME91bQuVI/wBYFkVvXOea5LXPgtrEV613o99b3tvtwB5gBx9KzjKhGXLUVn8zKdSfRnYDWIGsUZxjev7p/UHpXCWdnZ38sl7qcXn3qSEq3m42fnWlEk2k6K2nSzs91Avzqw5T2FZNpot5qVsNS06NgruA6yghQQOc/Wt4KMW3fTuOTlOysbvgrTob+XVNK3OJOsMobOJMZB/SuZ0/QtS8WePftWoxxL9gB85wMLhR1r1r4YaLHpJknldJrt8yM2edx4x9KyfFVxqVraavDoUFrbzXO4O7k5Bxzj864MTX5XLlfTc68PQlN7XsZmjWVlo3jKZ3IeG2+SItjjPJxXZeHorXU/F+seLlKRWVrELK1JHVgPnP58V4rrkF7KrPbXBdmOCVkz1r6F8JaAYfh/pemRgR4iDy/wC0x5P866KqUYqTeu3yMKqtuPj1u23eZCRcTsDkkZ+uKyIbhdX3LNC3zPuxj5RUOp6QdHv0VJFIcZBHB68/lV6713TtNiS3LxwserNj5jWPLH7Cuax25hsumaeI3jwJbhzwvpx0rB1Hwt4asLdWv7eyjmPXA5JqPxL4gkso7d7JP3lzIIw4PY965i3t477VL19SeQui5iIbKkk8fjWlOk7c17ImcrOxejv9Etw8VhaeXEDgyeX8prF8T6TLa3VvqGmTSEgg/Icgis+ztNUGpTRRWt26n7zD7p9s1a8RTT+FvDjG7dklnfd5JOdo+tbSpqLXK9Qp1mvi2Oi0CNhJ9oJwx6gn1rG8Z65DpGoRWE4LFCZFbqAM9CK6HwJe2mp+F5LyVhGyqD6nP+e1cV8SrFILg3jLGbm5j3kZ5UEcdeh6Vz0IctVqR04urz01ynPr4jbVdQtrZXRltyfLkI5QY5JPpVKw1qwTXH+wwNcSI/yEcZ967D4T/Dy11Dw1qGra3cLZWDHa8rnGU74Navhq48AQ6zNaaLptzeTw/dmUblb3NdE5RcpKKbsefSk00mzlr7WPG+p3kiaQ93HGq4MUJJ4967/wx4I1aSxh1HWJWW4KZbLbSP8A69ehaYUh09rm2sDLKV2qinYP/wBVYV3P4htrkG5tY2iYfLDsyMelZKtJrkjZGqh77Z12iKq6NGPMWRkBBccmvHvHUeqyfa5NMzPcRyDzYv8Apn1yK9J02+vUlDNbLaKcZUDAP4Gs7XrV7e/jvbRkKzfJKBx+NTSfJUv3FON1Yx9Phj0yCwv/ALSi/bjGkls68JIehGe9dTPqUcTrDcEkY+9jpWDZaPPqerq+pGI2sbCWMRZxwcg1z/iDXXk8STabpUfnXcWWkBz8orZxVSXL8yIvkVzP1mM+H/E15JfCNrS+LS207LkAkcgms5PENkEurR7tJJ5mGxYzgKoH+PFbGqeJ7bWPD7WOo2RSWMb0UD5iQK8NsobuXWbqd4TGYpVHlYxgdcflWsI8y5Z7r+kZym6bvE9TmjthLd28+GuLuPyi/XJrlT4S1y0a5mjtgdNU/fHQH613V9a2NzplpqlrDKjoy8Hpupnj3xJdeH9NttLhkTzZ1E0ik9CecVMZuMlGG77m86aceeRbSVfBPhiG71iU3l/cr/otsjc7j0JPYCsfSfh//ak8+ueILp728lbc0EP3VJGQM15nNc6lqepPdapcMwiI78L7Cu88O6/relXqT2zs1nzvVkwBirdGSTcXq/6sYwqxk7zWxk+PNCubS4+z2VncxhRkMB8uPpXMeF9JgfUFl1iUCBTkgtyfpXteseI5tbsGktZEjzHkqQAc+1eF6/BML59hIwcKV706fNycstAqcqnzLU3PHuv+fFHZWyKmmwECKAHg/Wn+FPD0+o2/9rXzeTbL8saDjP0rJ0+whkaIahKoK/Nhqk8Qa/eeXDb2khjgQkKg4FKCsuSn95crJ+0qbdj1fTNPtodNMcQcxffkyc54ryrx5r/9rajBDHE0UUPEeT711vgHWJZ7WaK6wqqu5m9hXOwaXbX9/wCU2POLHHPJ9qdOPJNuWti67dSEVHqJfNMl1aTSMGiKj6173eWunr4Jge8jEtqIlkZQeGJ7fWvJNb0lINDsYZsreZfaMdq9L8Kzpr/gFtPmILW8JiK579m+orGraUE+zLScbozLrSf7Gto9VumhNjI4AtWY49sEnmtfWdfkTwVPqunW5EMXyvuO7H0/KuTe01PUpYNK1TTpJpI2MUBabEKj+/1/GvV/Dei+FbTw0vh28vkn3DEwLEB2PXFOvUiop/E/LsYR54X0seF2viVPEkZvIVEN5ajMkanqM/fH09KS91sTWqiEHzyxJK8ZPrXqd78HdG0G4k1fRJJXtihHkZztyPX0rwq4zb6g8USldjcAelODpVn+76GsK9RQvJ3Oy0PUA9vNfxqhkdfLuImHU+v41h+J7YXurWdzHhLVxhs9FPoansCYtI1K5KFRlAM9feo9Nv0vrGSzkXDMQR6/WiMHGTlHobSlGcVCR0cgtHsxBbpsgWLYSB95/asnxHpvmaZbPGM24Tys46GpPEd1JprJbooCw4CnufWp9J8RoIJLS5QtHLg7cck+orOKbXNHuVNx+FnJQ6Xq9lfRCwSQStgDy+9d3caReGC0mmeRZUXzJQqgbSKwovF97N4l8lFEJDCNVA5Fe5vpcFxowMkuHkj/AHhbknNVWnOKjKSMKfIrpHi0VvfDxANc+0Wx8ngLOM/hW3qV7a6o00Ws2v2aZwMso4bPp6Vznijw5qGm6rlbmR7MncpT58exFVdZ1ZYIJIZWWe4mAO9jjFaunCpFNGEZypydzifF+kWdrqiw6Xc7e+ScYrd8P2mv2mlvLc6hNFagZRjKQCPasGbTJNQ1ZDErEuwzkcYr2y08IrceGY7d5QwQYjQng+vPalKThFJsVOPNKU0jzSGaWSeLAuZbiUF45FJJYDv711Oh+NNQcG2huTKAdvlTJjJ/Cp7LwtqFpfpPDEIZol2p5rgQoPx7VtR+EImJuYdd055VbzGs7Qg5f2NRV5GtzWlUanaSNTw/4pvLATRPHF5zLnahOc+1bU6mfTJ7i5Mn2mSMnBOMce1c6lpENVtH2EMSdx9B71salHcXNtNjKQqhxjoeK8XGSTj52Po8JTUdVocf8IdKXWpVS5l2qrg7WHLfSvpudY7G1jWMBUVcfQetfNPwbum228igeZFgk+vNer+PPEsskK2emyMs8mMYxXqYqEpVFFHzji5qPYq+PdesVtbmWOUNJEDgqc475r5q1nU9Uk8Qrdur3Su+BvPH4V3vjrWrjRdWMEEW8rCGmaVMq2RWz4Ij8Oa5ZwX8djGt3GwLx5Ix+B4rej+5jzWuhTiptQi9jR0TT5ZvBNvBrEbGV3yigkMg7EGubTS5LXXbuwttQulj2guZMZ9cZr1C4uRLMDJGkeMCIHis260uEaol6ltFIWTbOh6sexrKFW0m3pc1nT0VhPC2v6dYQtaahMQVjzGcdD3ya8w+M15FqsMTWtx5uGYFRjHWtbxhcXctvJHpdvCIiSecjafQVwehaRq/9ofarm2W4j3f6nIJP4VpCEVL2l9TGd7crR2Xwqv7rSdKdY4VZVG8iUZBNYPxN8QT63qDhEU3hP8ACOAOgAFdXcwS6TGLy3j/ANAuoigUKcxHuD7isDwpoS3Wtz39++wRJvEePvdxURcXUc5G9WN6SjE110K7vfCWm6Z4n1xNP01cOLSBfmc+rGvRPBXhTRNLii/siMgSAAuRliPrXE3eu6MLSWzbyvtt1GdsrpnmvSPg/FJ/YNiqRBpgv+tK8KKK/NyOT0OaDjG7XQ6W7b7JGqwRMsA5fbwR+fWs9r25EStciGRXOEdTgrXHfH/Wr/SbWDTLS4Kfal3kqSGYDgj8a8m8LXGqWniSxsoXuFW5kEZidyUw3t2IqKOF9pDnuHt0nax9BXcE13GDK+1QSrBRk+3Nc9can5E4sP3UsobOc/dFegaVpzaboM6ak43Fiyc5xgcYrgfFOji5P2qHyxdBhJJt4IHesKfK5eRvGfNsattcPBJCG4cLj5T8vsa4XVhF4X8S33iE2kl7HcQ7XHT6j27flUF34pm0dJoXgebZjLg4Az0roNH8RWt8Z7TU4/KlaAjaRuU+hxXQoSheVrombjLS+p5l4p16xmW0vkgmtreU7hGwAdeuc/nWv4H0/TtY066VXfzpJvME2MkkDgVyvxH+wzhLexVYWXlyg7DNbPwyn2WLLbh2UHKSEd+5rWrpS546Cw8b1fZy1PQNbtLWHThaWvzKjDg/xepP5V4Jq+q3HiLxzcysN8AY7fQBR0/SvWtce6S3ncyrJcXCGC3UcBUPG/61wOk2unaX58LXUL3rgxFVOSCepqMMrXk9Wa4pczjBaJC2elPL4cl1CCLzWjnxKuOD3Fa2oNf34jtLKzdVkiHz4P44ru/hLp1pLod1pd2cXbSCVVOMEV6TLqvhvRUW2vnt47gDnzh+laSxDg3FRuc8qasfM8Gn6jdvChtHj8rjy1BO706V0h8JPFHbyXVsRJjL7l4Fe0Xvjjw5Yw5tZbXzXGAYo+F+vFUNedbnRfPkKsVICMpyDmsq1epJaxsjbCRipany14yhmt9faKJSN2MAVraP4amvIvMlUg4Gdw6V3j6Kl7qEl7JFzFkpxnJrotE0p5A9zNGTDGOp4A/GiFflgkbywi53OT0OQtfD8dnZyWq8PIpLH0rg7yWXTNfsccvDIMY7jNen6hqtoNWEa3ySuDgiPkD2rir/AEZbzxe00bYtgwYA9sV0UpuLvPqc9aPNZQ6HdqRrCTeYiqyygRl+gHfmsizurzwxqVzNYMh8g/vLduhB6iuc1DxBNJez+Vu+zwfKpDdK2tOG+P7XM+Q1uU57nfgVm1KCTextFxqaRPUPDfiaw15VUf6PdBgro55/A1Q8Z+FbmG53xsVhPzB1I4715bcXIttQDQnD4yMd67WLVJDp6R3Ds0rjKDn5axjT5Wpw0NGuhsTeKp9G8FXdhFOZ2k/djd1QHvmvMCg+wQSXKoXQ8N/Efatq/V5bGZSDvJByaw7jxBp8INuto0hHU5yOO9bRWrstWZShGOr0LalpfCV5gnmWsLRYntXCsHafduUsMY5rrvD/ANn1XQbwWSlVIy4I71JbacwEe7CsMd+gqoz5G0Dpc9pGTr9552qB50BBUAg/SotYaDTtY0m9EQ+yYRyB0961dc0yOYK6D506+4qpLaR3ejRRygmKIkE/3OamLVk0Eoyu0yh4wto7addS0sB4Zn81JE+9E3p9K9s+FvjTQPE+h21pfXJt9RiASWF2C7yO4PpXjSJbaXLCWAAz0zkH8Kq6pFbjz7nS2hSUHzBGflbNKcVKHI7+T7GEqevNex9Z6r4Z0m70wQx28SL1BUDJ+prwbx34STQ79bhIo5rYkj51yRxXK+B/jHf6Bc+TrMdw9pnBUsWAH419D6Heab4pFveWksU1lJHvGOc57fhXPyVMM+Z6ozg01yt3PnLQwl1N5DKYrqBgAWXAK9vxr1HTI5bQKHH7oHqpyPrXSeNLfw9oOL6+ihQR8qQtcTofi63bU3+zxr/Z0n8Tn36itPaOtrBHTTcYRtJkPi2K4v7q6syCNkI2Fjxk1U8JNJ9m8zVfsVtCq7Eit8B2b3712V/p1rqrqt1IIAoCpKp4x6GrWj/DCytL5r1yWcjHmFsj8BTVeEYWloZzg1O7ZzMUDvdRPHkSP1BOai8YeI/7K0G6QYE7IUHtxW54liSz1mNYDuXAHyjHPrWN4h0+2urPyZ0AfBdpT24ryKklKbbWh9Iov6urM5L4X6hFZypCjbZA+QOxxXt7adYtZw6jGkaygDzBkd//AK9fKnhbUHtPEoku/ljBy34V6PdeNGuL9HsWZbWMfKrMSD9RXuV6MpyTifOU6sfZq/Qr/Ff7XN4raKwtDPLNGCBg8L059uK0vhl4Z1bRL1pdTtTaxXEe1QDkE5z+Fdx4N17TbqM3l7CEu3AHmFMgqBjH510gtZ9YCXdmrMqkhEYYB96zlVlGPs7Wt1EqaUudnMeNPEMOg6YGW2WZlAWIA4JNcNa+NtauI2uIo7Tb5fmGJlxj2zmvQde8PxJpF42v3HmhV37EABQj0rwzWl+z3IlmYpbMNsSuT835cZqqEKco7aiq1GnvodhreonUtLIhuLezmckSwmUAE+1ea39v4q0mZriEXIt92Vkj+ZR+Irp5tEHiHSLW0iuooZY8lFZCjEnsT3rmbSLxT4H1TYvn+QWG5RzFIPp0rSFovlT+TM6rcrNrTuj034Yavfa5pzaZr0he3Odm7AcMB15rZh0SaXVpILeTy2kjCJx1x2rzXxdrpt44Ly3j8p1wdqHaVz610Pww8XCfU7WefcVEm9AW+6e4rnqwkpe0WnkdNComnS6na+GvhTDrmsJJraSJBbEPtX5SSe2a9Yutc8PeErN7NbiC3eEBRFnn2zWR4q154NLttR0Nv3Vy3lyMuMoT0z6V5F41ZrYzCdGvruWJpXzgZI75pKMsRrN6djjlFbv7juvHsY8S6ZbahawCWVCQcDJaM9cVieEdGSLxdZ6hdRS+RZoSkITpIfWn/DmPUbbwZYXl6QjvKSkbtgiPHAA+td5oUR2GdFwzsd2e5NVKXsk4R2NFCM1exU17Vrm9nA2vGMHBYcCvOYdUlk12RZpJVjBw3p9c163qVuXsZtseQFJ+XtivKvH1vFbaY2oNFKBGAxji6kdzSw7i9C5S5UrHTJ4PsdetWuoJJbeaXkNHz06E15Z8QfCPiHw7qY1ATySW7jasycqn1HavZ/hBq0Oo+Ebea2UhQSuGHI56V1GpRRXMq28+yQTA/u2HGO9ZutOjUcd0TKKnqfId7dLeLNNLFJFNDFkMRxJ616D4IeO68HWM9tGI/KkcMF4+ma6b4l+E7DTvDF/NaxJFKHWVF28EA8iuL+GrtbR63boreQP3qIR04rSrNVKTceh0YRctVXM7x5qs+naZMlvGVvLmUQQY6hMfMR+grovhz8FFudLi1PxLftbTzjeIU5YfX0rH02wm1Tx1pJ1EhobdfNRPU56fWn/tAeM9X03xA2jadNNaW0USybozgyZAOPwq0pWjSpuzerfoc+IfvOpL5HfReEJ/B3iGHVtOuftVo48tz3A9x61zPxSklh1Rbl0+0F8bQTjePrXMfA3xVrF3rNxZX15Jd2EsJLiQ52HtzXouvXOnwyfZNXtxc27EbARymRkUWnRqpS10Ki1VpXWhymiQT3LvbQ2SRfaADsVdxj/HtXQ/EDxhpGi6Xb6FozxzXq4jcg5EWOv41w3jTUNViuWsbJXs7Jx96Lq/1xVDwn4DfUrg3L3C4i+Z3681vUUJJTqPRdP8zOmp8/LBanpPh3VbebT03JvZ/kXaO9c94pvvEPiOeTR9NR7axjbbKY12l/xrZ8J6HPqGqS2OnMyQ2yEvIvUD/Gsa81W90DxL9lhgP2cDLNnkjPU1z0VGU24rXoduJeihJ+pBF4HGhWSTzTbrleuWHFYG+70w6kJY3OYSQx5Kn617JpFtB4idJLl90Ua+YV6byORXG/EG6sbVjbxrlpDmQAcBaPbNtxlqyFSXQ8ahsomeIxyStKz/ADxg8V2stw1vBFahceUo3fWsy6jS0jW6VQjOflXv7GrGnObyQRr82QAPUmtas+fVBhqSpvle5La273N2kjxnywcluwNdhHHIihUygC9T1xXqHw38Gada6Is+pQLJK/8Az16Ae1b/AIg8FWeo2RKKtvKgyrIOPxrilXSduhq8RTjJxZ86+Jp3tLJ1Gd2zgVwWl6Lc6tfRtFMyZ/gQZzXqXxJ0x7cnfHsdBg9siuY0G6msopUtBGoWMvgLg5+tddGdouSMsRT9pJLobWiWo8Jt5NzJmSZ0YqecDFdDqltbxP58k4jjdd6nsPauHs4bjUJftV2xOT1PauzbRl1nRyLZ0eKAhnOfu8VnVWvNLc2pyUY2XQ52EXBSaFHDB+M+orOjeWC2kiII3Nhven2F3cQX/lIY5HyQEPWtrTLBtQiYqhB3EnI6VdpU3d7EqcaqsnqZutaNPd6el3YwM8UajcV5x9RXP2Vhsv2urnMrDhUY4ArvLLUG0a4P2aYjs8ZHBq1qV94Z1WDzdRtHtZOAZoug+oq4VmtLaGFbD/aOGudHuLiwnmhtFIDENEy5BHrWd8MvFM3hfXJIo7p4bdyQ0LH5Qfavc7bUPDd5a/ZdMuLYqygbQ2Ca8p8WfD+G21Z5YlMUIfLJ3IqI1lzOMlZMz9i2lKOrRpfEq21bxGsbWRlkspI/M3E5DN6Vzlt4U8RQwpcx28ojWP5sgjH4d67Dw9FqGk2C3mkXhS26tFN0GPUV6t8O/HOn+I82l3EsN5bfMZAMo/8AhS9rKnFqmrpBUpu/PI8w8PaxcTaNFBdxSABjHudcZFdX4ZbVobabN9O1kDlVbtXUfFOOwv8ARYjYxxyvFMDI8WAI17k1DDNDPoEb20kcsbIAWQ8Vx1a14uSVr9DvwqVTl5kc9qEam7SZ2JyvAPavP/idq2p6dPaLbOqW7xb2PGepz/KvQb2E/bLaFgSUIfjuKyfit4WfWtFiurCIebao3mD1H+NcdHl57z2PTxspKklT3PFbOybVNSuPLAG0kY9TWjpWnX2nzyveKfskRBZv4fatHS7TT9Mikv7uUi4Vf9UD95jUfjXVX1jR9LsbONo5LhnklUd+w/lX0PNK9o7bHzcoKKu9zX0Lxk95LHaaXDl92AqjOa+gPBmtwaLokdp4guYLe+QbhGzDcVPIr538MaJe+CNKOorChvZCAhlXG3Pfmsa/vLuTVVvtYvZ5J5ictnOT9KylRjWfKtF+oqk3yJT3Pol508Ua9fF4XltioQRdAVx1BrivF3wz1CNo5NHkNxbI/mC3ueSvt9K634TeMtOk0dFvoit8nyM6rkMOoNM8ffEKzMgi0mJ5LmEFmJOB/wDXrD97CpywVrDbT0a0PLNP0vxGdSnNxZJHF5/m4iOfLA7D8qn8Ualq19c+TFaTpGi8DGSKmstZu9VllmjuLiMyMQQvy5/AVjZ1jVfE9vpWnTSozZYux6AdSfSuhxbfvW0DmjCOhlr4vsrmIW2u6TE7Ipidim1nHv6GszRNPsBqXmeHdSAi3ZFtMcSA+gPeuiv006xuBcamEvt9wYmt2++QO4Ip/jL4fWZt/wC1tC8+xgIyu7lQf9r0qZKMd1ZMmPNfmWrR2uhaww0O/wBOmDRvIBhW4KMKYmjPOI9T+yzTXE0Xlhw5IiJ4IxXnGh63qOno0Wqw+fECP3rHLY+vcVqS+NNU8J3UN1bEXWkTNv2sfunNZxvCXKnudNRxqR9o1buel38N2y2wmVoUQYSLHPtXQ6FqxstJT7U5CIcb/U+laHh/VdF8e6FHqekyI0iKPMhJw0bY6Vk/Y2mi+yhAiLIHC+mD0qOdS9yas0RC0ldGiupz+fvEx+zMeFYcmsbXtMgmlF8YWkRR88YbnPsPStCJp77dDdIIreByvAwT71avZ7SG2eTzkUL0bPU0X5HoPl5lqQeGEGk2rSxQeTbhC7RbsH/9dcRqHxNj/wCEiDafBcvJGMsoA24/Gu+01P7QTecyq2fNyfbHFcQkmheFdU1TSvFkGLWceZa3ew79g6JkelOKi5NtXfYmbcUrF3xr4qsvEHge/aElJfLA8txhgcjisfwrpiwWQvLVsie3SOQDoHA6flWfdadc+NtXe90S3+xaY0eF3DBkwOuK6PwlZR2VgUSbfG8n645rOvy06bjHfsdmAi5TTaPNvGfiQaF4iszZH/UShzkce4r0m407wt8WtOtprxorLUY4whk3Yk+g7EV5F8TtLmn1eR40BOSoHpz6VX8E6brF0ZLa1eWGSA+YGU4xXQqcZUYyvZrqcVVydWUZLQ90sPDXgn4W6PPfz3CTOq5CyEFpGHQYrwnxx42k1K8huC2zzGLso6AHp/Ouf8cRaxaajEmsTSOr/MhySGFLP4fbUbuGO3aPIiDHccAD3NOnTjCSnKXM31MrzlGUYo7TwzrN3qWIrhRdW6AFfM659BXqmiTC18PXcMaxQkc7QuGOa888AaM1nD50zr8hxkH5cD3rsLUSvDqM5kO3rk9K58bOMm4x2PWwFJqKlPc7f4NWM9rYX09zB5Uly28s3XbzivHPindMnjPUJbWQtDGuwFeg9q6nxH471DT4U0fTpmiEiqskw6jI7V5zGBqFxeWd6Zw0ThxIo5cnp9a2wlGSk6kjz8Q71Ge2fDawuIfCA1B03u8IZFJxwe+fbrXjXjnWP7R8QTRRNmONsbgPvEV6z4q19/DXw+0/SonjivvKRXUnpxXgcYHml5zy5/hNZU1zVJT6dDW8uXUpatfSSXIALOi8bhXp3wn0cR6la3V9Gdsg+RdvGTXB21tDNewQwACME7ge9e9+CI4xpyliAYwAueOnpW1WSUEkOlB8zkz2dLVFs4444wVUDaPSppp0hsnkmYKqrlie1Y+leIbWS0AlbEqDDAnk15v8XfGF0+niz01SkLH94w6kelefGm5y5UcXsKjdpLRHM/FPUILq2knV96buABj/AD0rgNEuLS+uTawxSB3wHweB703xLq5k002wb92i7iPesD4cmRNUnn6KFzuxyc9q9CnRcU/I7Z1knGNj2m38MQWfg3ULx2/1SFhivNbLWNQ0y/fTLI5hu0AeMd+elerjXbbUPCd9pEKut7PESikfeIPT9K8si0u//teK4WIrcQkZBU5GDV0Lpy9oc9W837pt31rb2y21z8sl8q4JC4Ye1bfw41o2ul3wu9NaaJjvXzCFIGTmutuLKxubFL+6twJfLBdQPb261xd8y3WoXEEHk7V/drCWI2DHX3rNVPaJwaKceVqRa1Xw1b+Jbcz6Vc/ZZ852KcgDtzXB634d8QaREJ7q3e4sWO0yIPlI6V6Z4Lt0iv7u3laOOXaDsjzis3Utc1XXtdfw7pTPDpyMFmlVOTjrj8aFzKTitt9S5Tur9TxbUUuNOm+06d5gj4bI/gNdPY/FE3lh5GpDzbxMYmkHXFepa98MXtdOS6sZGkjZf3iyDkH3r5/8a+HBpd4XijZQRuK+hpxqQrPllrYzkpU17Sn8z2C91SC+8Bt9hcS3ZjDOqnpzWr+zkEj1C+kuUAMuE2svfvXzz4c128053jgkLIwKtGfQ16r8LPE9vY6mgurgW8Mrcyv91T74q5UrQlFdSfaKrqe4fGiS20HwRql7Coi3xGMhRwxbgV498EdVnbQbm3nLhZHPl7uhr1P4iyWHinwUbB9QtZ0LoxnVsAf41ynh3Rn0/T4LdjHLs+4U/ujpXmKShSlGW7Z2YGMnUi29EdEEMt/tUAfJjnvxV3wrPcXunajaT2hESB0Mp5DnHpVGEGK8tpTwRlDW74duktotXgYbVlQyISOOnIrit7kvRnrY7mUFbyPlOxA1/X7wxk/ZocyjnjrgV1gmTRrqG7ltWKoo8o446Vz3hSBbG0eM5E90wyD3RecfnXs81zoWq+F40lETJsxJGJArIR1Ir6KUmmkldHgQj7l38TOLufiGdd0k2V7YvNbquNx+/GfUGuW/sPUtqzxOrxnBjLdcV0fhvQtDvb65hilvFcnCYwVP1r1nw74BR4BG6fK4GCf4R2pVK0KGkVYmFHmXNVZ5r4EiksrwBnKFmG51XkcEHj0rsNW8GW87CeAtIGHVflPSvUNP8EQWMLJbmIO38TLkiqtv4JnhvTO99Iw5AHtXFLEXfNexoqtJKyZ5HZRQ6Rcoix/v92AJOTVHxRLZ2Ny8gT7PqsowGt+OPevWr3QItPlkjW2SZXBKuyZKn615d8QdHaKfz7eIpKrZDA9H+npWtOqpSuwkuaOiOFsZ9OtNeWTVUa4uM7huJyp/3TXq/h+LTtdhmjOo3EVrcjDLsyD2IryuVTrsoh16KO2vImzHcRrgtjtXoPgu0lNldTwrKsKkbImGCSB1/Gt6sVKN2zOk2ny20PPPFPhrVfAGoP8AMLzR5mIikIzj/DrVLS7nTtUEln5iqso+eCT19VNfSMX2W/0h7XU7RH4wFlTOOOtfLnxB8IX/AIf1+5VkKx53xPF0A7VhC1VuE9+43KVF3jquxtWFi3hJ2udMvJ4LonKFDhRjsfWvVfB3xDtPEX7u7kSDUEHKkY8w+1ePeG9UbUYnstXGPl+SUjrWF4g0i80m8W8sjJBIh3KV7HsRVJcz5Kr16M0m+WKqUlp+R9NeIZo57ESLIwRBl0T72O9eeWutajqUk11o0USWNpwwueQfc1yvhP4rPdTJa+KZHV87TNGoGfrWrJBbWkl5H4d1K1ntp8MVeUKT7c9aunHk0n/wDKVTnScGdX4M8cm11trK9aNorj5Y3jzgvWr8S2kuZIbuKOK4hVSFL9I/WvPLXT4ry9hu7qeK1EJ+UCQZzXX6RrEUVjdpsluNwALPgY596Jxjzc8ehdNSkrSPQrC4tD8PrSPTJIlu/suSgXBEmOSa47w9aXFhpNily2XAeRj7kmnaFcSy6TcXhiK+ZiMHGMDPQUmrarJG8cCW+dyZGOwrza9+ZpdWevgaSpq5yXiDRrzWfFWm2Vv80lw3mMScYTrkn6VY+MPiGy8Fppuj6EVhui4e5ZUyQM9j+dbum3y2PiPw5qiqoQobeUHsOmTWV+0H8Nr3WtSh17QYTOjgCaKMZI/2h7V0xmlKClolf7/M8rFqSk3HqYHxN0tbuHTLmKfz9N8vzY5GTBztztrh/h3MbzXLiKYllaBlr1rw3oS6j4b/ALJv5XBhUnYewx2rzD4ZWTW/jyS1WMhd0g59BV0ql1OL6A6TU4Nddz1bwzZRvpy5dfKi5EQqPxpcTWvhqS3s0xNICzbR2rfs7OAXavHGkW47eOAfU1wnxH8UNaWjW9qy+Yxw23qRXLG9Wskj2KtqOHd9Lnn0+tw3FzaRXUjxyIdjZ6Ee9ehzeJfDPhOwiu7dZtT1HbujL/LGrevqa8r03S1urh7q+kihgDZwTgtV+70+K9VZ7uTZbocIBxuFerUcZaXt3sfPwU+Vsp3PiDU/EupzX187bGYnHY+1NWyvL+63hWWNTjA44qrb3rz6itrpsDNBu2jC54r07R9D1KW2SOKxm3zMAuUIBo/hraxVOPtdG7mJomn/AGHUUDgngZJ7V6sZGtbBQkmN3B7Yp2h+FbrTr5ZNVsxll4yM1oeIIBLKIooWkBxhUH6VyVai0tqehSj0vYqxaXJdac1yLycyqMjb0rjPFN7KI0t5LwMjjGSOQRWp428QXHhSSGy0hf8ASZEDSRn5wvt9a81m1+TVZN16FEyP/CMVpGMpL2j2MPbRcuRMzr4SPI8ABLytt69RXo+l6NJofgIz/ZgbppYmXj5jXN6PbRXfia13jOMfLXpPxS1K20y/sNFvnNvBcRJOJV4wR2qvaNuMEt/0Iq01C7ZiaLdX2u3lmml2jWrWD7Z2l4ZyD0FeqS6fbeR9puUEbEfvD0/Osj4frofkoNMdZriTncxJJJ6mvQTo1jJbyR6k25nGWQNgfhWGIn71rWsRCSprU8M8W/EaG3vf7M8PKzpB8r3AGM+wzXlur32p3F9mB5ohK4lDKc8/UV6n448FaNp3iRWhuZYbeb52CgHFdnpHhHwrpljZ3emH7VN13O+/aPp2reFWnTgpRi9TKUXN2bOa+HMOpRxT3t75n2i4AySPmA9cV6Laz6BpzILm9giuQu5g3Bz6k1HGIl2bQg2jJIPWuD8feGl1O/S5sgTcpgNEOBIKwdqs/e0ubtWjaJ30HjbRpRLbR3LSoc5wOPpXnXxW8Ltc6ZHeWkXzJkhfVTzWlpegXV0iNe28dtFCckIAHfH0rrLiCLVNIkgjkw6r8oz1NTKEabUqbHDaz6nyBc6VJDcho0AfPIxXoHgnRRqKFLgRxOBhVU9frVnxnZppt/idljm25245xXKad4sNjdrJCoCIefmxmupTlUXKiPZ06MuZs7jWvCWoaVaPcWBZW5ZUzwcelN8E+MGN3FY3+5bgHCu3f2NW5/H6+KtPS1aZlnXHyMQMAe9Fl4fj1eRrlLbbcx87lOAw9awd1FxrI6aUrzUqbsej3DPNaEREAk9alRlGlSs5O4RkcfSq9nbS29sqSkEhQasJcxWVjcB8fMhBBOO3avGl7ql6Hvz9+CsjwCxWS912RrWMsIgeF7V0Wj+Hbi81iOK5+QyEADHAyazvDl82kSSTxjyw0w3FlBwPxr1n7WLrXdNt4hANoDswHzEdq+icpQSUVpY+bhCMrt7naeBvAFhpEzug34A3Z/vV6PHEkYG1QMcDFU9JRIbCJQNvy5+taGa8mcm3dnnV6jlK3RETQgjAJHvmmPL5aYl4PrU+cnimXESzR7G/P0qfUyT7kYWOQfMAQa5rxN4fhuo8bBgn73pVx4Lj7bsDt5cfO31rcQCaACQdRyKe2p08zotSTujytvB0UKLKfLmeLk/L0qeIR434SJRzgdxXaalBcQ28sdtGpQg/N3ry/VkuRA8NvcGKcfKehDDvn0+tb03zaM7YT9orkepapO95Ilu6K2epU4x7e9cpfNd6lfSW08zsZ/liDAFG4PXP8q6G+vrKDTGe6uIo5FXAY87fX61yvn22vyRQ20lwshbKMR5Yk9weMV0w32FNWVrmLd+GZtIeRljikjGJCiDgnuOelXtPNlr1q0LJtcrtMb/0rsfCvhiaG/nsp4iElGJfNPmcVyWveGdR8GeK0mlxJps03yyJ2qKqjUfKnr0NsPU9m1GWzOS8QeCbN45SA8Fwi/ImM78ehry69t5ftH2e1MmFPJPGK+vbO1tryBDcrG8LrvXcOQfasG/8B6KyTmKWO3DHJcKCR71nSxvLpNDxOWKTvTdjzv4YeFpzaW098kv7x9wmcfKqj09TXpvjHVfCFnYLp8d1D58IyHjGSW4zwO9c3reu2Nr4fg0Wy1KN5YwYlkU7RsJ7elYPh34cyXM4uzL9qRCGPlc5+tXOpzPmndGUKDSSi7nofhnU31DSYV+ztHZRnKbhgufU1YvI7e4lkPHmLjAFcX4g+IFtpUkmnW8ZElt+72BcKDXL2Pi/UrjUVZW5lYKVxxjNckqFWo3NKyPYpYmhSShe76nsEGnxSxquQEVvMyemK27nUdRghElhcx741/49nXKyY9D1FcVo2rCVHQudwOGUc4rbknLxrGGxnqehrm9q1a51TwkanTQs6hZxazpkmqWUT2d+g2yxqOD6msbwx4NW11BtSYRhh6Dnn1rtvDdhFbaY0Mblkk65681JqhFnYvFCAF4BPcmtZT0fLscFNcs/ZpdTk9RuFtpSkQAjRcGvG/GgsraeSaVN88hyi54/H2r0fW71IoLiaZtsYBrw7xZqStcebI6vM5xGo/gX1rTAKUptl5vKNOCiynDIkdw817KoI5EXb6V1Wn6Fe+NIoks8xW0YBmYngD0Fcl4M0JvEniCC3aXajPl2boB3NfRAu9E0Kyg0TQwrTP8A61geo9TXqVZcrVleX5HhUE5p32N34ceAvD+j2ULDZJd4++eor0OwlsVTy0YGeJsIvf61zmnSW3kxpBsl+XkqQcVcghiW8R41VG9c9K4Jpyd5HQ4K1kW9auGuYCsmEkOcMvUGvH9YubyG5ksrxyx3fK6nmvWi+642MhYFvm461xvjPQ2spHvHMXlb/Mdm4wKulZOz6jTUVZaHiF1YXljdyXBSV5mJ2OzbttchJMzar5eNp7jpgV3/AIl1M6lqE39ngR2se7D5IBrg9Ps5ZNUZn+dsMc13xcuX3zllGPOuQ6/wvMLfWY7snEcLK5+g613/AMaba38Rav4c1C4kMdhJFsVFU+a465x6Vw/gbSZNT1g6ap2+YpAx24rrfFniMXvh3Qikax6lZgwOccIV4xWahecXHp+TKrPuej+A7bR7fw99j0CeKSTdtZ2Uh1/2SD0rrINN8mfLtuIGVJNeL6XI+k32gX66pFNNqb4ubePjy8Dg5r1W31C9muo44I3nRhxIvbH86560HF3i9wpu6OQ+IuiXqSzXNtCJ7eRDuweVPb61Q8K2t4Cbt4GtweFjOMAd6u+NdVvotUEOyZsfNjYQtUPDmp3VzLYW0paJ9xz1+5zW9PmdLUlJKZq+Itbl0eyRoiruzFAmORXJXXjS90y/jgkuyt3cOAqeTkHj19K1PiZBd2L6fcx4FtG/77Iz17muHtdck1PX51exS4eQeXbSKuG+o9KqlCMo81riqSd7HqPh3Xp9Utrn7ZIIZFkIOOfwrT0hxbnAPDE4CtyBnvXE+CbNpLGc3JeGRpXjfcORXVaHbvM80clyJDHwnHSs6sEr2NKcrrU4n476WZI7S4hjzIFKO+O3Wvmy5d1umg5U5xX2T4lsBqugy2t2MPyVKivnPxL4Vt7DVg1wzBSRkqKMPUUVyMzxFCU/eiczoqzyahAkGcqcZA6mvV9P8RX+iTQbG5j4aLHDDvXEaV9msNRHks8cqvgBz39a9N0e10/UozBes3nODibsK0r1FZXWhphKbV0nqeh6Ld/23aR3oTZvG0Kp4Ark/FU11FIqhT5YYoTznNaXg9pdIsDb3Bx5D8H1FdFrNrbXOny3CKJAFyncZxXiVmoOUo7H0MLuKi+p4BPau+pwQyMVEzRliT2PXivV/DmP+E5Rk2yQiMAMOmMVw/jPVYrbQrIRRK1y0Z+cDnJ4xmum+GF1GfCtlJdP5N8s5C+4717spOVJP5HgRSVVxPpW0AMUeBhQvFTMHYED86yPDd0J9OQA5YetbaN7V5MlZ2PPqpxm0QRCZZmVyGQ8gjjFWqKPaoMm7lO6QCVWBwT1FTw4AwDSyRK4JIycYrOicJcjJIwcdKpao0S5427FvUU32zAAn2FeQ+LEWK9CSoyMB1B617Ofu14r8QZFbWGRjgA/XtWlH4jrwUt0zgfF9u00Mot94hBG5GOSfWuWv76/W9gi06eNIrUgK5HzFT1Fa2raojap9nuZ2W2A5ZuAaTT9GSSzhdI2CXRIO085zxXp0vdjdl1UpTsj13wZr1tc3cCuvmXfl4IRepxXIePLzVbM3S6vZXS2byoVbyz5SjPrXffDHw1H4XsxPdv9p1C4Hyk/wr6Cuw1ezn1bTp7WZIvs8q7WDLnIrhnNRqXS0H7Xle3zPKvDAttX0eSO2mkO1SUPvjpWH4i8QW2l2Z066dUAIQyE/MuRzj1rpLbTF8JuZLJNsauQy9q8N+Lfn3Xih5ixKMAylB8pNRSpxq1Wuh6VetOFJS7lPWfDuo3GorLp6farYYAkg53A+vpXrnwu07VdH06VNQLQrJ0XPIFcz8OdJv3sDcRyKhIysbtjNdrpV+JLs2t1GUmHQY60YjEyb9g9jXDYKCj7dPfocT4q+Gdzq+tzXmlukhlPzKxwfrXPnQZ/C6XU+qLHvgOI4WOMsehr27Rne11qQtlRsyENc78RLO18QXU8LrnMYAKjlW9ayjWlZQk/dFUwqU3KC1av8zyHwT4jujrEdsXzEz4K+mTXstyphkTnCr0+leZ+DfBbWuqid2VljbIAHJNXfFPjUaP4iNpJGxhjf53J6ewq8XSjXklQWptl9eeFh/tT0ueu6Jqqj9wVZXUZU9quazM0tq0jjbtWuO8OaomoJBc2p3xP0PrW/qUxljuE6BmWNQe1cGtrS3R3SpR9opx6nnHjq4/4l8lvCpaaUYRRXkWo6bb2zbr2ffePgCJedn1Nen/FO9fRQ/kkCWSPykPdQepryzw1ai93GTLyqwOTXsZfDlo8x8/m1T2mJ5DX055tAjjntwfPlOcqMlK1tDu7kX03m2zCeUcnPPPfFek68fD/AIf8MaeRatJqcsAVWHJY45FeRyeInOtSTqBFJGMhSMAH0rspS9qnoefP93JWZ6l4Ui1MTs0EhVmwCjdMV7RoaWVnozC9nDz8r833s+mK8v8ACl7dazY29w9lNCCo3EjGfpXTxWiaSZdSntZ7hiuEGTIy/hXNWXNozpaurpmtJqrw6sIDg/KWLZ4/Gsn4nx3GseEp1tsCQgbtvYZrz86tq2qeKftNrZPFZldnlMeSfpXq2m+FNbvPDc0U99b2r3HPEZYhfTOaU6Spcsm9TJ1IvfRHK3Pg/SF+FhkluhNNHb5LgDhhXzlLeG0iMcIALfKD04r6Qv8AwlZaP4c1AXOsPJLFGconCk9uK+XdTR5JtwYhQx5rWk1OUtbq5D/drQ9q+AkEcuvy3krALb27SN+A5qDwYbTXNc1jTry3lZZCZlZeCrGuA03W7rR7Bv7NlaM3ERjc55x6Vt/CHxxb6N4xH9s7hbT4QyAZIq4U2+eS7fkKrNKSueg6X4WsdE1BrqRmeC2JIDDG4ntk1JrXjHxLpa2d3D9litw+IYlH3h3zXqfjm106/wDBsz2LRuroHiVCPnPtXzrrX2N9FfzvtA1IvjEuR5YA7VlQkqus913Ccrr3T3Pwx470vxJYxNr9olrchjHkcgn2rV120sIohLpqRsxwFIH3a+ftJ0axhNldz3hltmQnyFPO/HrXpvw3t9QKTOjXUmnFR5IkJPPc89qVTDwheUXa3QKctTpNZUTwSpNCWKjIY9D+Fc3oujRxLcXzWqwyFBtxwR7j3rq5ZLhLiJL6Dy0fhSOckVlXmqaZHLPbT3KBsbVUHHOehrGF9kdDascc+m363I+zpLBCpLiUDk+ta/hxPsYaSeZnRmyZOjEntW4lrD/Zw2rLIq9SBgZNcF4kS4eV49MimmmibLbSa3jPn90lpR949GkuohDIzK3IwQRk15T8RbSGfRnviOIpSCcfpTNGk1H7anmNcL5sgRw5wAfrXV+LdAn1PRblYZQWY4dGPAOOKznTVJp3NIVOaLR4m2jSXWntq9jiYRAeYg6getdB4NZ5EZJVcFW4Vuv1rmfCF9PY6w1nKjLGSYnDZAOT0Ne2aL4WthJBdQ+Ym0AYPQ5q8RPkjyvrsVg4c0udfMtXVtLF4f8AOnH7xYdynPUe9ZHwq1S5vfBepi7JwrusZYdBzXWeLdx0OO0sVH3TGz+/pWLp0Qs/DDxRIkbgEbRxxjn8a8erO1Kem57NOm6k4vov8zy2DRzrNubkzCOK2jyWJzg9uK1/CWqRf2e9jdqBPG7SQSLxu9f5Vn/C60vPEOmXdnacTBeR7DvUth4J8RaZrSF7YvBA+/djgjNe9CyTpzex4U5e+qkFue7/AA91z5FR5Nyk4z6V6nEVZQynIIr5zhnk0OcXdsweCU58pT92vXfCPiVL+3iz8pZc4rgrU38SIxNH2nvR3O0+lAIPSmqwIyDxSk4Fcp5gHp6Vi6jCS6hH5Zh071rOwA61XECi484noOKqOhrSlyO4OWggKtJtwvB9K8D+IV2JLmWSQjzkbCEV6F8S/EMVnbrHEw80AglT0rxKG6+2vLcXK7skgAnOAO9dNCD+I78PBQjeW7OaQG/1EWzsojR037ky7ZPOPTHrXUeFEt4/iQNFlukeCBgy/OcDPT+dY91dPaaTq39nWS3E14AizF8GJehxW/8ACDwbdXN28915Szy/K/mdceg9a7rpRdzP3ue59Cy6XIl6lxCwZFVUCdgBWv5wEe1Fxx+VUPD+nz6ahhlmaZQBhmPT2q3N5gnwOIzzn0ry5O7tuYN8zs9TzP4guQssEakvtMjEdq4iNrW60i382CJ7mInO4ZyK9C+IhR7GXySFYkksfTvXmnh+Dz4oreKcCR3IyegFctTm15T6zA8jpL2hvSNo91YRJbMtneIueOAW9qxpjN9pinkbEqH73rTPFugtpa73k+TGcjpWFpt07/upH3RN0Oc4rjqSne7PVw6pctou6PRBqSXWDnypfLb5h64rw6LxDfaZ4juJZXmMgk/1T/1r1HT4wCkUh+avP/iZFGviSR5CBKwByB1wOK9TLKilJwktzxc5oeyUalN2sXNO8TX1jfK8mXjm+ZXK8bs9vTrWt8UPBT69oNtrmmxD7c6Azqv8fv8AWsXwpBcazpK2Wn20kk5mwWHReQcmvbbuyOl+F44L1lXbCVZl9+tdle1Jpw0a/I8yk/bLlqO6Z5p8NbKfS9PS2uiQ5cFY/wC70rs9SmaKVnOSqXCg+1Ymk3cE1/ZTwAYQbDjuRW1qciyWV84QgNJGee1eVUk5Tcpbn0VOChCMY7WOD+M2k/bPEIELKLWC23u5PAGM5rzTwQXW/eRQFVR8oI6k9K9K+JU3m2yxA5lnQDOey1594egKeJraw3jaSHJ7V7GEd6Fj5nGQ5MRqdBqjQu8cOqakLaSFcIzAsyk88AV2fwr8EeEr+8l1C9un1JocHypE2Dd7+tefa7pT6tqzCBVeSRiUBbt0rs/AF0fCX2iPWyyK2CxUDIXHH1rolF+ztF6nJbmndrQ9g0qdpNZliiijisY1xHFgetdSbYGL5TwK4LSNQtrmeDUtMl3wZ2sCMFPSu8a4aaICEZZuoFefVha2h0PpYg0m2tYbiaOcRpI/I3KBuzWtsuJC8EEgWNeMkZxWTNbLvyxZW28Hr+Fczq+p6noFy0+nz7wQS8VyPl/OpUOd6GcoN6o5z4w6Rf6bp8kxZLiF+S+MFD7CvnG7WP8Asq8LLl0cHP1r6F8WeIL/AMW+GbwXEcMBhTkITgn8a+bL6d5bCWOPqWC8e1ddJSUeWW4Sb5fe3LAITQI5XXodvI9T1rY8K+Ef+EhkMy+ZhMFigyQPwrPe1k/4R29MYLxW3lo+Oxwa7z4E6pP5skEP3BHkgjGRnpXTG8YScd0ZNKVRXNDxPq95oz2drE8sENvCEB5GK6vw0dG8e+HvLvQy30TElom27x7cVJ8Q9OTUdOkcKBNGD8uOorC+Elnc2uoSh1MCxnP3eT7CsY2nTbejRtJOMrdD2bwz8MNB0aFXS28ycry8nzYrsrKzhs7NE8tIxGMcdAKx7bxbpAiVJ7oRSqMFXBBzXDfE34hRQ2JsNJheeef5VboK4HGpUlZnNy1JaPRFv4jeKLS2tJ0t2VpIkLZj5x05/LNeEgTa9q4j0i7hW0STzmSYZZfXJPaoruxvmP2g3cV3fPII3h8zdsX2Ar0iDwNaasxZbM2by4VjEcYGORxXoQUKEdy+Vy0XQxrPxDPZxx2MNzHcwyAlyj58sg4wD6Vgy3esQyXgsi5iebfwCdprs/EvgrTNIsB9lYJbQqS5IC49ea5mw0zVZp4H06R2h2+ZH5n/AC0Ht604zjK8kW00kmW/D6Xt/b28cpnUxn5i2Rn3rungMtoXgLPsAyoOMisfQdKujIsdzFcR3WSQDINp/TiulRJoCWiUpzyrDAOKxrSvoa0dDwTV9XtdP8azxRWKyWyyjcSPu+or2Tw5e/adPjS1H+pIfHfaa5vW/h/b6vfajPbBkv7mQyKsfIz9K6fQPD97olkZph88ZC+WfTFY13B01bc6sI5RqNS6mpqKrFp0b7QF3ZrCtvLmtb15MgRxs3Hqa0NXu2m094I/ugbselZekypbW920sbETptXHavHq639GfQ0ouNJ97nnf7O8dyItWksHK3UcRK8ZJqzefELxGNee2u1ItgPL2JHjcR1J96z/gTq0+kass1pB53mfupYz3HrXrEtrapd315cW0fn3Dkglc+Wp7Zr6Oo1Gq243ufJQjJwTT2POjepfa0rwS7Ish/KlGA3r1rrotcOnJA9grr8wBUr09cVQvNIEHmT29sDGpDky4GPYVJpxvb1Z1khTzYxvAI4onaytsaQffc9k8K+LLe/sY8nLDgnIyPqK6iG9t5RlJV+ma+Qbm81HT9ZkdbpUTIGxOpY10cPj/AFHSoo/LlWRcZbJ5Fc08JtbqYSo06l2tD6ceaNgeMqB1rk/FviOx023xM4d8cJu6V52vj+51TRwLV1Nwy/dz/SvNfEfi+dr+OyljEkvpuwPzqIYaTdhwoxpe9JnWeIPEC6pdhZiEhU4Cxr1rD1+cNpNxBos0bSlcunR19ay/CerWGoSCyvYVDZPAfjI7Vi6xOIdWaS3k8pA+Dz+ea640lHQt1eZeQmk3tzk2RuGu7iXGEMf3c9ea+n/hrbva6DAuoW0QnUfezk4/pXO/A7wtaNZNrl1CjzTcQkrwq+o969dFrCGJ8pcn0Fc2IxCfupHPOcabcNyVGBjDDgY71BdxpLBIhJGVI+U1Y2gDgVm6/qEem6dNPKwUYwM+tcexz04uU0o7s8K+I93LpFhcWMc0s91O3GTnaDXlHiQnT4IZLPUJoNQjX7kchwfX8a7zxzrkN5qA2ASFeWavF9evrmTVnEx24Py8ZrTCzU526n0WNg6NKN+p6DeePrfXPBVto1y7SasSAGXr17+9angLTJILmSC9jchMOobua5zwt4PhlmtNRl3KjlZJCOx74r1p9W062LAxkDAUHuMVOKq0bckN+vqdWAw+IX7ya/4Yy2k+x3+90+VWzzx0Ncr8UtIlu7qPVltpY7IptzjOTXpGp2gudOt5NqtET9/vitjxvDL/AMIbbjR0R5Ao2rjPHtU4aShJSW4ZhLnioy2ON+EN1p2iafsupFW7dixUAkqnqQOlbfx71WLT/BDRpIBNduI4ip7dSfyrjvAsVzc28lpHIlvqDykncuenYisr9oC9leLRdGPLWSkyMoxyeg/ICvSlRUq8X1ueDOclT0K3wxhuoGulkyYgysrEdM9K9O1GNpdP1KNV2syrMo9cdaseGtLhuvAVhdQxBJ7q0Qt/vKMVYmPmQvuXEhtj+e2vNxrvWkz38vqfuIrsefWxstQupotSiD4gKxNnlT7fpXB6Jpc158Sb+KzKj7LGeWPA6Cu0jVVu7a5GQmSrCuN1Ga50S+1N7dTHNdOIyVHzY4PFdeBlzRst1ocOa0+WpzdNz13w/wCFNJtS11Lfh75QMImAo+tM8YaIs8MDJEJHDYBX075rzzSYNR36Rf25e3ju5RA0LHPmc8nmvaLHRiLE+dcusw5+XtXRNezkpXucMGpxM3w5olut7vIKRKmVC/IGPpXpWnqq24kO7p+WK5FrSPRdMa6llDQMNuSOck8VzJ1W9uLloob+SKJymcnj0rOSdZ6MbVkd9DrttJPM0smBG5AAFc1r+p2mqXqRwPHMFbc+4/dH0rC8XX66FYzxWcnnTqPnlY9Se3Fcl4Xsrqy0zUNYu9pEw8qHP8bnmnCjG3Ohc1nY3te1C3h0vUILURyhhyQa8E0S1EsE0spABmIXPoOtekavNPpmjTXt88Uu9GVQvykZHHHsa8ysJ2jto48hVVHkP41ai481vIUpKTVz0L4P6SNe0XWYZY/Ma5nI2+vH/wBevRvAfgmLwvBdSjmcYJJ7A9q4/wDZ3mKafqEkfEkU6n32kYNe5QRhkcqwkWX7yt2H9aitOUZNIdKK5UzntMMd1LezX8UcqRKFTcRtX3pml6nYeVdG18tmX7joeAe9cJ8UdRbw9G1tHKVW5zIe205xisn4fyOpDW8okjZS0vPGOtXGjzQc7ilVSnymV4lv7zU9ca0tFuLm+uJsbRwFx1xWsNbayS40rW4/PEafuWl/1sT+hPcVJLHdWWvHVbKASpMcBAfmweuK6DRvDMus6s19qum7IDH5MVs7evVifWt5SiopPb9TDlk5XR53bXt1DKVtp/35jLBbdACORivdvAGtXF74at3klEdw6/MhABODgn2rz26+GY0vVpG03UZVecECIAHaAeOTVLSdfm0TWYNKa0nIjQozocsfQ1M+StC0QjzQfvHoHjSGDU7O50q6nIhdl8wr1x3wa5LSdYfw9qUlvJqVu9jZQ+XbseHxjj+ldnZRNdaYssMccgQH7/XJ61ieItHVYhqP2VIREdv3QS5xWMGo+6zWcb6mP4Y8WX8Ws3d7K9zqCkEAMAMHHHNdfoOtT6uj/bUBKHBRTjaa8x0/V9MstTjlv7OVRkqJ1GAfqO1drot/GklxPZSkR3OEWIL3rSpBNXsTSlqdnorC11iC7Lny84YjnAPauw19re4sC8LKy5wxHfiuK8KaTqeqzm4nAgteRx3I9q7fW4YLDQTGg2BV4rzsRZI35l7aPc8ktpB9ruo3yQuVFXJ4Ei8Nbh94BqwfDsrzXMnmnhpMZNdHroW30OVN2Q3zZP05rzZ/DL0Pq29YpHmfwk077NrE7AfugMgA4NaPxM8S6vp91FFoy+WmMM7DJb2rL0PVRpFlHdopeR4RiPpncK6C51Cx1LwzFq2obZGhm2rtwGJr6JJ86nJXtofK1LKPJF2NbRhq13bWt5dMMywgyQMRzXQ2yWcENw0dqY7hV3HcvH0HNcj4R1y1t9Tla8cwjH7oseua7LUtStB5FzbzwXDl9pUODvGPapqJ3t0ErHByeCtYutUN9daeot5W3/e5B+nbiue+I3hq40C1eaQZZkDbkbO417OniW5+wNDLtQYxlsZUGuX1eAeJxLFKQAVILEcY9RSVSd/e2J5NGkeM21xdaPY2mtWhntgu0qJMkMc9BXd/F/RLe907w94qsoBbT3MY81Pu7j2NVJvDOovDDpklxHNpccwPzLgjBr0bx9pcUyWMG0y2q24SNN3HoaupNc0Wt9fu7GUabfuyPmK6Lw6kJiJYo2PyjOQT36V1dnHFJbLcMf3BO1iwyRUPi3RItLuo/LLTQk5Re6f/AFqj8LXM97rcdoUEsUropjI4IHArZvmSZFNcknFn2f4I0uPSPDVhZwSeZGkYIb1zzXQVk+HLX7Bo1rbkt+7jAw3bitWvFnrJnJP4mFeb/FbUI47TySfuKSR7mvQ5pliRnY4CjNfPPxCu5dS1Gd55vKtd3ODyfasau1j18loc9b2j2ieL+NLyezi/csS8hJJHam/DLwreeJNYSac5jOfv96k8XLcz3Ma21uwjZggIXivYvhz4fi8MaIbu+d/tDjC4HT1rspNUqF+rOqtCVfFu+yNi40uLTNBhsggedVGCowAK4nXdTstOUw3TRcnP3vmFdPrTXmtObSxY2u8YjZj8xPavKtb+Gmv/AGm4MoLyg5EjPwcVhQoUqj5qjsduIxdbDxUKauz0TwZ4gs9QUQRNIYSpADdq9I0nyfsiq0gJReQey14H4Ln+y213DcIEuYYSS0Yzn1wK1ptbW00o3EF75c4jLIqtyfwrf6paTUTCpjOeCctzum2LrolgCBt3yOowcZ/WsHUPh/qGs+KRLf3G21ml3vPKMfL6c1zvwk159S8dRR6nOEjbLkt0PtivYfi5qd1oejM7SLJaznYi7QNuPeui06M1GL1Z5861OqkmrFzWdW03TIrfTLHBWKMRxpGMgcVy3iZprXw/PLCD5yg9DR4TtEu9EtLpJP3crbipAJX2/WtS/aHY9pMmYlzk+1efVahP3u56uGhaly0+x5P4XvFvhqEEoPmqnnAemOtc945mkjvtM1SFtqxssbZ5APYn2rtZ/CN5o2pR6vpj+bbOpWVP9mqMmkWeoxGGR91udysMcgdj9Qa1jVhRrKcdia1GpiMO01qhbi0m0W8tb+8nQTXkbTQzEkxx8fwj8a2PDXiO4+2u0rrPDMcCZSefXIrnNCvLLXNb0rRPEtxJEumZtkeM8SkHAP5Yr16+HhDwwEa2to7q7YD9xGRjnqcV6M52smrt9jxISadkS68EXw7th2ursCoc/jmvObmc2ctxNM00u4bIxj5MY61p+NvGyxXFpa28KI55MfZQelV7iWK9sUccSMHCgcYPb8KineCvJbmr97RblNNX00yQW+17qVCGmaVcDHpXTeO57a28Hxx26eZMro4jC8AE1wuleH5mv41MJhYndczSycNz2rr5Vn1TVntXQJZwjzH7YUf4067jGzT2KoQlUvzHkHiLT5L21RBIVb/WNG2cjPauMb93NdEfcjXYv8q9d8RjztTvHEJIVOCg4rzfUdMaKzmYKSXlA4H41NGpz7jxNDktY9a+Alo6aPqrRKGd87c+vFes+DdVt9YtrlYSPOt28txjGCK434H2KN4KR0UiZriXd6jGOa474e+J3sfH3iSTdIljK7kFVyv3+v5VMoe2lNdUY83IkjU+PGnw6lf2OwAlcxyDpiqngXw9c2XhbVbqM4WGBxHgdc1r6pqsOu+IHl0+1n+yW52GZ1IyfU11FmV01FhQGS0lBMsaj+dUpSp01TD2UZPmPN3TUL1dMeG7TI/ckRn5Rz1r2izDBIod67mwpbPQ+tcnZ+EdNt9Qi1CFpVVPnWL0PpXQXstvarC7jDLgphu9FWanZIcYtEHiSzubK8nl0+Pz7gLtjZzgE+9c1o+m29tc2OqahAh1W4fEjRtk4A9PrXoFui6xYNKu6IAEPzz9a4ZdDe2uzBZ3zRwl/vN98Z7g1NOX2ZaNESjfUuXtzc2etKbZCkF3GSNxxjHU1F4pS41DQ5I4Lhmux0C44NaDafbaZtkhnkvblx8xmfeQPb0rlfEvjG101iGG984VFGWpX5muU0StH3jzHVjqctq1lei6N65xCgXCY7kmvQvh14dZbaG0vLoqzyb8/wB08VmweMrfVkVFj2Tj5RAR9/0wRXrfgzwqzywXc7MUVQVDDbsPcVvUqSjG0tDOKhH37nomk2iWlhFFH91Fx9a5P4n3n2fSSoJBIPA7iu2VAiBQMY6V5B8YbuWSWK2icAhhux3HpXkzl1ZeW03VxKOS0dGjs0kUfPISVFWfF92FjMW/cIYsH0zjmqpv4LK5tbOSQef5IkCelcp8RNS8jTpo0OJpVIXnoO9cMoya5e59lKcUnUb+H8zlL2Z49B05Gk2yGHCZ6EitG3S6uvDVpo9+Ps0LzG5MwxwcdPp3qbxV4fa78PQ3NopN3bSZKKP4Kh8Fa3Fpvi+xg1GINbu6/JKMgg9Rg/jX09Od02tz4utBqVpD9QE87297ZxTTw2pSEMP4/U1paVZ79XhuLUuZTJhk6DJr0i3v7GbxM8MNmkUDrgpGgA4PoKz7vVtI0vWpTZwrIkTZkJPK846U/at6colDl1uY/iKOSHUblb6eWNFhAQR/Pj1/lWfpOqXFvqkUSOI45YtwAOQCP5V1HiGaDVgmqaSRJGY2jmQAdcdwa8fuY7/R2N5qM0yuQFCkEGPPp+FKmlKNnuOUnGVz2u3kg+yyTSqWQjJ9DWd4p8W29vY2lvDHNuj+REBB3HOa5R7iy0vSIJrDVLnz51y0M8mVcEdh2rN1COWeys7+A73g3ExsM47cVHsl12L9o5bLUzfEHiC5GtLiyWGdIz8kncGtj4V6DPP4qtL5x5eZR+6+9knnNSeGvC2q+Kb9ZbqxkVGbBYqOF9u9fSfgjwlZaFpcCmJHulHMhXmlVqRpRstzBzt78zrI0PlICeQOal6U0HjpjFYniPWo9NtZSDlwOg7V5TOanSlWkoR3Zi+OfECWNu1vCRvbqc14zpthN4h1hhIS8UR3MO1afiC8uNbvVgtixdjg7evNdDF4XXSbIOdSS1ZUzKobluOlYN8zufX0qccDSUF8TPPfGlpa6TH5t58gWXKopGcdqx7T4kI8kMdzFIEU4XcdxH4VynjPxejeILq2ntxcWIfbl2O7juDT/Deh6VrurQpFebIyQdnQkelelSoQjTTqo82eLqVKr9k0e86LexaiLW9s2UwtHlhjBFYHxA8Q3FpFLMsjPIF8tPameMre40PwffHQhJaw26KGfdyAfevOvDWtXPiPyNL1N0nTbxIo+YY6ZrKhS571I/CmdOIrJNUpfE0avwm0tL/WZrm4lJLZDL35FZ/xWnt7LxnFBa2a2wgRFLY6/wCc13ng/wAJ/wBg3jXKSvvbs3GKxvjF4anvz/bNsPNZgEkPdccZrqhXi6610tY4q+HnChpuZOjeGJk1qzudPEr/ADgvgZAT2r2P422n9p/CphbCQzW4jkQgc8cH9K83+F/jmDwzp8kXiS6/driK3Gz5sDnnvjmvT9c8e6L/AMIPe60j+daiJo4128b8YqMQ6kZLTZqzOVqE46I5X4N3v2rwU0T8TxtxnqMf/qrY1I772WQAYYZryr4La/NNqWoFDstZnGQOi/54r1RIxdSTAdVBArjx8Wqr8z3sradPnOm0KxOoaONhVRH/AAkcN7V5Brwi0vxNMkIZIHJBXutemeF9ZXTjJau3zsdu0+vaoPHPhJtW037XpiI97Fywx96slBSQvayw9aXP8L2PINd0qNnF7a+UzuASWTh/8DVaXxNd6J5LLaxQoy8gDJFdz/Z066FNa6hCbe7jjJhWVepx0Brg/CGo6XrF5Po/ijba3anEEkgwD7fWumi6vK1ul95z4p0Oa6dm/uOI1zxU95qr3cZcyE8lu9S6T4k1C/uI4FmfrjaBXq2pfCONIy8Vl50Z5DR9cVF4a8IaDpurxvc+bAV52NGTk+ma6o42ny2tscH1Gs5Xi0/Q9F8AaYkmnpd6jGGmC4BcZzUk9pIL/UPstsJY7htpwQMAdK00vBc2v+jyJHDHwFXjpTdHjVMM115+7JyOB+VccqnO3I740nT3OZ1DTYo9NRvL2qSd+VxjFeKeNry3054rSPLySSF2GcbQa+jdeUtp8/lZ3heN1fI/jE3E/jHyWTaS6r9a2wVpVGmc+YVHGnF9T6Q+HlxPJ4QGl6Ou25vt377/AJ5g9ai1vXvB/wAOvC82hSAz6tghtkYLPJ/fbParP7P7xf2dfSySDbZknGckcHNeD+JBeePPiHez2is0bTFieypmtqceeo4y23f6Hn1nso7n05ousadqPgW0t9Nx5txCEclRlSfWvMPEF/fvf3i2k6La6eSLgGQoZvy7V0unW0NrHplrp80ax26gH1L964z4u6PJY6lJe2CsbW9QFwjY+bv9a0p8qqO3W/8AX3BOLjA6/wAD6m/n21g90LqG7tzNlcnyWHbNX7drhtUkMiptiPyuD2rzr4YXt1otx5csJCzRkRKvVT3Jrs5NRVYsXEyHy5dpfcATTqw9+6KotuOpq3Ouy2SNbWzHynbDkDqawtXvDLcrNcsnyLmTMmwD0zWdeavGJkNu5ngVSNymsfUbq0t7i0bUkuJUmj8wIU4z/XiqjEc5W1NjRvElqRco0zvKDiIxKcZ7V57rGpR3FhPp1vavNq14xdp0bGznoa0F1WQX0V/YRpFaxS7TABhnPTP5GvU/BnwvOqarFqerQS2sJXeqD5WI+tOTjT96Ri3zR1ZynwU+H95Jf2d3dQxmFG8wsc5FfU1tEIYQigAKMcVU0fSLPRrNbbT4FhiHOB1J9Sav1wV6zrO/Q5nK+iIL6Zba1klY4CjNeA+KrptU19hH/Cc16V8SNdWzsZLaJ8NjL+3oK8isUllLOhAllOMntXn1p6qJ9RkmEdOk6z3exxGlzzav8QLi4bPlKSqt2wOAK6fxDpMGoidJUyEUgH04rTg0q00nT2+yxqJCcBu59TUlnAWWWRhkCE59yRUYqtzS9zSy/Q9XC4bkotVNWzo7S0gl1aI3CpEu0qp6bT715r8TvAyKl7qOmGSSeyl/eHPBB7jHavRZEj3+XdSEsnRgOaiLXcME8KskkMh5U9x6V2UsQ6bPPxOBVb4Tz/4danPtguLn5ZFfYWJ7Vm6jpyLFqt5cXUguoZJDHGMnzOe1dBJ4bnsLt7myAS0Y5aMnpW/YeHbXWRHPaXbQzdOBgg+vNelDEQfvHk18HNK1tjjfhjqFxcaRqbXh3sZFwXGMe1bOrWsmq6YjQxR3boTIEIzkentWsPCd1o1tJDFFLISSdyjO715FdF4d8J3m+We0jkt9yYPzYHuKudSLfOmYKDjHlkeM61HJqktlANMlhu4/kVgOCPevX/ht4Clh0mNdRjcrcHoR2613fg3wlY2KvcXMCyXucb352j2rtYlWNQqgADpiueribrlijnlU9m2o7lHStLgsIgsUaqAMDArT4ReOAKpXF/DBne4GPeuM8Q+NYIRJFAct0BrilK2rHSwtbFS91HR65rkdnA5RgAOpJrxzxJrlxqU5iiJcyNgAVQ8YeIZ7TT5L68kYr/DE3FO8C3D3mh/2pdwpGr8xgDJx71jLmlFy6H0mCw1LCS5N5m94esv7Fs5r6YK0yYxx/Ef8KwvFGsJDHLf6hKdgPPufQVs3lwbyyjjjOFUklc9TWf4r8E3viDwrLb2HktPL90M2MYNRTipyUW9Dpr1PYQlVfxPRHiF3YaN4l1CY2LSQXfLGN/ut3wDXRfCXwRcXviE3Fx5kFvbfPxxkg8CtvwX8I9V0vUYpdVKQRqCW2kOSexr1rR7ez06IW1ucyMclu5r1q1eNFezpO54OHw7rfvpqzML4tJ5Pw/vbUYzPIpcnuO1eB+C9aOhanF9lt4ZHDjdleor6M8TWv9rxvYysGiK4IIrwLxloq+F9biktP3gz5m2ReMA8jNLA1YP9zLqVjaE6bWIR9Byxy6hHFdxRlQ8eeO3FZ3iKymXRHgsVY9y2M/WtPw1qhv8AwZZ6lBH5e6EZT+7XzhrHinX7TxfNNBeXEV0JflQPw3Pp06VNKg6s3FaWKrYv2UI3V0y14s8Ia4988sVs7JM2U2DcBxiullsbu3+DU+k6gqxst157DdjA6YrufCN3d3moQT3SlYXi3TocHD4zkelQa7caP4r0fW9J0qVXuzEWROh3ocjFaTq1LqElora/MxjQpOMpxvd7I4v4YaFcafpU91bMjRySALtOenrXpmks9qnnzZ2svPFcL8NPD2raJb3s+oylInwFh7k+vtXeaXctqKT2TQlDGMqW/jHqK4sa71XZ3PYwDSw6urHK+JXvEEup2TfOg2KPftXUeDfEk0Wivca3dfZ7mLlgfusPeua1aR9Okv7Yxh1ZNyZPGfSuO8Q+KgNHgU2jeYRhyDwfpVUKTqLlRnjakaavJnqur/Eaw1a28m3skkiVsb2bn8sV574n8MWXiGD7fGotrlTnco2kVynhLxFo1tftLcblVhgDBPNdf4sgufFOkwxeHJ0EDcN1XPtXTVo+za5fd8zzqE4yptaS8jsPA/xJm0y0trDWiJUhXaJl6sBWt4j1rQ9VxNbQyGV/4hwK+cPEum3PhDQRbX2oRNqTThkhhkLFVxyT6fSuo+D3jqC41CLStdjMombYrnoPSsa2Fc05Qdy8JjKFOouaLjI9M068XYYnt5P3fK4PFb2m384ZTJbSxRnhX7D8K8Q+It3deDviR5a3DNZSKsqxK5xsPYV7XpEMuo6Na3WmTv5ZUSqJ+D0zjNcvsJxgpvVM9OGOo4huG1i5cLJ5bus25WX50xjp6V4d4q8Lmb4nJ5WFt0HnMc8AcmvaYbiaXNtKuJW6EDvXIeOtPuUhnljjPnFQpZBg8f0qqFVwlf5GeLwvtY27annvw18Vz6Dres2CSBFu0dF3d2PFMmvbjw1dxW0UJtpZgXllK8sPSsHUtDurXVob1/kc4mwO4/yK911vS9P8a+FLG+sgDcqoGccg/wB016rnFNT6PR/oeCoTV4vcy/BkYvrFHiJM5IOR2+orf1GxluWjS/CTJEpAXp+INef+FH1TwdrEhngkMTNtdcZAFdJ4vurS+mGo6jcSRaTEAi+WDh3Pc+1Ocby916MtS933kV/D2geTfmNZXWOAGX5sZcVl/EKwk1F500oH92gkBXoR+FJqmraNA4W3ujHN5W9fLT5G/wBioZdTvhbKUQYkj2jA5/Gj3ovmYuVTVkZ+oaa2l6DDcWsimWLalyoOM5HpW3fW8+rxaZJZRuu2DJYDOfcVf8GfDG98QE3FxcyPp+OEOVDGvbdC8EWmm2McIAAVQB7D0pVcRGL3uzPSGk2eTfDz4aPehLjVydquCqIOn1r6KgQRxxrj7oA4FVtOsUs49iAD6CrYbqMdK4q1V1Hqc1WSk7RF6VieLNcj0TS3uXxuPCg+tUvG/jXSPB+mtc6tcBWP+riXl5D6AV4dqHi+/wDGR8+6jNvAPuxZ6Dt+Nc1STjHmO7LcC8VVSlsiTW9Vn1m+Z3PDNnjvT7Yi3ulaQfIhxgd6fp1oUjaUrtVRx7UMq/aFyM4BfHv2rzne9+p9zGMYx5VsQTu88pG4DHP0qUXa2thfPKQIlQ8nqTUdzst22HiRhkikurSG60m4jncq2Cw29uO9VBb3IrytC6MnxN46t9KhMN3EzzHkZPOff2pvhPxtLrdwllHCrAg4KtnpW58QfA2jap4htpJI5YTN8riFgAR+INW38EaL4c0+ObTIZFkBHLvur2akKLpc1tWfNYbFVnXUW/dRPHex2qHzgCehWs57iNL7zIFaL0KmrWpKsdvG6KoLHkY4rHe8laTBCYx/dFeTzuDPpeSMlsdjZ65fRxZB8/HA9a0tJ8U38UpMkGxccjNcXpi7polJbDHnnrW3EgjtWZODurWNZnLVwlGWjR0154zu48vZ27yZ4PBI/lWTN491diUZYEz0AByP1rN0e1/tVmS8nuGQMRtD4Faeo6JY6f5P2aHafUnJqnVlbQ5fqeHpztKFzm9Z1jVr1WkJcJ3OMCq9pZvbpHc6s8cKMwKxyuAze+OtUvE+uXi6rbafEY4rf/YXB/OvL/C0LeJvGF1Jq888rRrIy4fGMA4rehhPaXlJ7GGIzNUbQpx3PbNWsdN1yWOxluoLzgO0cZzgHpyO9TO8NpZRWEAKQR/wqemK5H4GwpBo+v6ggzdL8iu3O0e1desSR2BZR83HJrPGJUn7OL03Nstn7de1mtSFUNmBgGS5lxgdlFdPZXoS0QxShZFH0zXImZ4rPzlP7zd1NWdMYz24Z+vPSuanK2qPQxFNT0kZ3xD+Iy6GY7SErJdSDLA9FFVfhd4nufE2pyJMqWsqRE4j6EVy3xP0y1kntbh48ylthPqM1v8AwYsYLeeSWIFXKnJz6169ONJ4fmtqfOznWhiPZp+6bfiXVp9Cubh5MybyCDntmuT1LUdD8ZK8VvJ5t9GPkhkGCT149RXT/EKwgvLW5nnUmWJGKkHHavCfhcN/xA0hSThpxnHelhKcJpz2aHjsRUhONN2aZ6Nqvi3xFo3hc2xCJb48tVSMfu8Vy/w915L7xXCurWdjdPP8pkuIxlT2x6mvXPixDFbKfLjUhk5VuRwa8t0CSCW5huRZWkc0UgZTGhHP511UalOUb8u55tWMlNa7H0Pr2gRWHhDUhYx7Z3gdlZfvFgK+a/hVJfHx1bLh1ieRxnH+ySa+ttGlbUNPtftOG3Ic4rzbRtGsdN8V3KWcCR7mfLADPQ965aVf2cZqWtzohTdSpF3tY2L8xrKxiwdw49Kd4X0VV1Y3TFjIVymW4APGMVmliI3OclXIGa4iTxpq1r4wtbSAwrDtIxtPr9a4KX7ydj3cX7lJRXU7LxppCRagwdwu8gfMPWsTU/h+13p1iht45Y3yCFOAtdR41la6srOSYKWbrgVueEbuWXQYlkIIVsDirp1XCWhhXTlQjKWvQ8YuPhH5FzmFWji6kBxj8K6/RNHt9Pt2tbI7cD5geua9f1i1hk0u3d4wzKoIz9K5bUtIskkhuI4dsnk7jgnBOe9dM60pwtJnDhJU1O6ja54xr3w0t9avZgZnEz/OGJ61a8CfC+20i8Mk2ZbqFvvH+H8K7XU18vUIChZSOODWvBM6T27KcFhg+9ckcVUs430PSq4CjzKqo6nnPjbwHc6p4sh1FJYZ1VFUI+MqR04NejHVpk0+OymRYXUD7o2j8qw9cYo8jp8rZ7VPZXD3mlO1xhmjI2tjms3iZSjyPoa08BSpP2lr3NCNTcTbY5E89Rnjv7iq97LJcho2x5q9ARgkVCp/cpcr8kykYK8VqjbcW/nyohkwOce9Lm5lY1a5Gmefajoxd7hJYgpdCoPUr9Kq+ENQuPBtx5EifaLCYESLnlD2IFdD4jBi1d41dtiEEAnpWbf2kLylmTlRx7U6WJlDTdE18HTqxUtmem3GjaZ4h0yO4t2DCZeT3FcZrnw8mSwntYmea1duUUFtv4Vk6de3Niii0neJfRTxXffD/wAUanqUgS7kjcK20HbziuuliGtYnj4rCSpLe55qngwmzMVpod0bofJHI8ZG31Nej+BPAQt7aGPU4n3DBZXHbr1+teoq5x0FPVjitp4qU1ax4/tWvhQWVnBZwLFbII416KBVjgVFuODWH4k1S40/Tbia3Kb0BxuGRXO5W1MFFyZvSSrGCXYAD1OK858d/Eq00e0mh0gi7vsYG3lVP1rw2/8AHOv+Idaltr++cWwOBFENi1ftIkcrkdR2rLET9lZHv5fk8Ki9pUfyOUfTdY8U6+2peIJpZXZvlQngV63omgQ6TbRm5RGumX5E6hB6/WrWm6dbWjv5cQbbCHG/nnFX/Dw+3Xk89wSXUADHSpTdWzkekuTDpxprTr3ZhavJJBCyFtsfeslmMKWxz80n7xh6L2rT8dOUv44k4Qk5A/CsPVGK+Xj+5XHOaTZ6tH34JmXealDBOJb+YRpK2Fz1P0rtNL+yS+F72K4dI2uo32MT2xXzlcXM2o+MYkuZGKGUIADgAZ6CvoXWbSGXwtOWXBitxswcYwK9OWGjRorXWX+R4Lx0sTOStZRP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23509=[""].join("\n");
var outline_f22_61_23509=null;
var title_f22_61_23510="Induction of fertility in men with secondary hypogonadism";
var content_f22_61_23510=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Induction of fertility in men with secondary hypogonadism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23510/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23510/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23510/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23510/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23510/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23510/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/61/23510/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sperm production cannot be stimulated in men who are infertile as a result of primary hypogonadism due to damage to the seminiferous tubules. On the other hand, sperm production can usually be stimulated to a level sufficient to restore fertility in men who are infertile as a result of secondary hypogonadism, ie, due to damage to the pituitary or hypothalamus. Men who have pituitary disease can be treated with gonadotropins, while those with hypothalamic disease can be treated with gonadotropins or gonadotropin-releasing hormone (GnRH). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GONADOTROPIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary hypogonadism is associated with decreased secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in reductions in testosterone secretion and sperm production. This disorder should, in theory, respond to the administration of LH and FSH. In practice, testosterone secretion virtually always increases to normal after replacement of LH, and sperm production more often than not increases after replacement of LH alone or LH plus FSH. Testosterone replacement alone will not restore spermatogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Which patients are likely to respond?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of secondary hypogonadism must be firmly established before therapy is begun, since only patients whose infertility is due to this disorder will respond. We recommend treatment with gonadotropins for most men who have secondary hypogonadism due to either hypothalamic or pituitary disease who wish to become fertile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    .) Gonadotropin treatment will not increase the sperm count in men who have idiopathic oligospermia, in which a subnormal sperm count is associated with a normal serum testosterone concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors enhance the likelihood that the sperm count will be increased, and increased sooner after gonadotropin administration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Development of hypogonadism after puberty rather than before. In one study, as an example, all six men whose hypogonadism occurred postpubertally experienced an increase in total sperm count from less than one million to above 40 million per ejaculate when treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"       human chorionic gonadotropin",
"      </a>",
"      (hCG) (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Use of human chorionic gonadotropin'",
"      </a>",
"      below). In comparison, only one of eight men whose hypogonadism occurred prepubertally (but without cryptorchidism) had a similar response [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Partial hypogonadism, rather than complete, as judged by testes that are not as small [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/3-6\">",
"       3-6",
"      </a>",
"      ], and serum concentrations of FSH, inhibin B, and testosterone that are not as low [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Descent of both testes into the scrotum at birth or by one year of age, rather than unilateral or bilateral cryptorchidism (which may damage the seminiferous tubules) requiring surgical correction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/2,8\">",
"       2,8",
"      </a>",
"      ]. In one report, as an example, only one of the seven men with prepubertal hypogonadism and cryptorchidism had an increase in sperm count to within the normal range in response to hCG and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12565?source=see_link\">",
"       human menopausal gonadotropins",
"      </a>",
"      (hMG; a preparation containing LH and FSH) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Use of human menopausal gonadotropin (hMG)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Prior treatment with testosterone or with gonadotropins. Many patients have been described in which gonadotropin stimulation led to spermatogenesis even though they had received prior treatment with testosterone. However, in one study, prior testosterone treatment independently predicted a slower spermatogenic response to gonadotropin treatment than no prior treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/6\">",
"       6",
"      </a>",
"      ]. Prior gonadotropin treatment, in contrast, predicted a faster response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gonadotropin treatment of men with hypogonadotropic hypogonadism results in the appearance of sperm in the ejaculate in up to 90 percent of these men, but often not to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/4\">",
"     4",
"    </a>",
"    ]. Even if pregnancy does not occur spontaneously, the number of sperm is often sufficient that pregnancy can be achieved by insemination with the patient's semen (intrauterine insemination, IUI) or with the help of an assisted reproductive technique such as in vitro fertilization with or without intracytoplasmic sperm injection (ICSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Use of human chorionic gonadotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     Human chorionic gonadotropin",
"    </a>",
"    (hCG) has the biologic activity of LH but a longer half-life in the circulation; it stimulates the Leydig cells of the testes to synthesize and secrete testosterone. hCG is used to replace LH in men who have secondary hypogonadism and desire to become fertile. Both purified urinary and recombinant hCG preparations are available. There is no theoretical reason to use recombinant human LH, since it has a shorter half-life (10 hours) than hCG and therefore would probably not be effective given three times a week.",
"   </p>",
"   <p>",
"    LH, by the use of its substitute hormone, hCG, is always replaced",
"    <strong>",
"     before FSH",
"    </strong>",
"    for three reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      hCG stimulates the Leydig cells to secrete testosterone, which results in an",
"      <strong>",
"       intratesticular",
"      </strong>",
"      testosterone concentration 100 times that in the peripheral circulation, a concentration essential to stimulate spermatogenesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31800?source=see_link\">",
"       \"Male reproductive physiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      hCG alone may be sufficient for stimulation of spermatogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/2\">",
"       2",
"      </a>",
"      ]; FSH alone is not effective [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      hCG preparations are considerably less expensive than exogenous FSH preparations, in particular, recombinant FSH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After stopping testosterone therapy, hCG is administered according to the following regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are taught to self-administer hCG. Urinary hCG is given intramuscularly in the thigh at an initial dose of 2000 units three times a week. Although the package insert recommends intramuscular administration, some clinicians use the subcutaneous route. The recombinant preparation is administered subcutaneously.",
"     </li>",
"     <li>",
"      The serum testosterone concentration is measured every one to two months and, if it is not between 400 and 800",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      within three to four months, the dose is increased accordingly. Some patients require as little as 500 units per dose and others as much as 10,000 units. On rare occasions, the serum testosterone concentration fails to respond to hCG, a problem thought to be due to antibodies to hCG [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Men with a history of cryptorchidism may also have a poor response.",
"     </li>",
"     <li>",
"      The sperm count is measured every one to three months once the serum testosterone concentration is 400 to 800",
"      <span class=\"nowrap\">",
"       ng/dL,",
"      </span>",
"      but the value is not used to adjust the hCG dose. Most patients who eventually reach a normal sperm count (over 15",
"      <span class=\"nowrap\">",
"       million/mL",
"      </span>",
"      or 40",
"      <span class=\"nowrap\">",
"       million/ejaculate)",
"      </span>",
"      do so within six months, but some require 12 to 24 months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/3\">",
"       3",
"      </a>",
"      ]. An increase in testicular volume is usually associated with an increase in sperm count. If the sperm count does not reach one-half normal by 12 to 24 months, FSH should be added, as described in the following section. Some patients are reluctant to wait this long, however, so if the sperm count is still &lt;5",
"      <span class=\"nowrap\">",
"       million/mL",
"      </span>",
"      after six months of hCG alone, it is reasonable to consider adding hMG (a preparation that contains both LH and FSH) then. The sperm produced by this regimen are qualitatively normal; thus, less than a normal number of sperm is usually sufficient to restore fertility (",
"      <a class=\"graphic graphic_figure graphicRef59467 \" href=\"UTD.htm?27/3/27709\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse effects of hCG therapy are few and generally similar to those of testosterone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .) The frequency of gynecomastia, however, may be greater with hCG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Use of human menopausal gonadotropin (hMG)",
"    </span>",
"    &nbsp;&mdash;&nbsp;hMG contains purified extracts of FSH and LH and is the pharmaceutical preparation usually used to replace FSH in stimulating spermatogenesis in men who are infertile due to secondary hypogonadism. This effect of FSH is probably exerted via the Sertoli cells of the seminiferous tubules. FSH appears to be necessary for the initiation of spermatogenesis, but not for its maintenance or reinitiation. As mentioned above, only one of eight men with a prepubertal onset of secondary hypogonadism responded to hCG alone; five of the seven nonresponders showed an increase in sperm count to above 40 million per ejaculate when hMG was added [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/2\">",
"     2",
"    </a>",
"    ]. The likelihood of a response was much less (one of seven men) when prepubertal hypogonadism was accompanied by cryptorchidism, presumably due to seminiferous tubular damage induced by the cryptorchidism (",
"    <a class=\"graphic graphic_figure graphicRef54583 \" href=\"UTD.htm?33/18/34094\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the serum testosterone concentration has been maintained within the normal range for several months yet the sperm count has not reached at least half-normal, the following regimen is used to add hMG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial dose is 75 units (the contents of one vial) three times a week (an hMG preparation is now available that can be given subcutaneously); it is most conveniently administered in the same syringe as hCG.",
"     </li>",
"     <li>",
"      The sperm count is measured once every one to three months. The reason for such frequent measurement of the sperm count is that individual values fluctuate considerably, so that many samples are needed to detect a trend.",
"     </li>",
"     <li>",
"      The hMG dose can be increased to 150 units if the sperm count does not reach 20 million per ejaculate within six months. This will increase the serum FSH concentration from low-normal to high-normal, but it is less certain that it will increase the sperm count. As long as the sperm count is at least a few million, however, continuation of hCG and hMG administration is probably worthwhile, because even values this low can result in impregnation spontaneously [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/12\">",
"       12",
"      </a>",
"      ]. The time to achieve the first sperm in the ejaculate and the maximum amount varies considerably from patient to patient, partly due to the degree of hypogonadism, history of cryptorchidism, and prior testosterone or gonadotropin treatment, as described above. In a study of 75 men with hypogonadotropic hypogonadism treated with hCG and then hMG, the median time to achieve first sperm was 7.1 months (95% CI 6.3-10.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/6\">",
"       6",
"      </a>",
"      ]. The average time for conception in the 38 men who became fathers was 28.2 months (95% CI 21.6-38.5).",
"     </li>",
"     <li>",
"      If pregnancy does not occur spontaneously within 6 to 12 months of achieving any sperm in the ejaculate, assisted reproductive techniques should be recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"       \"In vitro fertilization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link\">",
"       \"Intracytoplasmic sperm injection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      hMG should be discontinued once pregnancy occurs because of its high cost. On the other hand, hCG (which is much less expensive) should be continued if the couple is considering another pregnancy. hCG administration alone in this setting will usually keep the serum testosterone concentration in the normal range and maintain at least some degree of spermatogenesis. hMG can be added again if the sperm count is not near-normal when another pregnancy is considered. Cryopreservation of sperm can be offered, especially if the sperm count is normal, for possible future attempts to achieve pregnancy. When the couple does not wish to have more children, virilization can be maintained by continuing hCG alone or by using testosterone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"       \"Testosterone treatment of male hypogonadism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21571940\">",
"    <span class=\"h2\">",
"     Recombinant human FSH (r-hFSH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;R-hFSH was developed for use in ovulation induction to avoid the small amount of LH present in hMG preparations. Although there is no advantage for such purity of FSH in stimulation of spermatogenesis, r-hFSH has been tested in men with hypogonadotropic hypogonadism and is commercially available. One report describes 100 men with severe hypogonadotropic hypogonadism, as indicated by azoospermia in all and baseline serum testosterone concentrations &lt;100",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    and testicular volume &lt;7 mL in most of them, but no history of cryptorchidism. Administration of the r-hFSH, in doses from 150 to 300 units subcutaneously every other day for 18 months increased the sperm density to &gt;1.5",
"    <span class=\"nowrap\">",
"     million/mL",
"    </span>",
"    in 46.2 to 88.9 percent of them [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    R-hFSH and urinary hMG (contains both LH and FSH) preparations have not been compared directly, but their efficacy when added to hCG in stimulating spermatogenesis in men with hypogonadotropic hypogonadism seems similar. Because the improved purity of r-hFSH is not necessary in men, the increased cost of r-hFSH (almost double that of urinary FSH products) does not seem warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PULSATILE GnRH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spermatogenesis can also be stimulated in men who have secondary hypogonadism by GnRH, as long as the hypogonadism is the result of hypothalamic disease. The rationale for this treatment is that replacement of GnRH in a physiologic manner, in pulses every two hours, will stimulate the gonadotroph cells of the pituitary to secrete LH and FSH, which in turn will stimulate the testes to produce testosterone and sperm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31800?source=see_link\">",
"     \"Male reproductive physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use of GnRH",
"    </span>",
"    &nbsp;&mdash;&nbsp;GnRH is administered in a pulsatile fashion by a pump and syringe that is programmed to deliver a bolus of GnRH every two hours and is connected to a subcutaneous needle. The apparatus is worn continuously until pregnancy occurs. The dose of GnRH initially is about 25",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    body weight and is increased, as necessary, until the serum testosterone concentration is normal. Doses as high as 600",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    body weight are necessary in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/15\">",
"     15",
"    </a>",
"    ]. Sperm may appear in the ejaculate as soon as 12 months after the initiation of treatment but more often three years or more are required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link&amp;anchor=H22#H22\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\", section on 'Induction of spermatogenesis in men'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Virtually all patients treated with this regimen attain a normal serum testosterone concentration, and most develop some sperm in the ejaculate. In one study of 23 men with idiopathic hypogonadotropic hypogonadism, as an example, 20 showed an increase in sperm count from less than one million to a mean of 96 million",
"    <span class=\"nowrap\">",
"     sperm/mL",
"    </span>",
"    of ejaculate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/15\">",
"     15",
"    </a>",
"    ]. The best predictors of a favorable response are a history of prior sexual maturation, absence of a history of cryptorchidism, and a serum inhibin B concentration &gt;60",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/16\">",
"     16",
"    </a>",
"    ]. Studies comparing gonadotropin to pulsatile GnRH treatment showed similar stimulation of spermatogenesis with both therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. GnRH is currently unavailable in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H701182\">",
"    <span class=\"h1\">",
"     CLOMIPHENE CITRATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate is a weak estrogen receptor antagonist that stimulates gonadotropin secretion in normal women and men. Many reports describe the use of clomiphene to attempt to increase sperm density in men with oligospermia or azoospermia and normal to mildly low serum testosterone concentrations with variable results, but few reports describe the use of clomiphene in men who have unequivocal secondary hypogonadism. One report, however, described three men with idiopathic hypogonadotropic hypogonadism, including markedly low serum testosterone concentrations and azoospermia or severe oligospermia, who demonstrated increases in testosterone and sperm density to normal or near-normal following administration of clomiphene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23510/abstract/19\">",
"     19",
"    </a>",
"    ]. Clomiphene has not been reported to improve sperm density in men who have secondary hypogonadism due to damage to the pituitary, nor would it be expected to. Clomiphene citrate is ineffective in treating idiopathic infertility in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend treatment with gonadotropins for most men who have secondary hypogonadism due to either hypothalamic or pituitary disease who wish to become fertile (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Which patients are likely to respond?'",
"      </a>",
"      above.) We suggest not using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate in these patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gonadotropins are more convenient to administer than pulsatile GnRH and GnRH is not widely available. In the United States, it is available only on an experimental basis.",
"     </li>",
"     <li>",
"      Patients should be treated initially with hCG alone to increase serum and intratesticular testosterone concentrations. If the sperm count is not normal within 12 to 24 months, an FSH preparation should be added (hMG or another FSH preparation), although adding FSH as early as six months is reasonable if the patient does not wish to wait longer. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Use of human chorionic gonadotropin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If pregnancy has not occurred spontaneously after a year or more of combined treatment, an assisted reproductive technique using the patient's semen should be strongly considered.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/1\">",
"      Knuth UA, H&ouml;nigl W, Bals-Pratsch M, et al. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. J Clin Endocrinol Metab 1987; 65:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/2\">",
"      Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. N Engl J Med 1985; 313:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/3\">",
"      Burris AS, Rodbard HW, Winters SJ, Sherins RJ. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab 1988; 66:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/4\">",
"      B&uuml;chter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998; 139:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/5\">",
"      Miyagawa Y, Tsujimura A, Matsumiya K, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol 2005; 173:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/6\">",
"      Liu PY, Baker HW, Jayadev V, et al. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 2009; 94:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/7\">",
"      McLachlan RI, Finkel DM, Bremner WJ, Snyder PJ. Serum inhibin concentrations before and during gonadotropin treatment in men with hypogonadotropic hypogonadism: physiological and clinical implications. J Clin Endocrinol Metab 1990; 70:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/8\">",
"      Ley SB, Leonard JM. Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens. J Clin Endocrinol Metab 1985; 61:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/9\">",
"      Zorn B, Pfeifer M, Virant-Klun I, Meden-Vrtovec H. Intracytoplasmic sperm injection as a complement to gonadotrophin treatment in infertile men with hypogonadotrophic hypogonadism. Int J Androl 2005; 28:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/10\">",
"      Schaison G, Young J, Pholsena M, et al. Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1993; 77:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/11\">",
"      Claustrat B, David L, Faure A, Francois R. Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. J Clin Endocrinol Metab 1983; 57:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/12\">",
"      Thau RB, Goldstein M, Yamamoto Y, et al. Failure of gonadotropin therapy secondary to chorionic gonadotropin-induced antibodies. J Clin Endocrinol Metab 1988; 66:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/13\">",
"      Burris AS, Clark RV, Vantman DJ, Sherins RJ. A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy. Fertil Steril 1988; 50:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/14\">",
"      Warne DW, Decosterd G, Okada H, et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril 2009; 92:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/15\">",
"      Spratt DI, Finkelstein JS, O'Dea LS, et al. Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism. A model for studies of the hormone's physiologic effects. Ann Intern Med 1986; 105:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/16\">",
"      Pitteloud N, Hayes FJ, Dwyer A, et al. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002; 87:4128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/17\">",
"      Liu L, Banks SM, Barnes KM, Sherins RJ. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1988; 67:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/18\">",
"      Kliesch S, Behre HM, Nieschlag E. High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. Eur J Endocrinol 1994; 131:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23510/abstract/19\">",
"      Whitten SJ, Nangia AK, Kolettis PN. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. Fertil Steril 2006; 86:1664.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7463 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23510=[""].join("\n");
var outline_f22_61_23510=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GONADOTROPIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Which patients are likely to respond?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Use of human chorionic gonadotropin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Use of human menopausal gonadotropin (hMG)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21571940\">",
"      Recombinant human FSH (r-hFSH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PULSATILE GnRH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use of GnRH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H701182\">",
"      CLOMIPHENE CITRATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7463|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/3/27709\" title=\"figure 1\">",
"      Sperm count at conception secondary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/18/34094\" title=\"figure 2\">",
"      Spermatogenic response to gonadotropins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31800?source=related_link\">",
"      Male reproductive physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_61_23511="Suture ligation round ligament";
var content_f22_61_23511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Suture ligation of the round ligament during hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 522px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23511=[""].join("\n");
var outline_f22_61_23511=null;
var title_f22_61_23512="The diffuse alveolar hemorrhage syndromes";
var content_f22_61_23512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The diffuse alveolar hemorrhage syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23512/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23512/contributors\">",
"     Marvin I Schwarz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23512/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23512/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/61/23512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding into the alveolar spaces characterizes the syndrome of diffuse alveolar hemorrhage (DAH) and is due to disruption of the alveolar-capillary basement membrane. This is caused by injury or inflammation of the arterioles, venules, or alveolar septal (alveolar wall or interstitial) capillaries. Hemoptysis is the usual presenting symptom; however it is not always present, even when hemorrhage is severe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the diffuse alveolar hemorrhage syndromes will be presented here. The evaluation and treatment of hemoptysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=see_link\">",
"     \"Etiology and evaluation of hemoptysis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of diseases is associated with the development of the diffuse alveolar hemorrhage syndrome (",
"    <a class=\"graphic graphic_table graphicRef52374 \" href=\"UTD.htm?42/62/44013\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/1,2,4-20\">",
"     1,2,4-20",
"    </a>",
"    ]. One of three different histologic patterns may be seen:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pulmonary capillaritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This pathologic pattern, also referred to as alveolar capillaritis, is characterized by neutrophilic infiltration of the alveolar septa (lung interstitium) (",
"    <a class=\"graphic graphic_picture graphicRef76904 graphicRef56943 \" href=\"UTD.htm?28/1/28696\">",
"     picture 1A-B",
"    </a>",
"    ). This sequentially leads to necrosis of these structures, loss of capillary structural integrity, and pouring of red blood cells into the alveolar space and interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/1,4-6,21-24\">",
"     1,4-6,21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the neutrophils undergo fragmentation and eventually become pyknotic, findings which support a pathogenetic role for neutrophil by-products (toxic oxygen radicals and proteolytic enzymes) in this form of lung injury. The fragmented neutrophils, nuclear dust, and fibrin also enter the alveolar spaces, and true fibrinoid necrosis of the interstitium may be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bland pulmonary hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;This pattern is characterized by hemorrhage into the alveolar spaces without inflammation or destruction of the alveolar structures (",
"    <a class=\"graphic graphic_picture graphicRef52466 \" href=\"UTD.htm?24/55/25462\">",
"     picture 2",
"    </a>",
"    ). Causes include elevated left ventricular end diastolic pressure, coagulopathy and anticoagulant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diffuse alveolar damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse alveolar damage (DAD), the underlying lesion of the acute respiratory distress syndrome (ARDS), is characterized by edema of the alveolar septa and by formation of hyaline membranes that line the alveolar spaces. DAD has a number of causes, including cytotoxic and noncytotoxic drugs, infection, and connective tissue diseases, and can lead to alveolar hemorrhage (",
"    <a class=\"graphic graphic_picture graphicRef53020 \" href=\"UTD.htm?15/17/15638\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diffuse alveolar hemorrhage present with a constellation of symptoms, signs, and laboratory results that can either suggest a specific underlying diagnosis (eg, granulomatosis with polyangiitis (Wegener's), complications of drug therapy) or only permit the general diagnosis of the syndrome without favoring a specific etiology.",
"   </p>",
"   <p>",
"    Issues relating to the general presentation of patients with DAH will be reviewed first. This will be followed by a discussion of those clinical findings that favor the diagnosis of a specific underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of DAH is most often abrupt or of short duration (less than seven days). Cough, hemoptysis, fever, and dyspnea are common initial symptoms. Some patients, however, present with acute severe respiratory distress requiring mechanical ventilation.",
"   </p>",
"   <p>",
"    Hemoptysis may be absent at presentation in up to 33 percent of patients with DAH from any cause. In this setting, new alveolar infiltrates (either localized or diffuse), a falling hemoglobin level, and the finding of increasingly hemorrhagic fluid on sequential bronchoalveolar lavage favor the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary examination is usually nonspecific, unless there are physical signs of an underlying systemic vasculitis or connective tissue vascular disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph is nonspecific and most commonly shows new patchy or diffuse alveolar opacities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61736 graphicRef73492 \" href=\"UTD.htm?8/41/8853\">",
"     image 1A-B",
"    </a>",
"    ). Recurrent episodes of DAH may lead to pulmonary fibrosis and interstitial opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/1\">",
"     1",
"    </a>",
"    ]. Thoracic CT scanning confirms the presence of ground glass or airspace-filling opacities that are usually diffuse and bilateral (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79321 \" href=\"UTD.htm?10/7/10353\">",
"     image 2",
"    </a>",
"    ), but may occasionally be unilateral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings in diffuse alveolar hemorrhage are often nonspecific. The erythrocyte sedimentation rate is usually increased, particularly in those cases of DAH caused by systemic diseases. An elevated white blood cell count and falling hematocrit are also common.",
"   </p>",
"   <p>",
"    A number of diseases that result in the pulmonary-renal syndrome present with pulmonary hemorrhage in combination with focal segmental necrotizing glomerulonephritis. In this setting, an elevated plasma creatinine concentration, usually with an abnormal urinalysis (red blood cells, white blood cells, proteinuria, red cell and white cell casts), is typically seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DAH have varying degrees of hypoxemia, which is often of sufficient severity to require ventilatory support. A sensitive marker for DAH is a sequential",
"    <strong>",
"     increase",
"    </strong>",
"    in diffusing capacity for carbon monoxide (DLCO). This results from the increased availability of hemoglobin within the alveolar compartment. Although informative, the DLCO often cannot be performed in patients with DAH due to the severity of the illness.",
"   </p>",
"   <p>",
"    The triad of an increase in the diffusing capacity, severe gas exchange abnormalities, and diffuse lung infiltration is also of utility for diagnosing more subtle presentations and for detecting exacerbations in established cases.",
"   </p>",
"   <p>",
"    In addition, obstructive airways disease is sometimes associated with recurrent DAH and pulmonary capillaritis secondary to microscopic polyangiitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequential bronchoalveolar lavage (BAL) is performed in an area where radiographic opacities are noted. The fiberoptic bronchoscope is wedged into a subsegmental bronchus and three aliquots of 50 to 60 mL sterile nonbacteriostatic saline are instilled and retrieved sequentially. Alveolar hemorrhage is confirmed when lavage aliquots are progressively more hemorrhagic, a finding characteristic of DAH from all causes. Hemosiderin-laden macrophages, which may be demonstrated by Prussian blue staining, are also characteristically found in BAL fluid from patients with DAH [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/31\">",
"     31",
"    </a>",
"    ]. This modality is therefore helpful in the diagnosis of diffuse pulmonary opacities without hemoptysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLUES TO A SPECIFIC ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history and physical examination, directed serologic and radiographic studies, and biopsy of affected tissues may elicit clues to the underlying cause of DAH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Useful diagnostic clues include a history of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to possible offending drugs or other causative agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , crack cocaine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"       propylthiouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , or trimellitic anhydride [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conditions associated with the development of ARDS, including bone marrow transplantation and exposure to cytotoxic drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"       \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14745?source=see_link\">",
"       \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A systemic vasculitis, connective tissue disease, or mitral valve disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the physical examination in the patient with DAH is generally nonspecific, the presence of uveitis, a leukocytoclastic vasculitis (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"UTD.htm?9/36/9794\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58626 \" href=\"UTD.htm?22/16/22786\">",
"     picture 5",
"    </a>",
"    ), or arthritis may suggest an underlying systemic disorder responsible for DAH (such as a vasculitis or connective tissue disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of specific antibodies, positive culture, or positive drug screen may suggest or permit the diagnosis of a particular underlying disorder of DAH. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antineutrophil cytoplasmic antibodies &mdash; A positive ANCA can be associated with DAH due to granulomatosis with polyangiitis (Wegener's) or microscopic polyarteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/7-10,34\">",
"       7-10,34",
"      </a>",
"      ]. Cytoplasmic ANCA (C-ANCA), as determined by immunofluorescence and anti-proteinase 3 antibodies (by enzyme linked immunosorbent assay, anti-PR3 ELISA), is most consistent with granulomatosis with polyangiitis (90 percent of patients), while perinuclear ANCA (P-ANCA) with antimyeloperoxidase specificity (anti-MPO ELISA) favors the diagnosis of microscopic polyarteritis or Churg-Strauss syndrome; there is, however, some overlap (",
"      <a class=\"graphic graphic_picture graphicRef66748 graphicRef78968 \" href=\"UTD.htm?26/1/26640\">",
"       picture 6A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-glomerular basement membrane antibodies &mdash; The presence of anti-GBM antibodies in the serum is diagnostic for anti-GBM antibody disease, which is called Goodpasture's syndrome when accompanied by alveolar hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. The diagnosis of this condition is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"       \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic findings suggestive of systemic lupus erythematosus &mdash; The presence of hypocomplementemia, antinuclear antibodies, and anti-DNA antibodies is consistent with the diagnosis of systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"       \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antiphospholipid antibodies &mdash; The presence of IgG and IgM anticardiolipin antibodies, IgG and IgM anti-&szlig;2-glycoprotein I,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a lupus anticoagulant is consistent with the antiphospholipid syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antistreptococcal antibodies or positive blood cultures &mdash; Antibodies directed against streptococcal antigens, including antistreptolysin O, anti-DNase B or hyaluronidase, or the documentation of positive blood cultures can suggest a diagnosis of poststreptococcal glomerulonephritis or bacterial endocarditis, respectively.",
"     </li>",
"     <li>",
"      Drug screening &mdash; Drug screening can be used in patients with suspected cocaine abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=see_link\">",
"       \"Pulmonary complications of cocaine abuse\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiographic and echocardiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain radiographic or echocardiographic findings may suggest a possible underlying disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the heart size is usually normal, cardiomegaly from myocarditis or pericardial effusion is occasionally seen in DAH associated with the systemic vasculitides and connective tissue diseases.",
"     </li>",
"     <li>",
"      Kerley B lines point to the possible presence of mitral stenosis or pulmonary veno-occlusive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/35\">",
"       35",
"      </a>",
"      ]. Echocardiography can be used to confirm the diagnosis of mitral stenosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=see_link\">",
"       \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=see_link\">",
"       \"Pulmonary veno-occlusive disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage (BAL) is a key step in the diagnosis of DAH, although it is of limited utility in identifying a specific etiology for DAH. In the setting of ARDS, culture and cytologic analysis of BAL fluid can be helpful in identifying an infectious agent responsible for the syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic clues can be found from the biopsy of affected tissue (usually kidney or lung):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Linear IgG deposition along the capillary basement membranes is virtually diagnostic of Goodpasture's syndrome, which sometimes is isolated to the lungs (5 to 10 percent of cases) (",
"      <a class=\"graphic graphic_picture graphicRef63060 \" href=\"UTD.htm?1/33/1552\">",
"       picture 7",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Marked granular immune complex deposition is found in the connective tissue diseases, particularly systemic lupus erythematosus. If, however, the immune deposits are primarily IgA, then Henoch-Sch&ouml;nlein purpura (IgA vasculitis) or IgA nephropathy are the probable diagnoses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are few, if any, deposits by immunofluorescence or electron microscopy (therefore called pauci-immune) in patients with granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, or isolated pulmonary capillaritis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, skin biopsy of a lesion can demonstrate a leukocytoclastic vasculitis. Alternatively, the presence of IgA deposits is suggestive of Henoch-Sch&ouml;nlein purpura (IgA vasculitis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     The patient with DAH and without systemic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the clinician has excluded drug and environmental exposures, mitral valve disease, a coagulation disorder, or a predisposing condition that could lead to ARDS as a possible cause for DAH",
"    <strong>",
"     without",
"    </strong>",
"    systemic findings, four principal diagnostic possibilities remain:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anti-GBM antibody disease (Goodpasture's syndrome) confined to the lung",
"     </li>",
"     <li>",
"      Isolated pulmonary capillaritis with P-ANCA",
"     </li>",
"     <li>",
"      Isolated pulmonary capillaritis without autoantibodies",
"     </li>",
"     <li>",
"      Idiopathic pulmonary hemosiderosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Goodpasture's syndrome can occasionally present or recur as DAH without glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/12\">",
"     12",
"    </a>",
"    ]. In this setting, circulating anti-GBM antibodies are often absent, and the only way to establish the diagnosis is by demonstrating linear immunofluorescence in lung tissue. The underlying histology may be either bland hemorrhage or pulmonary capillaritis.",
"   </p>",
"   <p>",
"    Isolated pulmonary capillaritis with or without P-ANCA positivity is a form of small vessel vasculitis limited to the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/8,16,22\">",
"     8,16,22",
"    </a>",
"    ]. These entities do not fit into the usual vasculitic syndromes. Follow-up evaluation of ANCA-negative patients four years after initial presentation has found no evidence of further systemic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiopathic pulmonary hemosiderosis (IPH) is a diagnosis of exclusion. The disease is primarily seen in younger patients, as only 20 percent of reported cases occur in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/37\">",
"     37",
"    </a>",
"    ]. In the pediatric age group, this disorder is associated with celiac disease and elevated IgA levels in 50 percent of patients. These associations are lacking, however, in the majority of affected adults. The diagnosis of IPH is established by lung biopsy, which demonstrates bland pulmonary hemorrhage without immune complexes. It is likely, however, that cases of isolated pulmonary capillaritis have been diagnosed as IPH, since pathologists are generally unfamiliar with the capillaritis lesion described above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=see_link\">",
"     \"Idiopathic pulmonary hemosiderosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an underlying cause is identified, specific treatment is appropriate when available. Thus, cessation of implicated drugs and exposures, treatment of infection, and reversal of excess anticoagulation are key. DAH due to autoimmune diseases, the retinoic acid syndrome, and sometimes drug-induced is typically treated with systemic glucocorticoids, with additional immunosuppressive therapy as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10847695\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are the mainstay of therapy for the DAH syndrome associated with systemic vasculitis, connective tissue disease, Goodpasture's syndrome, and isolated pulmonary capillaritis. Most authors recommend intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (500 to 2000 mg in divided doses daily) for up to five days followed by gradual tapering and then maintenance on an oral preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10847702\">",
"    <span class=\"h2\">",
"     Additional immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to start additional immunosuppressive therapy for DAH (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) is dependent upon the severity of the illness, the responsiveness to glucocorticoids, and the underlying disease (eg, granulomatosis with polyangiitis (Wegener's) versus drug-induced DAH). If initiated, it is our practice to give one intravenous dose of cyclophosphamide (0.75",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    if renal function is relatively normal). We subsequently pay close attention to the nadir of the peripheral white blood cell count and initiate oral therapy in approximately two weeks if neutropenia does not occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma exchange is generally used in the treatment of DAH associated with Goodpasture's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7432?source=see_link\">",
"     \"Treatment of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    .) In addition, plasma exchange is sometimes used for refractory vasculitis syndromes or DAH associated with a connective tissue disease, but its role in these diseases is less clear (except perhaps in patients with vasculitis involving the kidney who require dialysis during the acute episode) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12597?source=see_link\">",
"     \"Indications for therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible role of intravenous immunoglobulin (IVIG) in patients with DAH due to vasculitis or other connective tissue disease is unknown.",
"   </p>",
"   <p>",
"    In addition to treatment of the capillaritis and underlying disease, patients with severe hemoptysis require general supportive therapy that is based on the degree of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective review of diffuse alveolar hemorrhage in allogeneic hematopoietic cell transplant found an improved survival in 8 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    infusion in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , compared with methylprednisolone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of recombinant human coagulation factor VIIa in patients with diffuse alveolar hemorrhage and other causes of pulmonary hemorrhage is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated episodes of DAH can result in irreversible interstitial fibrosis, particularly in patients with underlying idiopathic pulmonary hemosiderosis, granulomatosis with polyangiitis (Wegener's), and mitral stenosis. In addition, a post-DAH syndrome that consists of severe progressive obstructive lung disease and emphysema has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/30\">",
"     30",
"    </a>",
"    ]. This appears to occur in patients with recurrent DAH due to microscopic polyarteritis, the small vessel variant of polyarteritis nodosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short and long term survival rates vary with the underlying cause of DAH. Patients with systemic lupus erythematosus, vasculitis, anti-GBM antibody disease, and idiopathic pulmonary hemosiderosis have a very high early mortality with rates ranging from 25 to 50 percent (",
"    <a class=\"graphic graphic_table graphicRef79907 \" href=\"UTD.htm?20/53/21339\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23512/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10847330\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The syndrome of diffuse alveolar hemorrhage (DAH) is caused by injury or inflammation of the arterioles, venules, or alveolar septal (alveolar wall or interstitial) capillaries. DAH is associated with a wide variety of disease processes (",
"      <a class=\"graphic graphic_table graphicRef52374 \" href=\"UTD.htm?42/62/44013\">",
"       table 1",
"      </a>",
"      ) that can be divided into three categories, pulmonary capillaritis (",
"      <a class=\"graphic graphic_picture graphicRef76904 graphicRef56943 \" href=\"UTD.htm?28/1/28696\">",
"       picture 1A-B",
"      </a>",
"      ), bland alveolar hemorrhage (",
"      <a class=\"graphic graphic_picture graphicRef52466 \" href=\"UTD.htm?24/55/25462\">",
"       picture 2",
"      </a>",
"      ), and diffuse alveolar damage (DAD) (",
"      <a class=\"graphic graphic_picture graphicRef53020 \" href=\"UTD.htm?15/17/15638\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cough, hemoptysis, fever, and dyspnea are common initial symptoms, although hemoptysis may be absent in up to 33 percent of patients with DAH from any cause. In the absence of hemoptysis, new radiographic opacities (either localized or diffuse), a falling hemoglobin level, and the finding of increasingly hemorrhagic fluid on sequential bronchoalveolar lavage favor the diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Useful diagnostic clues include a history of exposure to possible offending drugs or other causative agents, (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , crack cocaine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"       propylthiouracil",
"      </a>",
"      , anticoagulants, trimellitic anhydride), an underlying process (eg, diarrhea suggestive of Henoch-Sch&ouml;nlein purpura [IgA vasculitis], bone marrow transplant, immunosuppression), or cutaneous evidence of a systemic disease (eg, Raynaud&rsquo;s, palpable purpura). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clues to a specific etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The finding of concomitant renal disease, specific auto-antibodies (eg, antinuclear, anticardiolipin, antiglomerular basement membrane), a positive culture, or positive drug screen may suggest or permit the diagnosis of a particular underlying disorder. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thoracic CT scanning typically shows ground glass or consolidative opacities that are diffuse and bilateral (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79321 \" href=\"UTD.htm?10/7/10353\">",
"       image 2",
"      </a>",
"      ), but may occasionally be unilateral. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sequential bronchoalveolar lavage (BAL) is a key step in the diagnosis of DAH, although it rarely identifies a specific etiology. BAL is performed in an area where radiographic opacities are noted. Progressively more hemorrhagic lavage returns and the presence of hemosiderin-laden macrophages on cytologic staining confirm the presence of alveolar hemorrhage. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bronchoalveolar lavage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of DAH is made, the underlying cause is sought through careful review of the history, physical examination, and laboratory tests. A skin biopsy may be helpful diagnostically in patients with a rash suggestive of vasculitis or Henoch-Sch&ouml;nlein purpura (IgA vasculitis). When the underlying cause remains unclear after a careful evaluation, a lung or kidney biopsy may be necessary to determine the underlying cause. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When an underlying cause of DAH is identified, specific treatment is appropriate when available. Thus, cessation of implicated drugs and exposures, treatment of infection, and reversal of excess anticoagulation are key. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids are the mainstay of therapy for the DAH syndrome associated with systemic vasculitis, connective tissue disease, Goodpasture's syndrome, and isolated pulmonary capillaritis. The initial dose is usually given as a pulse of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (500 to 2000 mg in divided doses daily) for up to five days, followed by gradual tapering and then maintenance with an oral preparation. (See",
"      <a class=\"local\" href=\"#H10847695\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to start additional immunosuppressive therapy for DAH (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , plasmapheresis) is dependent upon the severity of the illness, the responsiveness to glucocorticoids, and the underlying disease. For patients with granulomatosis with polyangiitis (Wegener's) or anti-glomerular basement membrane (Goodpasture) disease, treatment follows guidelines for those diseases. For patients with a drug-induced DAH, cessation of the drug and initiation of systemic glucocorticoids may be adequate. (See",
"      <a class=\"local\" href=\"#H10847702\">",
"       'Additional immunosuppressive agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/1\">",
"      Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Clin Chest Med 2004; 25:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/2\">",
"      Franks TJ, Koss MN. Pulmonary capillaritis. Curr Opin Pulm Med 2000; 6:430.",
"     </a>",
"    </li>",
"    <li>",
"     Fontenot AP, Schwarz MI. Diffuse alveolar hemorrhage. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.632.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/4\">",
"      Mark EJ, Ramirez JF. Pulmonary capillaritis and hemorrhage in patients with systemic vasculitis. Arch Pathol Lab Med 1985; 109:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/5\">",
"      Leatherman JW. The lung in systemic vasculitis. Semin Respir Infect 1988; 3:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/6\">",
"      Travis WD, Colby TV, Lombard C, Carpenter HA. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990; 14:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/7\">",
"      Lenclud C, De Vuyst P, Dupont E, et al. Wegener's granulomatosis presenting as acute respiratory failure with anti-neutrophil-cytoplasm antibodies. Chest 1989; 96:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/8\">",
"      Bosch X, L&oacute;pez-Soto A, Mirapeix E, et al. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. Arch Pathol Lab Med 1994; 118:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/9\">",
"      Gaudin PB, Askin FB, Falk RJ, Jennette JC. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol 1995; 104:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/10\">",
"      Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/11\">",
"      Kelly PT, Haponik EF. Goodpasture syndrome: molecular and clinical advances. Medicine (Baltimore) 1994; 73:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/12\">",
"      Tobler A, Sch&uuml;rch E, Altermatt HJ, Im Hof V. Anti-basement membrane antibody disease with severe pulmonary haemorrhage and normal renal function. Thorax 1991; 46:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/13\">",
"      Myers JL, Katzenstein AA. Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol 1986; 85:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/14\">",
"      Schwarz MI, Sutarik JM, Nick JA, et al. Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis. Am J Respir Crit Care Med 1995; 151:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/15\">",
"      Torralbo A, Herrero JA, Portol&eacute;s J, Barrientos A. Alveolar hemorrhage associated with antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Chest 1994; 105:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/16\">",
"      Jennings CA, King TE Jr, Tuder R, et al. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med 1997; 155:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/17\">",
"      Gertner E, Lie JT. Pulmonary capillaritis, alveolar hemorrhage, and recurrent microvascular thrombosis in primary antiphospholipid syndrome. J Rheumatol 1993; 20:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/18\">",
"      Robboy SJ, Minna JD, Colman RW, et al. Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases. Chest 1973; 63:718.",
"     </a>",
"    </li>",
"    <li>",
"     Haselton PS. Adult respiratory distress syndrome. In: Spencers Pathology of the Lung, Haselton PS (Ed), McGraw Hill, New York 1996. p.375.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/20\">",
"      Schwarz MI, Zamora MR, Hodges TN, et al. Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease. Chest 1998; 113:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/21\">",
"      Colby TV, Fukuoka J, Ewaskow SP, et al. Pathologic approach to pulmonary hemorrhage. Ann Diagn Pathol 2001; 5:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/22\">",
"      Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax 2000; 55:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/23\">",
"      Lazor R, Bigay-Gam&eacute; L, Cottin V, et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore) 2007; 86:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/24\">",
"      Dhillon SS, Singh D, Doe N, et al. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 1999; 116:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/25\">",
"      Bansal, S, Khan, R, Cicenia, J. et al. Alveolar hemorrhage associated with administration of glycoprotein IIA/IIIB inhibitor eptifibatide. Crit Care Med 2006; 34:A165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/26\">",
"      Kim EA, Lee KS, Primack SL, et al. Viral pneumonias in adults: radiologic and pathologic findings. Radiographics 2002; 22 Spec No:S137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/27\">",
"      Alexandrescu DT, Dutcher JP, O'Boyle K, et al. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/28\">",
"      Anantham D, Chan KP, Chuah KL, et al. Pulmonary capillaritis in IgA nephropathy. South Med J 2007; 100:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/29\">",
"      Luks AM, Lakshminarayanan S, Hirschmann JV. Leptospirosis presenting as diffuse alveolar hemorrhage: case report and literature review. Chest 2003; 123:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/30\">",
"      Schwarz MI, Mortenson RL, Colby TV, et al. Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation. Am Rev Respir Dis 1993; 148:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/31\">",
"      De Lassence A, Fleury-Feith J, Escudier E, et al. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 1995; 151:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/32\">",
"      Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004; 79:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/33\">",
"      Zeiss CR, Wolkonsky P, Chacon R, et al. Syndromes in workers exposed to trimellitic anhydride. A longitudinal clinical and immunologic study. Ann Intern Med 1983; 98:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/34\">",
"      Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies \"Orphelines\" Pulmonaires (GERM\"O\"P). Medicine (Baltimore) 2000; 79:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/35\">",
"      Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/36\">",
"      Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest 2010; 137:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/37\">",
"      Yeager H Jr, Powell D, Weinberg RM, et al. Idiopathic pulmonary hemosiderosis: ultrastructural studies and responses to azathioprine. Arch Intern Med 1976; 136:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/38\">",
"      Savage CO, Pusey CD, Bowman C, et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986; 292:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/39\">",
"      Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996; 7:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/40\">",
"      Glassock RJ. Intensive plasma exchange in crescentic glomerulonephritis: help or no help? Am J Kidney Dis 1992; 20:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/41\">",
"      Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/42\">",
"      G&oacute;mez-Puerta JA, Hern&aacute;ndez-Rodr&iacute;guez J, L&oacute;pez-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 2009; 136:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23512/abstract/43\">",
"      Wanko SO, Broadwater G, Folz RJ, Chao NJ. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant 2006; 12:949.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4341 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23512=[""].join("\n");
var outline_f22_61_23512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10847330\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pulmonary capillaritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bland pulmonary hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diffuse alveolar damage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLUES TO A SPECIFIC ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiographic and echocardiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      The patient with DAH and without systemic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10847695\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10847702\">",
"      Additional immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10847330\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4341|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/49/3857\" title=\"diagnostic image 1A\">",
"      DAH PA I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/29/33247\" title=\"diagnostic image 1B\">",
"      DAH PA II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/7/10353\" title=\"diagnostic image 2\">",
"      DAH CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4341|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/16/14592\" title=\"picture 1A\">",
"      Pulmonary capillaritis DAH I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/35/18998\" title=\"picture 1B\">",
"      Pulmonary capillaritis DAH II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/55/25462\" title=\"picture 2\">",
"      Bland alveolar hemorrhage DAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/17/15638\" title=\"picture 3\">",
"      Diffuse alveolar damage DAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9794\" title=\"picture 4\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/16/22786\" title=\"picture 5\">",
"      Leukocytoclastic vasculitis - lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/51/39742\" title=\"picture 6A\">",
"      C ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/6/17518\" title=\"picture 6B\">",
"      P ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/33/1552\" title=\"picture 7\">",
"      Anti GBM disease IF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4341|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/62/44013\" title=\"table 1\">",
"      Causes of DAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/53/21339\" title=\"table 2\">",
"      Survival in DAH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=related_link\">",
"      Etiology and evaluation of hemoptysis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12597?source=related_link\">",
"      Indications for therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14745?source=related_link\">",
"      Pulmonary complications after autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=related_link\">",
"      Pulmonary complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=related_link\">",
"      Pulmonary veno-occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7432?source=related_link\">",
"      Treatment of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_61_23513="Ischemic stroke in children and young adults: Etiology and clinical features";
var content_f22_61_23513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ischemic stroke in children and young adults: Etiology and clinical features",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23513/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23513/contributors\">",
"     Sabrina E Smith, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23513/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23513/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23513/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23513/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/61/23513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more common in older adults, stroke also occurs in neonates, infants, children, and young adults, resulting in significant morbidity and mortality.",
"   </p>",
"   <p>",
"    An overview of the epidemiology, risk factors, etiology, clinical presentation, and differential diagnosis of arterial ischemic stroke (AIS) in children one month of age or older and adults younger than 50 years of age is provided here. Other aspects of ischemic stroke in children and young adults are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link\">",
"     \"Ischemic stroke in children: Evaluation, initial management, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27063?source=see_link\">",
"     \"Ischemic stroke in children: Secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link\">",
"     \"Stroke in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual incidence rates of arterial ischemic stroke (AIS) in infants and children range from 0.6 to",
"    <span class=\"nowrap\">",
"     7.9/100,000",
"    </span>",
"    children per year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In adults younger than 45 years old, incidence ranges from 3.4 to",
"    <span class=\"nowrap\">",
"     11.3/100,000",
"    </span>",
"    people per year in primarily white populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], while the incidence in young black adults is as high as",
"    <span class=\"nowrap\">",
"     22.8/100,000",
"    </span>",
"    people per year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have found that pediatric ischemic stroke is more common in boys than in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. As an example, among 1187 children in a multinational pediatric registry of arterial ischemic stroke and cerebral sinovenous thrombosis cases, boys made up 710 of 1187 cases (60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/9\">",
"     9",
"    </a>",
"    ]. Male predominance was present regardless of age, stroke subtype, or a history of trauma. The explanation for the apparent male predominance is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologies and risk factors for arterial ischemic stroke (AIS) in children and young adults differ from those typical in older adults",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children and young adults, congenital and acquired heart problems, hematologic conditions, vasculopathies, metabolic disorders, and drug ingestion are more common (",
"      <a class=\"graphic graphic_table graphicRef55210 \" href=\"UTD.htm?19/42/20142\">",
"       table 1",
"      </a>",
"      ). These are discussed individually below.",
"     </li>",
"     <li>",
"      In older adults, hypertension, smoking, diabetes, and hypercholesterolemia are more common. These risk factors are also present in some young adults [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/10,11\">",
"       10,11",
"      </a>",
"      ] and rarely in children [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Etiologies and risk factors in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common etiologies and risk factors for ischemic stroke in children include cardiac abnormalities, vascular lesions, hematologic abnormalities, infection, head and neck trauma, and genetic conditions; the incidence of these factors varies greatly depending on the population being studied.",
"   </p>",
"   <p>",
"    Data on pediatric stroke come from several population-based or referral-based cohorts, as well as smaller case series. None were conducted with standardized evaluations in all patients, so the true incidence of risk factors cannot be inferred.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multi-center report that evaluated over 600 children (age 29 days to 18 years) with AIS identified from the referral-based cohort of the International Pediatric Stroke Study, the most frequent conditions associated with AIS were arteriopathy, cardiac disorders, and infection, seen in 53, 31, and 24 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single center retrospective study from the United Kingdom involving 212 children with first arterial ischemic stroke, 54 percent were previously healthy with no known risk factors for stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/12\">",
"       12",
"      </a>",
"      ]. Cerebral vascular abnormalities were identified in 147 of 185 patients (79 percent) who had arterial imaging, while cardiac abnormalities were present in 48 of 164 patients (28 percent) who had either known cardiac disease or were evaluated by echocardiography. Complete thrombophilia evaluation was not obtained in all patients, but 40 percent were anemic and 16 percent had sickle cell disease. Elevated temperature at the time of the stroke was present in 43 percent.",
"     </li>",
"     <li>",
"      In a population-based registry from Germany involving 324 children with first stroke who had comprehensive hematologic testing, 12 percent had cardiac abnormalities, 18 percent had vasculopathy, 10 percent had infection, and 56 percent had a prothrombotic defect [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A nested case-control study within a retrospective population-based cohort from California evaluated 126 incident cases of childhood arterial ischemic stroke and 378 matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/15\">",
"       15",
"      </a>",
"      ]. The most prevalent independent risk factors for arterial ischemic stroke were minor acute infection in the preceding 4 weeks and head or neck trauma in the preceding 12 weeks, present in 33 and 12 percent of cases, respectively. Additional independent risk factors were autoimmune disease, cardiac disease, and hematologic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Etiologies and risk factors in young adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young adults with stroke, data on causes and risk factors come from just a few single center or population-based cohorts. Conditions associated with ischemic stroke include vasculopathy (such as arterial dissection), cardiac defects, recent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/16\">",
"     16",
"    </a>",
"    ], other hypercoagulable states, smoking, illicit drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/17\">",
"     17",
"    </a>",
"    ], premature atherosclerosis, hypertension, and possibly migraine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link\">",
"     \"Headache, migraine, and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest cohorts consisted of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke from Finland [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/18\">",
"       18",
"      </a>",
"      ]. The following observations were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stroke occurrence increased exponentially with age (",
"      <a class=\"graphic graphic_figure graphicRef64724 \" href=\"UTD.htm?23/10/23713\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Overall, the most frequent risk factors were dyslipidemia, smoking, and hypertension, found in 60, 44 and 39 percent, respectively",
"     </li>",
"     <li>",
"      The most common etiologies were cardioembolism and cervicocephalic arterial dissection in 20 and 15 percent respectively; the proportions of small vessel disease and large artery atherosclerosis (14 and 8 percent) increased beginning at age 30 to 35, while the frequency of undetermined etiology (33 percent) decreased with age (",
"      <a class=\"graphic graphic_figure graphicRef52939 \" href=\"UTD.htm?21/10/21679\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center prospectively identified cohort of 324 patients (14 to 47 years old) undergoing standardized clinical assessment, traditional risk factors such as smoking (56 percent), hypertension (23 percent), dyslipidemia (15 percent), and diabetes mellitus (2 percent) were not uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/19\">",
"       19",
"      </a>",
"      ]. Oral contraceptives were used by 38 percent of the women. After evaluation, the stroke etiology was considered cardioembolic in 34 percent, hematologic in 12 percent, atherothrombotic in 12 percent, and secondary to other vasculopathies in 14 percent.",
"     </li>",
"     <li>",
"      In a retrospective case-control study of 466 women with ischemic stroke (15 to 49 years old) and 604 matched controls, the risk of ischemic stroke increased in direct relationship to the number of cigarettes smoked per day [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single center consecutive cohort of 273 young adults with stroke or transient ischemic attack (TIA), 24 percent had structural cardiac abnormalities including patent foramen ovale (PFO) and mitral valve prolapse, and 13 percent had arterial dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral contraceptive use is associated with stroke, but some studies of women using formulations containing low-dose estradiol have not confirmed this association. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H10#H10\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital heart disease is a risk factor for cardioembolic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/14,22,23\">",
"     14,22,23",
"    </a>",
"    ], especially in the perioperative period or following catheterization or extracorporeal membrane oxygenation (ECMO). However, the role of common cardiac abnormalities such as PFO and mitral valve prolapse remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acquired cardiac lesions, including endocarditis, cardiomyopathy, and prosthetic valve placement, are risk factors for stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell disease is the most common cause of stroke in children, with a rate approximately 300 times higher than that seen in children without SCD. The rate is highest in hemoglobin SS. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link&amp;anchor=H2#H2\">",
"     \"Cerebrovascular complications of sickle cell disease\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous other inherited or acquired prothrombotic disorders have been associated with pediatric stroke in case series, case-control studies, and prospective cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/12,25-28\">",
"     12,25-28",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia (particularly iron deficiency)",
"     </li>",
"     <li>",
"      Antiphospholipid syndrome",
"     </li>",
"     <li>",
"      Abnormal activated protein C resistance (usually related to the Factor V Leiden mutation)",
"     </li>",
"     <li>",
"      Protein C deficiency",
"     </li>",
"     <li>",
"      Protein S deficiency",
"     </li>",
"     <li>",
"      Antithrombin III deficiency",
"     </li>",
"     <li>",
"      Prothrombin gene mutation",
"     </li>",
"     <li>",
"      Elevated lipoprotein(a)",
"     </li>",
"     <li>",
"      Elevated homocysteine, often associated with homozygous mutation of the methylenetetrahydrofolate reductase (MTHFR) gene",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The strongest evidence supporting an association of prothrombotic conditions with pediatric stroke comes from a meta-analysis of 22 observational studies that included 1526 children with AIS, 238 with cerebral venous sinus thrombosis, and 2700 control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/29\">",
"     29",
"    </a>",
"    ]. Summary odds ratios (OR) for AIS were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two or more genetic thrombophilias, OR 18.6 (95% CI 6.5-54.1)",
"     </li>",
"     <li>",
"      Protein C deficiency, OR 11.0 (95% CI 5.1-23.6)",
"     </li>",
"     <li>",
"      Antiphospholipid",
"      <span class=\"nowrap\">",
"       antibodies/lupus",
"      </span>",
"      anticoagulant, OR 7.0 (95% CI 3.7-13.1)",
"     </li>",
"     <li>",
"      Elevated lipoprotein(a), OR 6.5 (95% CI 4.5-9.6)",
"     </li>",
"     <li>",
"      Factor V Leiden mutation, OR 3.7 (95% CI 2.8-4.9)",
"     </li>",
"     <li>",
"      Antithrombin III deficiency, OR 3.3 (95% CI 0.7-15.5)",
"     </li>",
"     <li>",
"      Prothrombin gene mutation, OR 2.6 (95% CI 1.7-4.1)",
"     </li>",
"     <li>",
"      MTHFR TT genotype, OR 1.6 (95% CI 1.2-2.1)",
"     </li>",
"     <li>",
"      Protein S deficiency, OR 1.5 (95% CI 0.3-6.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association with AIS was statistically significant for all of the above traits except antithrombin III deficiency and protein S deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/29\">",
"     29",
"    </a>",
"    ]. The strength of these findings is limited by the observational methodology of the included studies, the uncertain quality of the control subjects, and the potential for confounding from transient acquired abnormalities of some thrombophilic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In young adults, several of these factors are associated with venous thromboembolism but not clearly with AIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/31\">",
"     31",
"    </a>",
"    ]. Because of the small size of many of the studies reporting associated prothrombotic abnormalities in patients with stroke and the high frequency of some of these abnormalities in the general population, the precise contribution of these prothrombotic states to stroke pathophysiology remains unclear. A systematic review and meta-analysis of 18 case-control studies in young adults found that factor V Leiden mutation was present in a significantly greater proportion of 2045 stroke cases compared with 5307 controls (7.5 versus 4.1 percent, odds ratio [OR] 2.0, 95% CI 1.59-2.51) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/32\">",
"     32",
"    </a>",
"    ]. However, among eight studies that included cases from consecutive neurology referrals or hospitalizations (&ldquo;unselected cases&rdquo;) rather than referrals for cryptogenic stroke or thrombophilic evaluation (&ldquo;selected cases&rdquo;), the association between factor V Leiden mutation and stroke just missed statistical significance (OR 1.4, 95% CI 0.99-1.95). These results suggest that Factor V Leiden is associated with an increased risk of ischemic stroke in young adults, but this effect was largely seen in patients with cryptogenic stroke or referred for a thrombophilic evaluation.",
"   </p>",
"   <p>",
"    Prothrombotic medications such as L-asparaginase and oral contraceptives are also associated with stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H10#H10\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the cerebral vasculature, whether inherited or acquired, predispose to AIS in the young. These can be divided into noninflammatory and inflammatory etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/33\">",
"     33",
"    </a>",
"    ]. A report from the Pediatric Stroke Study of 525 children (age 29 days to 19 years) with AIS and vascular imaging found arteriopathy in 277 (53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/13\">",
"     13",
"    </a>",
"    ]. In the 277 cases with arteriopathy, the following types were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal cerebral arteriopathy of childhood, 25 percent",
"     </li>",
"     <li>",
"      Primary or secondary moyamoya disease, 22 percent",
"     </li>",
"     <li>",
"      Dissection, 20 percent",
"     </li>",
"     <li>",
"      Vasculitis, 12 percent",
"     </li>",
"     <li>",
"      Sickle cell disease arteriopathy, 8 percent",
"     </li>",
"     <li>",
"      Postvaricella arteriopathy, 7 percent",
"     </li>",
"     <li>",
"      Miscellaneous types, 4 percent",
"     </li>",
"     <li>",
"      Unspecified, 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent predictors of arteriopathy were sickle cell disease, age group five to nine years, and recent upper respiratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Focal cerebral arteriopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal cerebral arteriopathy of childhood (FCA) is the term used by the International Pediatric Stroke Study (IPSS) group to describe an unexplained focal arterial stenosis in a child with AIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/13\">",
"     13",
"    </a>",
"    ]. The term FCA encompasses cases that others have labeled \"transient cerebral arteriopathy of childhood\", described immediately below. In the IPSS study, the only independent predictor of FCA was recent upper respiratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient cerebral arteriopathy of childhood is a clinical syndrome characterized by unilateral focal or segmental stenosis of the distal carotid arteries and proximal Circle of Willis vessels (the middle, anterior, and posterior cerebral arteries). The stenosis may worsen in the first three months after stroke, sometimes associated with new neurologic symptoms, but stabilizes and can even improve by six months after initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/34\">",
"     34",
"    </a>",
"    ]. While the term \"transient\" implies complete resolution, many patients are left with some degree of residual arterial stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/33,35\">",
"     33,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemic stroke associated with transient cerebral arteriopathy of childhood typically occurs in the distribution of the lenticulostriate branches that arise from the proximal segments of the middle cerebral artery and anterior cerebral artery, supplying the basal ganglia and internal capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In a subset of cases, this finding is associated with antecedent varicella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/35-37\">",
"     35-37",
"    </a>",
"    ] and other viral infections may underlie the pathophysiology in idiopathic cases.",
"   </p>",
"   <p>",
"    The etiology of focal cerebral arteriopathy and transient cerebral arteriopathy of childhood is unknown, but is probably multifactorial. Possible causes are inflammation and vasculitis due to infection (eg, antecedent varicella infection) or autoimmune disease, thromboembolic arterial occlusion or stenosis followed by variable recanalization, intracranial dissection, arterial spasm, and prothrombotic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, some investigators distinguish postvaricella arteriopathy from transient cerebral arteriopathy of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one retrospective review of 24 children with AIS and preceding varicella infection, all had arteriopathy affecting the M1 segment of the middle cerebral artery and ischemic stroke in that distribution, while 10 children had additional arteriopathy affecting other intracranial vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Moyamoya",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moyamoya syndrome is characterized by progressive stenosis of the internal carotid arteries and formation of collateral vessels that give a \"puff of smoke\" appearance on angiography. Moyamoya disease occurs mainly in Japanese and other Asian populations and may have a genetic basis. Secondary moyamoya syndrome is seen in association with neurofibromatosis, Down syndrome, Williams syndrome, sickle cell disease, and as a sequela of cranial irradiation. In children, moyamoya typically presents with recurrent TIAs or ischemic strokes, while intracranial hemorrhage is more common in young adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=see_link\">",
"     \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial dissection is the most common vascular abnormality in some young adult series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/10,19,21,42,43\">",
"     10,19,21,42,43",
"    </a>",
"    ], and is a cause of stroke in children as well [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/2,7,12\">",
"     2,7,12",
"    </a>",
"    ]. While definite or probable trauma is identified in some patients, spontaneous dissection also occurs. Connective tissue disorders such as vascular Ehlers-Danlos syndrome and Marfan syndrome can predispose to dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=see_link\">",
"     \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis (inflammatory changes in the cerebral vessels) can be primary or secondary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary vasculitides associated with stroke include Takayasu arteritis, giant cell arteritis, polyarteritis nodosa, Kawasaki disease, and primary angiitis of the central nervous system. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=see_link\">",
"       \"Clinical features and diagnosis of Takayasu arteritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"       \"Clinical manifestations of giant cell (temporal) arteritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link\">",
"       \"Primary angiitis of the central nervous system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary vasculitides are associated with collagen vascular diseases such as lupus or infections. Bacterial meningitis, viral infections including HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/44,45\">",
"       44,45",
"      </a>",
"      ] and varicella [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/36\">",
"       36",
"      </a>",
"      ], syphilis, central nervous system tuberculosis, and fungi can cause cerebral vasculitis resulting in stroke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"       \"Systemic lupus erythematosus in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"       \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=see_link&amp;anchor=H13#H13\">",
"       \"Neurologic complications of bacterial meningitis in children\", section on 'Cerebrovascular complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"       \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"       \"Neurosyphilis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link\">",
"       \"Central nervous system tuberculosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840561#H18840561\">",
"       \"Natural history and classification of pediatric HIV infection\", section on 'Other'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other abnormalities of vessel structure have been associated with ischemic stroke, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arterial tortuosity syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia",
"     </li>",
"     <li>",
"      Vasospasm resulting from subarachnoid hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Metabolic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several metabolic conditions are associated with AIS, generally through effects on the vessel wall.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CADASIL (cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is caused by a mutation in the Notch3 gene, which leads to progressive degeneration of smooth muscle cells in the vessel wall. Patients with CADASIL may present with migraine, TIA, or ischemic stroke in late childhood or early adulthood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11530?source=see_link\">",
"       \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fabry disease, an X-linked lysosomal storage disorder due to deficiency of a-galactosidase A, may result in vessel narrowing and infarction in affected young adult males and carrier females. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=see_link\">",
"       \"Neurologic manifestations of Fabry disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Homocystinuria is a rare condition associated with stroke in which elevated plasma homocysteine results from a deficiency of cystathionine beta-synthase. Thromboembolism has been implicated as the stroke mechanism in a small case series and a case report [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Menkes' disease, a rare X-linked condition resulting in impaired copper transport, is associated with cerebral vessel tortuosity and stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     MELAS and disorders causing metabolic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some metabolic conditions are associated with metabolic stroke rather than arterial stroke. This category includes the syndrome of mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), a maternally inherited multisystem disorder caused by mutations of mitochondrial DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The hallmark of this syndrome is the occurrence of stroke-like episodes that result in hemiparesis, hemianopia, or cortical blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/51,53\">",
"     51,53",
"    </a>",
"    ]. Other common features include focal or generalized seizures, recurrent migraine-like headaches, vomiting, short stature, hearing loss, and muscle weakness.",
"   </p>",
"   <p>",
"    MELAS usually manifests in childhood after a normal early development [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/51,53\">",
"     51,53",
"    </a>",
"    ]. A relapsing-remitting course is most common, with stroke-like episodes leading to progressive neurologic dysfunction and dementia.",
"   </p>",
"   <p>",
"    A multitude of transfer RNA mutations in mitochondrial DNA can be responsible for MELAS but 80 percent of cases are related to the A3243G mutation and 10 percent to the T3271C transfer RNA mutation.",
"   </p>",
"   <p>",
"    The original diagnostic criteria for MELAS required stroke-like episodes before age 40 years, encephalopathy characterized by seizures or dementia, and either blood lactic acidosis or the presence of ragged red fibers in skeletal muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. However, a broader range of phenotypes is now recognized as compatible with the diagnosis, including clinical onset after age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other metabolic disorders associated with metabolic stroke typically present in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/57\">",
"     57",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organic acid disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Methylmalonic acidemia",
"     </li>",
"     <li>",
"      Propionic acidemia",
"     </li>",
"     <li>",
"      Isovaleric acidemia",
"     </li>",
"     <li>",
"      Glutaric aciduria types 1 and 2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ornithine transcarbamylase deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"       \"Urea cycle disorders: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Carbohydrate deficient glycoprotein syndrome type Ia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of sympathomimetic drugs, such as cocaine and methamphetamine, can cause stroke due to hypertension, vasospasm, or vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with stroke may present with focal weakness, but are more likely than older children to present with seizures and altered mental status [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/22\">",
"     22",
"    </a>",
"    ]. Older children usually have hemiparesis or other focal neurologic signs such as aphasia, visual disturbance, or cerebellar signs, although seizures, headache, and lethargy are not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Neck pain can be associated with cervical artery dissection, and a Horner's syndrome may accompany carotid dissection.",
"   </p>",
"   <p>",
"    Early infarct signs, such as cortical effacement with loss of gray-white differentiation, loss of the insular ribbon, and hyperdense artery sign, may be observed on noncontrast head CT acutely, and within 24 hours hypodensity in an arterial territory may be appreciated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H3#H3\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Early signs of infarction on noncontrast CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On brain MRI, acute stroke is associated with restricted diffusion in an arterial territory on diffusion weighted imaging (DWI), just as in older adults. This can persist for 7 to 14 days after stroke onset, at which time restricted diffusion transitions to increased diffusion. Subacute stroke is associated with increased T2-weighted signal and enhancement with gadolinium. Chronic stroke is associated with increased diffusion, increased T2 signal, and evidence of volume loss, including ex vacuo dilatation of the lateral ventricles or porencephaly. Gradient echo imaging is sensitive to the presence of blood products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H10#H10\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from a prospectively identified cohort of 63 children with acute arterial ischemic stroke suggest that hemorrhagic transformation is observed in approximately 30 percent of children within one month of stroke onset [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/62\">",
"     62",
"    </a>",
"    ]. In most cases, the hemorrhage is clinically asymptomatic and has a petechial appearance on brain imaging with CT or MRI.",
"   </p>",
"   <p>",
"    As in adults, the diagnosis of stroke is often delayed in children. In a retrospective series of 209 children (one month to 18 years old) who presented with acute arterial ischemic stroke, the mean interval from symptom onset to diagnosis was 22.7 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of arterial ischemic stroke (AIS) is broad, as numerous other conditions can present with acute neurologic deficits. In addition, the differential is further extended in young children because stroke may present with nonspecific signs such as seizures or lethargy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular abnormalities such as intracranial hemorrhage, aneurysm, arteriovenous malformation, and cerebral venous sinus thrombosis can present much like AIS.",
"     </li>",
"     <li>",
"      Nonvascular conditions that mimic stroke in children include tumors and other structural brain lesions, prolonged postictal paresis (Todd's), complicated migraine, familial alternating hemiplegia, reversible posterior leukoencephalopathy syndrome, metabolic stroke, intracranial infection (brain abscess or meningoencephalitis), demyelinating conditions such as acute disseminated encephalomyelitis, idiopathic intracranial hypertension, drug toxicity, postinfectious cerebellitis, musculoskeletal conditions, and psychogenic conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/64\">",
"       64",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      In adults, the differential diagnosis includes seizure and postictal deficits, migraine, systemic infection, psychiatric disorders, brain tumor, toxic-metabolic abnormalities, cranial neuropathy, transient global amnesia, and syncope or presyncope [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23513/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"       \"Differential diagnosis of transient ischemic attack and stroke\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiologies and risk factors for arterial ischemic stroke in children and young adults differ from those typical in older adults, although hypertension, smoking, diabetes, and hypercholesterolemia are found in some young adults and rarely in children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conditions commonly associated with arterial ischemic stroke in children and young adults include congenital and acquired cardiac lesions, vascular lesions, hematologic abnormalities, infection, head and neck trauma, and genetic conditions (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sickle cell disease is the most common cause of stroke in children, and numerous inherited or acquired prothrombotic disorders have been associated with stroke in children and young adults.",
"     </li>",
"     <li>",
"      Abnormalities of the cerebral vasculature predispose to arterial ischemic stroke and include arterial dissection, focal (or transient) cerebral arteriopathy of childhood, fibromuscular dysplasia, moyamoya syndrome, and vasculitis.",
"     </li>",
"     <li>",
"      Metabolic conditions associated with arterial ischemic stroke, generally through effects on the vessel wall, include CADASIL, Fabry disease, homocystinuria, and Menkes' disease.",
"     </li>",
"     <li>",
"      MELAS and other rare disorders are associated with metabolic stroke",
"     </li>",
"     <li>",
"      Arterial dissection is the most common vascular abnormality in some young adult series. Additional risk factors in young adults include recent pregnancy, drug use, premature atherosclerosis, and possibly migraine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with stroke often present with seizures, altered mental status, or focal weakness. Children with stroke typically present with hemiparesis or other focal neurologic signs such as aphasia, visual disturbance, or cerebellar signs, although seizures, headache, and lethargy are not uncommon. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of arterial ischemic stroke is broad, as numerous other conditions can present with acute neurologic deficits. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/1\">",
"      Giroud M, Lemesle M, Gouyon JB, et al. Cerebrovascular disease in children under 16 years of age in the city of Dijon, France: a study of incidence and clinical features from 1985 to 1993. J Clin Epidemiol 1995; 48:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/2\">",
"      Earley CJ, Kittner SJ, Feeser BR, et al. Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study. Neurology 1998; 51:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/3\">",
"      Tuckuviene R, Christensen AL, Helgestad J, et al. Paediatric arterial ischaemic stroke and cerebral sinovenous thrombosis in Denmark 1994-2006: a nationwide population-based study. Acta Paediatr 2011; 100:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/4\">",
"      Nencini P, Inzitari D, Baruffi MC, et al. Incidence of stroke in young adults in Florence, Italy. Stroke 1988; 19:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/5\">",
"      Kristensen B, Malm J, Carlberg B, et al. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden. Stroke 1997; 28:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/6\">",
"      Kittner SJ, McCarter RJ, Sherwin RW, et al. Black-white differences in stroke risk among young adults. Stroke 1993; 24:I13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/7\">",
"      Str&auml;ter R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study. Lancet 2002; 360:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/8\">",
"      Fullerton HJ, Wu YW, Zhao S, Johnston SC. Risk of stroke in children: ethnic and gender disparities. Neurology 2003; 61:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/9\">",
"      Golomb MR, Fullerton HJ, Nowak-Gottl U, et al. Male predominance in childhood ischemic stroke: findings from the international pediatric stroke study. Stroke 2009; 40:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/10\">",
"      Leys D, Bandu L, H&eacute;non H, et al. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology 2002; 59:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/11\">",
"      Naess H, Waje-Andreassen U, Thomassen L, et al. Do all young ischemic stroke patients need long-term secondary preventive medication? Neurology 2005; 65:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/12\">",
"      Ganesan V, Prengler M, McShane MA, et al. Investigation of risk factors in children with arterial ischemic stroke. Ann Neurol 2003; 53:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/13\">",
"      Amlie-Lefond C, Bernard TJ, S&eacute;bire G, et al. Predictors of cerebral arteriopathy in children with arterial ischemic stroke: results of the International Pediatric Stroke Study. Circulation 2009; 119:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/14\">",
"      Mackay MT, Wiznitzer M, Benedict SL, et al. Arterial ischemic stroke risk factors: the International Pediatric Stroke Study. Ann Neurol 2011; 69:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/15\">",
"      Hills NK, Johnston SC, Sidney S, et al. Recent trauma and acute infection as risk factors for childhood arterial ischemic stroke. Ann Neurol 2012; 72:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/16\">",
"      Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/17\">",
"      de los R&iacute;os F, Kleindorfer DO, Khoury J, et al. Trends in substance abuse preceding stroke among young adults: a population-based study. Stroke 2012; 43:3179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/18\">",
"      Putaala J, Metso AJ, Metso TM, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 2009; 40:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/19\">",
"      Rasura M, Spalloni A, Ferrari M, et al. A case series of young stroke in Rome. Eur J Neurol 2006; 13:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/20\">",
"      Bhat VM, Cole JW, Sorkin JD, et al. Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke 2008; 39:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/21\">",
"      Cerrato P, Grasso M, Imperiale D, et al. Stroke in young patients: etiopathogenesis and risk factors in different age classes. Cerebrovasc Dis 2004; 18:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/22\">",
"      Zimmer JA, Garg BP, Williams LS, Golomb MR. Age-related variation in presenting signs of childhood arterial ischemic stroke. Pediatr Neurol 2007; 37:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/23\">",
"      Rodan L, McCrindle BW, Manlhiot C, et al. Stroke recurrence in children with congenital heart disease. Ann Neurol 2012; 72:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/24\">",
"      Ricci S. Embolism from the heart in the young patient: a short review. Neurol Sci 2003; 24 Suppl 1:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/25\">",
"      deVeber G, Monagle P, Chan A, et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998; 55:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/26\">",
"      Nowak-G&ouml;ttl U, Str&auml;ter R, Heinecke A, et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94:3678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/27\">",
"      Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/28\">",
"      Maguire JL, deVeber G, Parkin PC. Association between iron-deficiency anemia and stroke in young children. Pediatrics 2007; 120:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/29\">",
"      Kenet G, L&uuml;tkhoff LK, Albisetti M, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010; 121:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/30\">",
"      Trenor CC 3rd, Michelson AD. Thrombophilia and pediatric stroke. Circulation 2010; 121:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/31\">",
"      Waddy SP. Disorders of coagulation in stroke. Semin Neurol 2006; 26:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/32\">",
"      Hamedani AG, Cole JW, Mitchell BD, Kittner SJ. Meta-analysis of factor V Leiden and ischemic stroke in young adults: the importance of case ascertainment. Stroke 2010; 41:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/33\">",
"      S&eacute;bire G, Fullerton H, Riou E, deVeber G. Toward the definition of cerebral arteriopathies of childhood. Curr Opin Pediatr 2004; 16:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/34\">",
"      Chabrier S, Rodesch G, Lasjaunias P, et al. Transient cerebral arteriopathy: a disorder recognized by serial angiograms in children with stroke. J Child Neurol 1998; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/35\">",
"      Braun KP, Bulder MM, Chabrier S, et al. The course and outcome of unilateral intracranial arteriopathy in 79 children with ischaemic stroke. Brain 2009; 132:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/36\">",
"      Askalan R, Laughlin S, Mayank S, et al. Chickenpox and stroke in childhood: a study of frequency and causation. Stroke 2001; 32:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/37\">",
"      Danchaivijitr N, Cox TC, Saunders DE, Ganesan V. Evolution of cerebral arteriopathies in childhood arterial ischemic stroke. Ann Neurol 2006; 59:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/38\">",
"      S&eacute;bire G. Transient cerebral arteriopathy in childhood. Lancet 2006; 368:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/39\">",
"      Mineyko A, Narendran A, Fritzler ML, et al. Inflammatory biomarkers of pediatric focal cerebral arteriopathy. Neurology 2012; 79:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/40\">",
"      Lanthier S, Armstrong D, Domi T, deVeber G. Post-varicella arteriopathy of childhood: natural history of vascular stenosis. Neurology 2005; 64:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/41\">",
"      Miravet E, Danchaivijitr N, Basu H, et al. Clinical and radiological features of childhood cerebral infarction following varicella zoster virus infection. Dev Med Child Neurol 2007; 49:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/42\">",
"      Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/43\">",
"      Nedeltchev K, der Maur TA, Georgiadis D, et al. Ischaemic stroke in young adults: predictors of outcome and recurrence. J Neurol Neurosurg Psychiatry 2005; 76:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/44\">",
"      Ortiz G, Koch S, Romano JG, et al. Mechanisms of ischemic stroke in HIV-infected patients. Neurology 2007; 68:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/45\">",
"      Tipping B, de Villiers L, Wainwright H, et al. Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry 2007; 78:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/46\">",
"      Coucke PJ, Wessels MW, Van Acker P, et al. Homozygosity mapping of a gene for arterial tortuosity syndrome to chromosome 20q13. J Med Genet 2003; 40:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/47\">",
"      Cartwright MS, Hickling WH, Roach ES. Ischemic stroke in an adolescent with arterial tortuosity syndrome. Neurology 2006; 67:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/48\">",
"      Kelly PJ, Furie KL, Kistler JP, et al. Stroke in young patients with hyperhomocysteinemia due to cystathionine beta-synthase deficiency. Neurology 2003; 60:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/49\">",
"      Alehan F, Saygi S, Gedik S, Kayahan Ulu EM. Stroke in early childhood due to homocystinuria. Pediatr Neurol 2010; 43:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/50\">",
"      Hsich GE, Robertson RL, Irons M, et al. Cerebral infarction in Menkes' disease. Pediatr Neurol 2000; 23:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/51\">",
"      Pavlakis SG, Phillips PC, DiMauro S, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984; 16:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/52\">",
"      Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci 2008; 1142:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/53\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-1998. A 13-year-old girl with a relapsing-remitting neurologic disorder. N Engl J Med 1998; 339:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/54\">",
"      Hirano M, Ricci E, Koenigsberger MR, et al. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992; 2:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/55\">",
"      Dimauro S, Tay S, Mancuso M. Mitochondrial encephalomyopathies: diagnostic approach. Ann N Y Acad Sci 2004; 1011:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/56\">",
"      Dickerson BC, Holtzman D, Grant PE, Tian D. Case records of the Massachusetts General Hospital. Case 36-2005. A 61-year-old woman with seizure, disturbed gait, and altered mental status. N Engl J Med 2005; 353:2271.",
"     </a>",
"    </li>",
"    <li>",
"     Clarke JTR. A clinical guide to inherited metabolic diseases, 2nd, Cambridge University Press, Cambridge 2003. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/58\">",
"      deVeber G. Arterial ischemic strokes in infants and children: an overview of current approaches. Semin Thromb Hemost 2003; 29:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/59\">",
"      Chadehumbe MA, Khatri P, Khoury JC, et al. Seizures are common in the acute setting of childhood stroke: a population-based study. J Child Neurol 2009; 24:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/60\">",
"      Abend NS, Beslow LA, Smith SE, et al. Seizures as a presenting symptom of acute arterial ischemic stroke in childhood. J Pediatr 2011; 159:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/61\">",
"      Yock-Corrales A, Mackay MT, Mosley I, et al. Acute childhood arterial ischemic and hemorrhagic stroke in the emergency department. Ann Emerg Med 2011; 58:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/62\">",
"      Beslow LA, Smith SE, Vossough A, et al. Hemorrhagic transformation of childhood arterial ischemic stroke. Stroke 2011; 42:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/63\">",
"      Rafay MF, Pontigon AM, Chiang J, et al. Delay to diagnosis in acute pediatric arterial ischemic stroke. Stroke 2009; 40:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/64\">",
"      Shellhaas RA, Smith SE, O'Tool E, et al. Mimics of childhood stroke: characteristics of a prospective cohort. Pediatrics 2006; 118:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23513/abstract/65\">",
"      Harbison J, Hossain O, Jenkinson D, et al. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 2003; 34:71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6213 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23513=[""].join("\n");
var outline_f22_61_23513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Etiologies and risk factors in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Etiologies and risk factors in young adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hematologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Focal cerebral arteriopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Moyamoya",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Metabolic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - MELAS and disorders causing metabolic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/6213\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/6213|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/10/23713\" title=\"figure 1\">",
"      Age and stroke rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/10/21679\" title=\"figure 2\">",
"      Age and stroke etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/6213|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/42/20142\" title=\"table 1\">",
"      Causes ischemic stroke children and young adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11530?source=related_link\">",
"      Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=related_link\">",
"      Differential diagnosis of transient ischemic attack and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=related_link\">",
"      Ischemic stroke in children: Evaluation, initial management, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27063?source=related_link\">",
"      Ischemic stroke in children: Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=related_link\">",
"      Neurologic manifestations of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_61_23514="Treatment of active variceal hemorrhage";
var content_f22_61_23514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of active variceal hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23514/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23514/contributors\">",
"     Jasmohan S Bajaj, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23514/contributors\">",
"     Arun J Sanyal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23514/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/61/23514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/61/23514/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/61/23514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal treatment of active variceal hemorrhage would be universally effective, completely safe, easy to administer, and inexpensive. The current treatment options include medications (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    and somatostatin and their analogs), endoscopy, surgery, and transjugular intrahepatic portosystemic shunting. None of the existing modalities come close to being ideal and the choice of one modality over another depends upon their relative efficacy, ease of administration, safety, and cost considerations.",
"   </p>",
"   <p>",
"    This topic will review the treatment modalities for active variceal hemorrhage. The general principles involved in the management of patients with variceal hemorrhage as well as a more detailed discussion of endoscopic variceal ligation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles of support of patients presenting with variceal bleeding such as transfusion, prevention of aspiration, and use of recombinant factors are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROPHYLACTIC ANTIBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trials evaluating the effectiveness of prophylactic antibiotics in cirrhotic patients hospitalized for bleeding suggest an overall reduction in infectious complications and possibly decreased mortality. Antibiotics may also reduce the risk of recurrent bleeding in hospitalized patients who bled from esophageal varices. Thus, patients with cirrhosis who present with upper GI bleeding (from varices or other causes) should be given prophylactic antibiotics, preferably before endoscopy (although effectiveness has also been demonstrated when given after endoscopy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H30\">",
"     'AASLD guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The AASLD guidelines recommend short-term (maximum seven days) antibiotic prophylaxis in any patient with cirrhosis and GI hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/1\">",
"     1",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    (400 mg twice daily) or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (in patients in whom oral administration is not possible) is the recommended antibiotic. A randomized trial found superiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    over norfloxacin in preventing bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with advanced cirrhosis, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    may be preferable, particularly in centers with a high prevalence of quinolone-resistant organisms.",
"   </p>",
"   <p>",
"    Once patients are able to take pills by mouth, IV antibiotics can be converted to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    400 mg twice daily to complete seven days of total antibiotic therapy. Since some patients are discharged in less than seven days, this approach allows them to complete their antibiotic courses on an outpatient basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTRAVENOUS VASOPRESSIN AND ITS ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    (0.4 unit bolus followed by an infusion of 0.4 to 1",
"    <span class=\"nowrap\">",
"     units/min)",
"    </span>",
"    directly constricts mesenteric arterioles and decreases portal venous inflow, thereby reducing portal pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/3\">",
"     3",
"    </a>",
"    ]. A number of studies have evaluated the role of vasopressin in the management of active hemorrhage. Vasopressin can achieve initial hemostasis in 60 to 80 percent of patients, but has only marginal effects on early rebleeding episodes and does not improve survival from active variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of bleeding cessation may be counterbalanced by enhanced mortality due to extrasplanchnic vasoconstrictive properties and resultant myocardial, cerebral, bowel, and limb ischemia. Furthermore, there is evidence that the portal hypotensive effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    is attenuated when variceal hemorrhage occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/3\">",
"     3",
"    </a>",
"    ]. Because of these considerations and the seemingly greater benefit with somatostatin or one of its analogs, vasopressin is rarely used for the management of variceal hemorrhage in the United States.",
"   </p>",
"   <p>",
"    Patients in whom it is considered despite the concerns described above should receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    in combination with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (10 to 50",
"    <span class=\"nowrap\">",
"     mcg/min),",
"    </span>",
"    which may accentuate the portal hypotensive action of vasopressin while reducing its systemic hemodynamic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Terlipressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terlipressin (triglycyl lysine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    ) is a synthetic analog of vasopressin that is released in a slow and sustained manner, permitting its administration via intermittent injections. Terlipressin is not available in the United States, but is used in several other countries.",
"   </p>",
"   <p>",
"    Terlipressin is administered at an initial dose of 2 mg IV every four hours and can be titrated down to 1 mg IV every four hours once hemorrhage is controlled. At least 20 clinical trials have evaluated its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/4\">",
"     4",
"    </a>",
"    ]. A meta-analysis found a statistically significant reduction in all-cause mortality compared with placebo (RR 0.66, 95% CI 0.49 to 0.88) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only a few studies directly compared terlipressin to somatostatin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , or endoscopic treatment. Those studies suggest that terlipressin has similar efficacy for the control of acute bleeding. A study comparing the acute hemodynamic effects of terlipressin to octreotide in stable patients with cirrhosis found a sustained effect of terlipressin on portal pressure and blood flow compared with only a transient effect from octreotide, suggesting that terlipressin might have more sustained hemodynamic effects in patients with bleeding varices [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/9\">",
"     9",
"    </a>",
"    ]. A randomized controlled trial comparing variceal ligation in combination with terlipressin or octreotide found that terlipressin was not inferior to octreotide for control of esophageal variceal bleeding or in-hospital survival [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SOMATOSTATIN AND ITS ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin inhibits the release of vasodilator hormones such as glucagon&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/11\">",
"     11",
"    </a>",
"    ], indirectly causing splanchnic vasoconstriction and decreased portal inflow. It has a short half-life and disappears within minutes of a bolus infusion.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    is a long-acting analog of somatostatin. Somatostatin is not available in the United States, but octreotide is. Octreotide is given as a 50 mcg bolus followed by a continuous infusion of 50 mcg per hour and is continued for three to five days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a bolus injection of somatostatin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , portal venous inflow, portal pressures, azygos flow, and intravariceal pressures decrease within seconds. Of these effects, the most consistently observed is the decrease in collateral flow (azygos flow), whereas the changes in portal pressures, as measured by wedged hepatic pressures, are the most variable.",
"   </p>",
"   <p>",
"    One of the most detailed studies to evaluate the pharmacodynamics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    included 68 patients with cirrhosis who were given octreotide by four different intravenous methods [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 50 mcg bolus, a 500 mcg bolus, or a placebo bolus",
"     </li>",
"     <li>",
"      A 50 mcg bolus followed by a continuous infusion of 50 or 250 mcg per hour or a placebo infusion",
"     </li>",
"     <li>",
"      An initial 50 mcg bolus followed by repeated 50 mcg boluses or placebo boluses",
"     </li>",
"     <li>",
"      A placebo bolus followed by continuous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      50 mcg per hour",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    caused a marked but transient decrease in portal pressure and azygos blood flow and an increase in mean arterial pressure. These effects lasted only five minutes, even with the addition of continuous infusions. Repeated bolus injections had shorter, less marked effects, while continuous infusion did not decrease portal pressure, suggesting that there was rapid desensitization.",
"   </p>",
"   <p>",
"    These findings make it unclear why",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    should be of any benefit in portal hypertension since its effect on portal pressure is short-lived. However, the potential benefits of octreotide (and somatostatin) in portal hypertension may extend beyond the measures noted above. Both inhibit the release of glucagon and other hormones that have important roles in mediating the normal increase in mesenteric blood flow that occurs postprandially [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Variceal hemorrhage is associated with an increase in intestinal blood flow, presumably mediated by pathways that are activated by the presence of blood, a high protein substance, in the gut [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/16\">",
"     16",
"    </a>",
"    ]. Octreotide can blunt this response for at least 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, activation of somatostatin receptors may decrease the rebound increase in portal venous pressure that occurs when blood enters the gastrointestinal tract and during correction of hypovolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical trials have compared somatostatin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    or placebo in the management of active bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Somatostatin versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial placebo controlled trial failed to demonstrate a benefit for somatostatin. However, over 80 percent of those treated with placebo spontaneously stopped bleeding, which may have obscured a treatment benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/18\">",
"     18",
"    </a>",
"    ]. Several subsequent studies have shown somatostatin to be superior to placebo with respect to achievement of hemostasis and prevention of early rebleeding (",
"    <a class=\"graphic graphic_table graphicRef52632 \" href=\"UTD.htm?26/61/27611\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Somatostatin versus vasopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin is also superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    and balloon tamponade, due in part to the virtual absence of side effects. A meta-analysis of trials comparing somatostatin to vasopressin found two benefits with somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher relative risk (1.62) of achieving initial control of the bleeding. The absolute benefit was such that only three or four patients had to be treated with somatostatin for one to derive benefit over therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"       vasopressin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A lower risk of adverse effects (0 versus 10 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"       vasopressin",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these beneficial effects on bleeding have not been shown to improve survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Somatostatin versus sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin has been compared to sclerotherapy for the treatment of active variceal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. A systematic review concluded that sclerotherapy was not superior to somatostatin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    for any outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/20\">",
"     20",
"    </a>",
"    ]. In one trial, for example, 70 patients who were actively bleeding were randomized to receive somatostatin or sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/21\">",
"     21",
"    </a>",
"    ]. Initial bleeding control (80 versus 83 percent), early rebleeding rates (25 versus 17 percent), and mortality (29 versus 23 percent) were similar between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Somatostatin plus sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with somatostatin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    infusions when used in addition to sclerotherapy is superior to sclerotherapy alone or somatostatin alone for the prevention of early rebleeding and possibly survival [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In one trial, for example, 199 patients were treated with sclerotherapy and then randomized to an intravenous infusion of octreotide (25",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    for five days) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/24\">",
"     24",
"    </a>",
"    ]. Survival without rebleeding at five days was significantly higher with octreotide (87 versus 71 percent) but there was no difference in 15-day cumulative survival (88 percent in both groups, estimated by the Kaplan-Meier method).",
"   </p>",
"   <p>",
"    In a second randomized controlled trial that included 262 patients, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (100 mcg subcutaneously three times daily for 15 days) was associated with significantly less rebleeding among patients treated with sclerotherapy and beta blockers (16 versus 26 percent), though mortality was unaffected by treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/26\">",
"     26",
"    </a>",
"    ]. However, another large study found no additional benefit when subcutaneous octreotide was added to sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third study comparing somatostatin alone to somatostatin plus sclerotherapy in 100 actively bleeding patients found that combined therapy was superior for controlling bleeding (92 versus 76 percent) and the prevention of early rebleeding (93 versus 76 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/28\">",
"     28",
"    </a>",
"    ]. On multivariate analysis, the presence of shock at admission and active bleeding during endoscopy were associated with failure of somatostatin monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Somatostatin plus endoscopic variceal ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated combination therapy with variceal ligation plus pharmacologic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A systematic review found that combination therapy improved the five-day success rate compared with endoscopic variceal ligation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, no mortality benefit could be demonstrated. As an example, a study of 100 patients demonstrated a reduction in the rebleeding rate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    infusion in combination with endoscopic variceal ligation compared with endoscopic variceal ligation alone (9 versus 38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study included 184 actively bleeding patients who were randomly assigned to a somatostatin analogue (vapreotide) or placebo, followed by endoscopic therapy (band ligation or sclerotherapy for esophageal varices and band ligation or cyanoacrylate injection for gastric varices) performed within 12 hours of starting the infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/32\">",
"     32",
"    </a>",
"    ]. Combination therapy was associated with significantly better survival and control of bleeding at five days (66 versus 50 percent for the combined endpoint). However, overall mortality at 42 days was similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, somatostatin (250 mcg bolus followed by 250",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    by intravenous infusion for five days) is more effective for controlling bleeding than placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    and has fewer side effects than vasopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/19,33\">",
"     19,33",
"    </a>",
"    ]. It has therefore replaced vasopressin as the pharmacologic treatment of choice for active variceal bleeding. As noted above, a continuous intravenous infusion of 500",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    achieves control of bleeding in a significantly higher proportion of patients than the 250",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    dose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, the higher dose can be suggested for those who continue to bleed despite the 250",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    infusion. Somatostatin is not available in the United States.",
"   </p>",
"   <p>",
"    Although the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (50 mcg bolus followed by 50",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    by intravenous infusion for five days) is less well established, it is the current drug of choice in the United States because of its easy availability compared to somatostatin. Higher doses of octreotide do not increase its portal hypotensive effects and may be associated with an increase in systemic venous pressure. The optimal duration of therapy is unclear, although many studies have used octreotide for five days. In one study, subcutaneously administered octreotide along with sclerotherapy did not improve outcomes compared to sclerotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their widespread use, neither somatostatin nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    has a clearly established benefit on mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/29,35\">",
"     29,35",
"    </a>",
"    ]. In contrast, terlipressin is preferred in countries where it is available, since it is the only pharmacologic treatment associated with a reduction in mortality compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic therapy is currently the definitive treatment of choice for active variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/36\">",
"     36",
"    </a>",
"    ]. It can be performed at the same time as diagnostic endoscopy by virtually all trained gastroenterologists. Two forms of endoscopic treatment are commonly used: sclerotherapy and variceal band ligation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sclerotherapy involves injection of a sclerosant solution into the varices through an injection needle that is placed through the endoscope using a freehand technique. A number of sclerosant solutions are available and one has not been found to be superior to another. The volume and frequency of injections also vary widely. We use 1 to 2 mL of 5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/21/43346?source=see_link\">",
"       sodium morrhuate",
"      </a>",
"      per injection for a total of 12 to 20 mL per session. A commonly used alternative is 1 to 2 mL injections of 5 percent ethanolamine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link&amp;anchor=H70339962#H70339962\">",
"       \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\", section on 'Endoscopic sclerotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Variceal band ligation is similar to hemorrhoidal banding; it involves placing small elastic bands around varices in the distal 5 cm of the esophagus (",
"      <a class=\"graphic graphic_picture graphicRef54194 \" href=\"UTD.htm?3/13/3282\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"       \"Endoscopic variceal ligation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both esophageal and gastroesophageal varices types I and II can be treated by sclerotherapy or band ligation. However, isolated gastric varices do not usually lend themselves to these modalities of treatment (",
"    <a class=\"graphic graphic_picture graphicRef58644 \" href=\"UTD.htm?14/18/14639\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link&amp;anchor=H129709543#H129709543\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\", section on 'Location of varices'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H27\">",
"     'Gastric varices'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following conclusions regarding treatment can be drawn from a multitude of studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sclerotherapy is superior to balloon tamponade alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"       vasopressin",
"      </a>",
"      alone, and a combination of vasopressin and balloon tamponade for control of active hemorrhage, prevention of early rebleeding, complication rates, and survival in patients with esophageal and gastroesophageal varices (",
"      <a class=\"graphic graphic_table graphicRef55379 \" href=\"UTD.htm?21/27/21948\">",
"       table 2",
"      </a>",
"      ). Both intravariceal and paravariceal injections are effective.",
"     </li>",
"     <li>",
"      As noted above, somatostatin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      is as effective as sclerotherapy for acute management of variceal bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/21,22\">",
"       21,22",
"      </a>",
"      ] but combined therapy is more effective than sclerotherapy or band ligation alone [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/24,25,31\">",
"       24,25,31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Somatostatin and its analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Terlipressin is as effective as sclerotherapy for control of bleeding, rebleeding, and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Band ligation is at least as effective as sclerotherapy for achieving hemostasis (86 versus 77 percent in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/38\">",
"       38",
"      </a>",
"      ]) and for prevention of early rebleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/38-40\">",
"       38-40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the clinical trials suggest an advantage of band ligation over sclerotherapy in the long-term, it has been our experience that, in the setting of active hemorrhage, the band ligator often limits visibility. In addition, once bands have been deployed, it may be technically difficult to maneuver the scope back into the stomach if required. Thus, both procedures are reasonable choices for active hemorrhage. It may be more convenient to perform sclerotherapy acutely and follow-up with band ligation in one to two weeks. The experience and expertise of the endoscopist should dictate the selection of the specific modality. Band ligation can also be used in patients who fail sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of sclerotherapy may be categorized as local, regional, and systemic (",
"    <a class=\"graphic graphic_table graphicRef71037 \" href=\"UTD.htm?33/41/34459\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local complications &mdash; ulceration, bleeding, dysmotility, stricture formation, and portal hypertensive gastropathy",
"     </li>",
"     <li>",
"      Regional complications &mdash; esophageal perforation and mediastinitis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82026 \" href=\"UTD.htm?14/2/14383\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Systemic complications &mdash; sepsis and aspiration with ventilation perfusion mismatch and hypoxemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these complications occur more frequently when endoscopy is performed emergently rather than electively. In the controlled trial noted above, the rate of complications was significantly lower with band ligation than sclerotherapy (2 versus 22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/38\">",
"     38",
"    </a>",
"    ]. In a meta-analysis, a much lower rate of esophageal stricture was the major advantage of band ligation in terms of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/40\">",
"     40",
"    </a>",
"    ]. However there are no reliable data comparing sclerotherapy and band ligation for adverse events specifically in the setting of acute variceal bleeding. Both variceal ligation and sclerotherapy have the potential to worsen portal hypertensive gastropathy following obliteration of varices (",
"    <a class=\"graphic graphic_picture graphicRef75725 \" href=\"UTD.htm?35/5/35935\">",
"     picture 3",
"    </a>",
"    ), which could result in bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link&amp;anchor=H21#H21\">",
"     \"Endoscopic variceal ligation\", section on 'Portal hypertensive gastropathy and gastric varices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Failure of endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent endoscopic treatment fails to control bleeding in 10 to 20 percent of patients. These patients are at high risk for exsanguination and other complications related to active bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors define failure of endoscopic treatment for acute variceal hemorrhage and are based upon a consensus definition [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/44\">",
"     44",
"    </a>",
"    ]. Failure is defined as death or need to change therapy defined by one of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fresh hematemesis or NG aspiration of &ge;100 mL of fresh blood &ge;2 hours after the start of a specific drug treatment or therapeutic endoscopy",
"     </li>",
"     <li>",
"      Development of hypovolemic shock",
"     </li>",
"     <li>",
"      3 g drop in hemoglobin (or a 9 percent drop in hematocrit) within any 24 hour period if no transfusion is administered",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria do not require documentation of bleeding and can potentially be met without continued bleeding. Thus, it is necessary to exercise clinical judgment.",
"   </p>",
"   <p>",
"    Any bleeding that occurs more than 48 hours after the initial admission for variceal hemorrhage after a 24 hour or more bleed-free period is considered to represent rebleeding. Rebleeding that occurs within six weeks of the onset of active bleeding is considered to be \"early rebleeding\", while rebleeding episodes at later time-points are referred to as \"late rebleeding\". Patients are at highest risk for failure to control bleeding or for early rebleeding in the first 72 hours after the onset of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who fail endoscopic treatment have already received a trial of pharmacologic treatment by the time a diagnosis of failed endoscopic treatment is established. There are no data to support the use of higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    or somatostatin in those who have failed endoscopic treatment. A second attempt at endoscopic hemostasis can be made (eg, band ligation for failed sclerotherapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/41\">",
"     41",
"    </a>",
"    ], an approach supported by widely accepted guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/45\">",
"     45",
"    </a>",
"    ]. If bleeding is not quickly and effectively stopped, more definitive therapy must be instituted immediately with balloon tamponade or creation of a portosystemic shunt. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Balloon tamponade'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Placement of self expanding metal stents (SEMS) for the control of refractory variceal hemorrhage has also been described. In a case series of 10 patients who had contraindications to transjugular intrahepatic portosystemic shunt placement or balloon tamponade, a SEMS was successfully placed in nine patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/46\">",
"     46",
"    </a>",
"    ]. Bleeding was not controlled in three patients, though two of those patients had gastric varices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BALLOON TAMPONADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloon tamponade is an effective way to achieve short-term hemostasis, but due to complications and rebleeding upon balloon deflation, its use is reserved for temporary stabilization of patients until more definitive treatment can be instituted.",
"   </p>",
"   <p>",
"    Three balloons have been used: the Sengstaken-Blakemore tube (which has a 250 cc gastric balloon, an esophageal balloon, and a single gastric suction port), the Minnesota tube (a modified Sengstaken-Blakemore tube with an esophageal suction port above the esophageal balloon), and the Linton-Nachlas tube (which has a single 600 cc gastric balloon) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial control of variceal bleeding with balloon tamponade has been observed in 30 to 90 percent of patients in a number of reports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. The variability in success rates is probably due to patient selection, the concomitant use of other types of therapy, and experience of the staff in using these tubes. Balloon tamponade appears to be less successful in patients who have failed pharmacologic therapy and in patients with early rebleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Balloon placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before balloon tamponade is attempted, the patient should be intubated to prevent aspiration. Since this is a temporizing measure in most cases, arrangements for upper endoscopy (or a transjugular intrahepatic portosystemic shunt [TIPS] if endoscopy has failed) should be made.",
"   </p>",
"   <p>",
"    Equipment that is required is:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A tamponade tube kit (with the tube and clamps)",
"     </li>",
"     <li>",
"      A manometer (not needed for Linton tubes)",
"     </li>",
"     <li>",
"      Large-volume syringes",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       traction/pulley",
"      </span>",
"      system to maintain constant tension on the tube",
"     </li>",
"     <li>",
"      Adequate suction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before tube placement, all equipment should be readily at hand. The balloon(s) should be inflated with air and held underwater to assess for leakage and then deflated. With the patient in the supine or left-lateral position, the tube is lubricated and carefully inserted through the mouth (preferable in intubated patients) or nostril until at least 50 cm of the tube has been introduced.",
"   </p>",
"   <p>",
"    Once the tube is placed, the ports are suctioned to remove all air. The gastric balloon is then inflated with 450 to 500 mL of air. Once inflated, the air inlet for the gastric balloon should be clamped. To confirm that the tube is in the stomach, air can be injected through the stomach port (not the balloon port) while auscultation is performed over the stomach. Alternatively, a radiograph can be obtained.",
"   </p>",
"   <p>",
"    After the gastric balloon is inflated, the tube is pulled until resistance is felt, at which point the balloon is tamponading the gastroesophageal junction. The tube is then securely fastened to either a pulley device or taped to a football helmet to maintain tension on the tube (and thus continued tamponade at the gastroesophageal junction). A one to two pound weight (500 mL IV fluid bag) can be used to maintain tension on the tube. This is often sufficient to stop the variceal hemorrhage.",
"   </p>",
"   <p>",
"    If bleeding continues despite inflation of the gastric balloon, the esophageal balloon should be inflated to 30 to 45 mmHg and the pressure should be checked periodically (at least once per hour). It is important not to overinflate the esophageal balloon as it puts the patient at risk for esophageal necrosis or rupture. Once the bleeding is controlled, the pressure in the esophageal balloon should be reduced by 5 mmHg to a goal pressure of 25 mmHg. If bleeding resumes, the pressure is increased by 5 mmHg. If the bleeding continues to be controlled, the balloon should be maintained at 25 mmHg for 12 to 24 hours.",
"   </p>",
"   <p>",
"    The tube can be left in place for 24 to 48 hours. The gastric balloon (along with the esophageal balloon if used) should be deflated every 12 hours to check for rebleeding. If the bleeding has ceased, the tube can be left in place and the balloons reinflated if bleeding resumes. If the bleeding resumes upon deflation of the balloon(s), the balloon(s) should immediately be reinflated. As mentioned above, balloon tamponade is a temporizing measure and endoscopy (or, if endoscopy has failed, TIPS) should be arranged for ongoing or recurrent bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Rebleeding and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the main problems with balloon tamponade is the high risk of rebleeding following deflation of the balloon. In addition, balloon tamponade is associated with significant complications, the most lethal of which is esophageal rupture.",
"   </p>",
"   <p>",
"    Major complications have been observed in approximately 14 percent of patients, occurring more frequently in series in which tubes were inserted by relatively inexperienced staff [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, these tubes should only be used in settings in which experienced staff are available.",
"   </p>",
"   <p>",
"    The tubes should also be used cautiously in patients with respiratory failure, cardiac arrhythmias, and or a hiatal hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/53\">",
"     53",
"    </a>",
"    ]. The airway must be protected in all patients receiving such treatment due to their failure to clear oral secretions and high risk for aspiration.",
"   </p>",
"   <p>",
"    An AASLD survey with 234 respondents found that the majority (89 percent) believed that balloon tamponade should be used for stabilization before transjugular intrahepatic portosystemic shunting (TIPS). The reasons cited for not using balloon tamponade were: complications (23 percent), low benefit (11 percent), high success rate of endoscopy alone (29 percent), or all of the above (37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/54\">",
"     54",
"    </a>",
"    ]. Importantly, none of the trainee respondents were comfortable with this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vast body of literature exists on the use of surgery for the control of variceal hemorrhage. The ideal patient for surgical therapy is one with well preserved liver function who fails emergent endoscopic treatment and has no complications from the bleeding or endoscopy. The choice of surgery is usually dependent upon the training and expertise of the surgeon.",
"   </p>",
"   <p>",
"    There are two basic types of operations: shunt operations and nonshunt operations. Shunt operations can be categorized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonselective &mdash; those that decompress the entire portal tree and divert all flow away from the portal system, such as portacaval shunts",
"     </li>",
"     <li>",
"      Selective &mdash; those that compartmentalize the portal tree into a decompressed variceal system while maintaining sinusoidal perfusion via a hypertensive superior mesenteric-portal compartment, such as a distal splenorenal shunt",
"     </li>",
"     <li>",
"      Partial &mdash; those that incompletely decompress the entire portal tree and thereby also maintain some hepatic perfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonshunt operations generally include either esophageal transection (in which the distal esophagus is transected and then stapled back together after varices have been ligated) or devascularization of the gastroesophageal junction (Sugiura procedure).",
"   </p>",
"   <p>",
"    The data are difficult to combine due to heterogeneity of patients studied, different types of operations used, and varying protocols used for supportive management. However, the following general conclusions can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both portal decompressive surgery and esophageal transection are highly effective in achieving hemostasis.",
"     </li>",
"     <li>",
"      Emergency portacaval shunts may be more likely to thrombose than elective shunts. In addition, portacaval shunts alter vascular anatomy, complicate future liver transplant surgery, and are associated with an approximately 40 to 50 percent incidence of encephalopathy. Complications associated with surgery have led to a decline in their use as first-line treatment for variceal hemorrhage. Nevertheless, surgical portal decompression remains an effective way to arrest variceal hemorrhage and prevent rebleeding. In experienced hands, selective portosystemic shunts are effective therapy for active variceal hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. Unfortunately, few centers have the expertise and experience to obtain optimal results from this operation.",
"     </li>",
"     <li>",
"      Although a selective shunt has some physiologic advantages, it may significantly exacerbate marked ascites. Thus, a portacaval shunt would be preferable in patients with marked ascites.",
"     </li>",
"     <li>",
"      Esophageal transection appears to be as effective as sclerotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/57\">",
"       57",
"      </a>",
"      ]. However, bleeding can occur from the suture line and varices recur after a variable period of time because transection does not treat the portal hypertension. Thus, transection is not routinely performed. The Sugiura procedure may be used in patients who are not candidates for a shunt operation, such as those with extensive portal vein thrombosis with extension into the splenic and superior mesenteric veins [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transjugular intrahepatic portosystemic shunt (TIPS) is created by passing a needle catheter (Colapinto catheter) via the transjugular route into the hepatic vein and wedging it there (",
"    <a class=\"graphic graphic_figure graphicRef72311 \" href=\"UTD.htm?3/10/3239\">",
"     figure 1",
"    </a>",
"    ). The needle is then extruded and advanced through the liver parenchyma to the intrahepatic portion of the portal vein. A TIPS functions like side-to-side surgical portacaval shunt, but does not require general anesthesia or major surgery for placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=see_link\">",
"     \"Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large-scale, randomized trials are needed to establish the roles of surgery and TIPS in average-risk subjects with active hemorrhage who have failed endoscopic and medical treatment. At present, TIPS is generally preferred in patients who are poor risks for surgery, but the relative roles of TIPS and surgery in those who are good candidates (and where highly-trained surgeons are available) is less clear.",
"   </p>",
"   <p>",
"    In a study of the role of TIPS as first-line therapy for active variceal bleeding, selected patients with high hepatic venous pressure gradients benefited from early TIPS placement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/59\">",
"     59",
"    </a>",
"    ]. However, further studies are needed to adequately address this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In initial studies, hemostasis was achieved in the vast majority of patients with refractory variceal hemorrhage despite endoscopic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. However, interpretation of the efficacy of TIPS in the setting of active hemorrhage was confounded by the heterogeneous patient populations and failure to define the nature of active bleeding.",
"   </p>",
"   <p>",
"    A later study described patients who were actively bleeding despite emergent endoscopic treatment within the previous 72 hours and considered to be at high risk of dying from emergent surgery (defined by the presence of sepsis or deep coma, pneumonia, multiorgan failure, renal failure, severe comorbid conditions) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/62\">",
"     62",
"    </a>",
"    ]. The patients were stabilized by balloon tamponade and had TIPS performed within 12 hours. Hemostasis was achieved in 90 percent and the 30-day survival was 63 percent. In those without pulmonary compromise, the 30-day survival was above 90 percent. These data are far superior to those obtained with surgery for patients in whom a 10 to 20 percent survival would have been expected. Other studies have confirmed these results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another study compared TIPS to surgically implanted small diameter H-graft portacaval shunts in 70 patients with active hemorrhage. In that study, a higher rate of rebleeding and failure of treatment was noted in the patients undergoing TIPS (57 versus 26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/63\">",
"     63",
"    </a>",
"    ]. While these data show that surgery is a reasonable treatment option in some patients, they are not easily generalizable because of the exceptionally high rebleeding rates associated with TIPS in this study. In another, nonrandomized trial, TIPS was superior to esophageal transection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of TIPS in prevention of rebleeding is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     GASTRIC VARICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding gastric varices can be technically difficult to treat. Successful hemostasis and obliteration of gastric varices has been reported with variceal band ligation and with intravariceal injections of sclerosant, absolute alcohol, fibrin glue, and cyanoacrylate glue (cyanoacrylate is not routinely available in the United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/65-74\">",
"     65-74",
"    </a>",
"    ]. There has also been a case report of treating bleeding gastric varices with hemostatic nanopowder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H97407830#H97407830\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Hemostatic nanopowder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, gastric varices frequently rebleed despite initially successful endoscopic therapy and as a result, with the exception of treatment with cyanoacrylate, the use of endoscopic treatment should be limited to clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Approach to patients with bleeding gastric varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, bleeding intragastric varices should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (or somatostatin or terlipressin) and balloon tamponade followed by either transjugular intrahepatic portosystemic shunt (TIPS) or surgery. Emergency TIPS appears to be as effective for short-term control of bleeding gastric varices as well as esophageal varices [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/77\">",
"     77",
"    </a>",
"    ]. However, TIPS may be less effective than surgery in patients with bleeding gastric varices who have spontaneous splenorenal collaterals. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Surgery'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=see_link&amp;anchor=H6#H6\">",
"     \"Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding\", section on 'Bleeding gastric varices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyanoacrylate can be used in centers where it is available and with the appropriate expertise. When introduced into an aqueous medium (such as the lumen of a varix), cyanoacrylate glue immediately polymerizes into a firm clot. In the United States, it is used only in a few centers under research protocols and its use is not approved by the United States Food and Drug Administration. However, it can provide a valuable alternative for patients with life-threatening bleeding in whom TIPS is not an option. In two small controlled trials, cyanoacrylate injection appeared to be more effective and safer than band ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/72\">",
"     72",
"    </a>",
"    ] or alcohol injection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, cyanoacrylate may prevent rebleeding. In one trial, 77 patients who had bled from gastric varices were assigned to receive either cyanoacrylate or a beta-blocker for secondary prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/78\">",
"     78",
"    </a>",
"    ]. After a median follow-up of 26 months, cyanoacrylate was associated with a lower rebleeding rate compared with beta-blockers (15 versus 55 percent) and was also associated with a lower mortality rate (3 versus 25 percent).",
"   </p>",
"   <p>",
"    The addition of beta-blockers to treatment with cyanoacrylate does not appear to decrease the risk of rebleeding. In a randomized trial, 95 patients with bleeding gastric varices that were successfully treated with cyanoacrylate were assigned to received treatment with beta-blockers plus repeated cyanoacrylate injections (every three to four weeks until the varices were obliterated) or repeated cyanoacrylate injections alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/79\">",
"     79",
"    </a>",
"    ]. Rebleeding rates were similar between those who received combination therapy and those treated with cyanoacrylate alone at six months (89 versus 94 percent), one year (77 versus 77 percent), two years (62 versus 58 percent), and three years (52 versus 47 percent). Mortality rates were also similar between the groups.",
"   </p>",
"   <p>",
"    Complications from cyanoacrylate injection were reported in a series of 753 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/80\">",
"     80",
"    </a>",
"    ]. The complications included rebleeding due to extrusion of the glue cast (4.4 percent), sepsis (1.3 percent), distant emboli (pulmonary, cerebral, splenic; 0.7 percent), gastric ulcer formation (0.1 percent), major gastric variceal bleeding (0.1 percent), and mesenteric hematoma associated with hemoperitoneum and bacterial peritonitis (0.1 percent). The complication-related mortality rate was 0.5 percent.",
"   </p>",
"   <p>",
"    To decrease the risk of glue embolization, some have proposed combining cyanoacrylate injection with endoscopic-ultrasound guided coil placement. The idea is to place the coil immediately prior to injection of the cyanoacrylate so that the coil (which has synthetic fibers attached to it) may act as a scaffold for the glue, preventing embolization. This was shown to be feasible in a study of 30 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/81\">",
"     81",
"    </a>",
"    ]. Whether it decreases this risk of embolization requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Alternative treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variceal band ligation was examined in a study of 27 patients with gastric varices [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/82\">",
"     82",
"    </a>",
"    ]. Band ligation was successful in stopping acute bleeding in 16 of 18 patients (88 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/82\">",
"     82",
"    </a>",
"    ]. However, 6 of the 27 patients (22 percent) died and bleeding recurred in 5 of the 27 patients (19 percent). Many of these patients had noncirrhotic portal hypertension due to schistosomiasis. Thus, it is uncertain if similar results would be obtained in patients with advanced hepatic synthetic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another promising approach is the intravariceal injection of thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. One of the largest series looking at the use of thrombin included 52 patients with bleeding gastric varices treated with intravariceal injections of bovine thrombin (average of 1070 IU administered during two treatment sessions) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/84\">",
"     84",
"    </a>",
"    ]. Initial hemostasis was achieved in 94 percent. Bleeding related mortality within 72 hours of the index bleed was 6 percent. After six weeks of follow-up, 9 of 49 surviving patients (18 percent) rebled, and an additional patient died.",
"   </p>",
"   <p>",
"    Another report described the successful use of elastic bands and detachable snares in controlling acute rebleeding and achieving gastric variceal eradication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Balloon-occluded retrograde transvenous obliteration (BRTO) is another technique that has been used for bleeding gastric varices as well as ectopic varices (eg, small bowel varices). BRTO is an interventional radiologic technique that involves occluding blood flow by inflation of a balloon catheter within a draining vessel, followed by instillation of a sclerosant proximal to the site of balloon occlusion. BRTO requires the presence of a spontaneous shunt into which a balloon catheter is retrogradely introduced. In the case of gastric varices, there frequently is a spontaneous gastrorenal shunt. Small bowel varices usually drain into dilated collateral vessels that connect to the portal vein through systemic shunts. Observational studies suggest that patients with gastric varices treated with BRTO have good long-term bleeding control (90 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/87\">",
"     87",
"    </a>",
"    ]), but technical failure occurs in approximately 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Complications of BRTO include increased portal pressure, resulting in the development or worsening of esophageal varices and ascites. In addition, systemic vein thrombosis has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/89\">",
"     89",
"    </a>",
"    ]. While commonly performed in Japan, this procedure is not widely practiced in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21562738\">",
"    <span class=\"h1\">",
"     BLEEDING ECTOPIC VARICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varices occasionally develop at sites other than the stomach and esophagus and come to clinical attention when they bleed. Examples are duodenal, rectal, and peristomal varices (which develop around the stoma in patients who have a colostomy). Endoscopic treatment is often unsuccessful in these cases, and traditional treatment has been surgical.",
"   </p>",
"   <p>",
"    Anecdotal reports have noted that the bleeding can also be controlled by TIPS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. It is unlikely that enough cases will be seen by any center to generate \"hard data\" upon which to base therapy. One disadvantage with TIPS is that it requires close follow-up for several years. A guideline issued by the American Association for the Study of Liver Diseases recommends TIPS as the preferred approach for prevention of rebleeding in patients with ectopic varices [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with gastric varices, small bowel varices can be treated with balloon-occluded retrograde transvenous obliteration (BRTO). In a study of seven patients, six were candidates for the procedure and were treated by balloon inflation followed by an injection of 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40082?source=see_link\">",
"     ethanolamine oleate",
"    </a>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/45/36565?source=see_link\">",
"     iopamidol",
"    </a>",
"    into the draining vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/94\">",
"     94",
"    </a>",
"    ]. Bleeding was controlled in all of the patients, with one patient experiencing rebleeding after 30 months. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Alternative treatments'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     AASLD GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2007 the American Association for the Study of Liver Diseases (AASLD) issued guidelines for management of variceal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Treatment of esophageal varices",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute GI hemorrhage in a patient with cirrhosis is an emergency that requires prompt attention with intravascular volume support and blood transfusions, being careful to maintain a hemoglobin of approximately 8",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Short-term (maximum seven days) antibiotic prophylaxis should be instituted in any patient with cirrhosis and GI hemorrhage. Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      (400 mg twice daily) or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (in patients in whom oral administration is not possible) is the recommended antibiotic. A randomized trial found superiority of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      over norfloxacin in preventing bacterial infections [",
"      <a class=\"abstract\" href=\"UTD.htm?22/61/23514/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with advanced cirrhosis, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      may be preferable, particularly in centers with a high prevalence of quinolone-resistant organisms.",
"     </li>",
"     <li>",
"      Pharmacologic therapy (somatostatin or its analogues",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      and vapreotide; terlipressin), should be initiated as soon as variceal hemorrhage is suspected and continued for three to five days after the diagnosis is confirmed.",
"     </li>",
"     <li>",
"      Upper endoscopy, performed within 12 hours, should be used to make the diagnosis and to treat variceal hemorrhage either with endoscopic variceal ligation or sclerotherapy.",
"     </li>",
"     <li>",
"      Transjugular intrahepatic portosystemic shunting (TIPS) is indicated in patients in whom hemorrhage from esophageal varices cannot be controlled or in whom bleeding recurs despite combined pharmacological and endoscopic therapy.",
"     </li>",
"     <li>",
"      Balloon tamponade should be used as a temporizing measure (maximum 24 hours) in patients with uncontrollable bleeding for whom a more definitive therapy (eg, TIPS or endoscopic therapy) is planned.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment of gastric varices",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who bleed from gastric fundal varices, endoscopic variceal obturation using tissue adhesives such as cyanoacrylate is preferred, where available. Otherwise, endoscopic variceal ligation is an option.",
"     </li>",
"     <li>",
"      TIPS should be considered in patients in whom hemorrhage from fundal varices cannot be controlled or in whom bleeding recurs despite combined pharmacological and endoscopic therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=see_link\">",
"       \"Patient information: Screening for esophageal varices (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy of a variceal bleed is aimed at hemodynamic resuscitation, prevention and treatment of complications (including use of prophylactic antibiotics), and supportive measures (",
"    <a class=\"graphic graphic_algorithm graphicRef59327 \" href=\"UTD.htm?5/30/5614\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with cirrhosis who present with upper GI bleeding (from varices or other causes) be given prophylactic antibiotics, preferably before endoscopy (although effectiveness has also been demonstrated when given after endoscopy) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 g IV) as the preferred antibiotic, particularly in centers with a high prevalence of quinolone-resistant organisms (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"       \"General principles of the management of variceal hemorrhage\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upper endoscopy should be performed for diagnosis and possible treatment in patients with significant upper gastrointestinal bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"       \"General principles of the management of variceal hemorrhage\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H15\">",
"       'Endoscopic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that bleeding esophageal varices be treated by esophageal band ligation or sclerotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). When bleeding is brisk and the field of vision is limited, we prefer initial sclerotherapy because it is faster, provides better visualization, and is as effective as band ligation for achievement of hemostasis. We use band ligation for subsequent elective endoscopic treatment sessions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Endoscopic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend pharmacologic treatment in addition to endoscopic treatment of bleeding esophageal varices (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest terlipressin in countries where it is available and somatostatin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      where terlipressin is unavailable (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although there are limited data comparing terlipressin to these other agents, some studies have suggested more sustained hemodynamic effects with terlipressin in patients with bleeding varices. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Terlipressin'",
"      </a>",
"      above.) Only octreotide is available in the United States. Octreotide is probably only effective when used in conjunction with endoscopic therapy. It can be started (50 mcg bolus followed by 50",
"      <span class=\"nowrap\">",
"       mcg/hour",
"      </span>",
"      by intravenous infusion) in the emergency department in patients where a high index of suspicion for variceal hemorrhage exists. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intravenous vasopressin and its analogs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Somatostatin and its analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend salvage treatment (transjugular intrahepatic portosystemic shunt placement or surgery) when pharmacologic and endoscopic measures fail to control bleeding from esophageal varices (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Transjugular intrahepatic portosystemic shunts'",
"      </a>",
"      above.) The ideal patient for surgery is one with well preserved liver function who fails emergent endoscopic treatment and has no complications from the bleeding or endoscopy. The choice of surgery usually depends upon the availability, training, and expertise of the surgeon. Although a selective shunt has some physiologic advantages, it may significantly exacerbate marked ascites. Thus, a portacaval shunt would be preferable in patients with marked ascites. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who experience rebleeding episodes from esophageal varices following initial control of bleeding be managed with an additional session of endoscopic treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend that transjugular intrahepatic portosystemic shunt (TIPS) or surgery be performed if bleeding from esophageal varices continues or recurs (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Transjugular intrahepatic portosystemic shunts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that bleeding intragastric varices be treated with endoscopic variceal obturation using the tissue adhesive cyanoacrylate where available (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In settings where it is not available, we suggest TIPS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Gastric varices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/1\">",
"      Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/2\">",
"      Fern&aacute;ndez J, Ruiz del Arbol L, G&oacute;mez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131:1049.",
"     </a>",
"    </li>",
"    <li>",
"     Blei AT, Groszmann RJ. Vasopressin and vasoconstrictors. In: The Physiology of the Intestinal Microcirculation, Shepherd AP, Granger DN (Eds), Raven Press, New York 1984. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/4\">",
"      Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003; :CD002147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/5\">",
"      Groszmann RJ, Kravetz D, Bosch J, et al. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 1982; 2:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/6\">",
"      Gimson AE, Westaby D, Hegarty J, et al. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986; 6:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/7\">",
"      Tsai YT, Lay CS, Lai KH, et al. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. Hepatology 1986; 6:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/8\">",
"      Bosch J, Groszmann RJ, Garc&iacute;a-Pag&aacute;n JC, et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology 1989; 10:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/9\">",
"      Baik SK, Jeong PH, Ji SW, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005; 100:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/10\">",
"      Abid S, Jafri W, Hamid S, et al. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol 2009; 104:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/11\">",
"      Bloom SR, Polak JM. Somatostatin. Br Med J (Clin Res Ed) 1987; 295:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/12\">",
"      Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/13\">",
"      Albillos A, Colombato LA, Lee FY, Groszmann RJ. Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats. Gastroenterology 1993; 104:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/14\">",
"      McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992; 16:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/15\">",
"      Spahr L, Giostra E, Frossard JL, et al. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol 2007; 102:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/16\">",
"      Chen L, Groszmann RJ. Blood in the gastric lumen increases splanchnic blood flow and portal pressure in portal-hypertensive rats. Gastroenterology 1996; 111:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/17\">",
"      Ludwig D, Sch&auml;del S, Br&uuml;ning A, et al. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. Dig Dis Sci 2000; 45:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/18\">",
"      Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989; 10:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/19\">",
"      Imperiale TF, Teran JC, McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995; 109:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/20\">",
"      D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003; 124:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/21\">",
"      Planas R, Quer JC, Boix J, et al. A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. Hepatology 1994; 20:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/22\">",
"      Sung JJ, Chung SC, Lai CW, et al. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 1993; 342:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/23\">",
"      Bildozola M, Kravetz D, Argonz J, et al. Efficacy of octreotide and sclerotherapy in the treatment of acute variceal bleeding in cirrhotic patients. A prospective, multicentric, and randomized clinical trial. Scand J Gastroenterol 2000; 35:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/24\">",
"      Besson I, Ingrand P, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/25\">",
"      Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997; 350:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/26\">",
"      D'Amico G, Politi F, Morabito A, et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998; 28:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/27\">",
"      Primignani M, Andreoni B, Carpinelli L, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. New Italian Endoscopic Club. Hepatology 1995; 21:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/28\">",
"      Villanueva C, Ortiz J, S&agrave;bat M, et al. Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: a prospective randomized trial. Hepatology 1999; 30:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/29\">",
"      Ba&ntilde;ares R, Albillos A, Rinc&oacute;n D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/30\">",
"      D'amico G, Criscuoli V, Fili D, et al. Meta-analysis of trials for variceal bleeding. Hepatology 2002; 36:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/31\">",
"      Sung JJ, Chung SC, Yung MY, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995; 346:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/32\">",
"      Cal&egrave;s P, Masliah C, Bernard B, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med 2001; 344:23.",
"     </a>",
"    </li>",
"    <li>",
"     Ferayorni, L, Polio, J, Groszmann, RJ. Drug therapy for portal hypertension: A 5 year review. In: Portal Hypertension: Proceedings of the Second Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies, DeFranchis, R (Eds), Blackwell Science, Oxford 1996. p.68.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/34\">",
"      Moitinho E, Planas R, Ba&ntilde;ares R, et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/35\">",
"      Gotzsche PC. Somatostatin or octreotide for acute bleeding oesophageal varices. Cochrane Database Syst Rev 2000; :CD000193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/36\">",
"      Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997; 92:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/37\">",
"      Escorsell A, Ruiz del Arbol L, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 2000; 32:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/38\">",
"      Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992; 326:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/39\">",
"      Lo GH, Lai KH, Cheng JS, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997; 25:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/40\">",
"      Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/41\">",
"      Saeed ZA, Michaletz PA, Winchester CB, et al. Endoscopic variceal ligation in patients who have failed endoscopic sclerotherapy. Gastrointest Endosc 1990; 36:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/42\">",
"      Schuman BM, Beckman JW, Tedesco FJ, et al. Complications of endoscopic injection sclerotherapy: a review. Am J Gastroenterol 1987; 82:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/43\">",
"      Sanowski RA, Waring JP. Endoscopic techniques and complications in variceal sclerotherapy. J Clin Gastroenterol 1987; 9:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/44\">",
"      de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/45\">",
"      Grace ND, Groszmann RJ, Garcia-Tsao G, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998; 28:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/46\">",
"      Wright G, Lewis H, Hogan B, et al. A self-expanding metal stent for complicated variceal hemorrhage: experience at a single center. Gastrointest Endosc 2010; 71:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/47\">",
"      D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/48\">",
"      Chojkier M, Conn HO. Esophageal tamponade in the treatment of bleeding varices. A decadel progress report. Dig Dis Sci 1980; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/49\">",
"      Hunt PS, Korman MG, Hansky J, Parkin WG. An 8-year prospective experience with balloon tamponade in emergency control of bleeding esophageal varices. Dig Dis Sci 1982; 27:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/50\">",
"      Fort E, Sautereau D, Silvain C, et al. A randomized trial of terlipressin plus nitroglycerin vs. balloon tamponade in the control of acute variceal hemorrhage. Hepatology 1990; 11:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/51\">",
"      Paquet KJ, Feussner H. Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophagogastric varices: a prospective controlled randomized trial. Hepatology 1985; 5:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/52\">",
"      Pitcher JL. Safety and effectiveness of the modified Sengstaken-Blakemore tube: a prospective study. Gastroenterology 1971; 61:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/53\">",
"      Minocha A, Richards RJ. Sengstaken-Blakemore tube for control of massive bleeding from gastric varices in hiatal hernia. J Clin Gastroenterol 1992; 14:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/54\">",
"      Bajaj JS, Ananthakrishnan A, Saeian K. Survey of attitudes of AASLD members toward balloon tamponade. Hepatology 2005; 41:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/55\">",
"      Orloff MJ, Isenberg JI, Wheeler HO, et al. Randomized trial of emergency endoscopic sclerotherapy versus emergency portacaval shunt for acutely bleeding esophageal varices in cirrhosis. J Am Coll Surg 2009; 209:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/56\">",
"      Cello JP, Grendell JH, Crass RA, et al. Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and variceal hemorrhage. N Engl J Med 1984; 311:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/57\">",
"      Burroughs AK, Hamilton G, Phillips A, et al. A comparison of sclerotherapy with staple transection of the esophagus for the emergency control of bleeding from esophageal varices. N Engl J Med 1989; 321:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/58\">",
"      Selzner M, Tuttle-Newhall JE, Dahm F, et al. Current indication of a modified Sugiura procedure in the management of variceal bleeding. J Am Coll Surg 2001; 193:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/59\">",
"      Monescillo A, Mart&iacute;nez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/60\">",
"      LaBerge JM, Ring EJ, Gordon RL, et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/61\">",
"      R&ouml;ssle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/62\">",
"      Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996; 111:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/63\">",
"      Rosemurgy AS, Goode SE, Zwiebel BR, et al. A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices. Ann Surg 1996; 224:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/64\">",
"      Jalan R, John TG, Redhead DN, et al. A comparative study of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage. Am J Gastroenterol 1995; 90:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/65\">",
"      Sarin SK. Long-term follow-up of gastric variceal sclerotherapy: an eleven-year experience. Gastrointest Endosc 1997; 46:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/66\">",
"      Trudeau W, Prindiville T. Endoscopic injection sclerosis in bleeding gastric varices. Gastrointest Endosc 1986; 32:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/67\">",
"      Soehendra N, Nam VC, Grimm H, Kempeneers I. Endoscopic obliteration of large esophagogastric varices with bucrylate. Endoscopy 1986; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/68\">",
"      Kind R, Guglielmi A, Rodella L, et al. Bucrylate treatment of bleeding gastric varices: 12 years' experience. Endoscopy 2000; 32:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/69\">",
"      Huang YH, Yeh HZ, Chen GH, et al. Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: long-term efficacy and safety. Gastrointest Endosc 2000; 52:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/70\">",
"      Lee YT, Chan FK, Ng EK, et al. EUS-guided injection of cyanoacrylate for bleeding gastric varices. Gastrointest Endosc 2000; 52:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/71\">",
"      Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001; 33:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/72\">",
"      Sarin SK, Jain AK, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol 2002; 97:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/73\">",
"      Datta D, Vlavianos P, Alisa A, Westaby D. Use of fibrin glue (beriplast) in the management of bleeding gastric varices. Endoscopy 2003; 35:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/74\">",
"      Seewald S, Ang TL, Imazu H, et al. A standardized injection technique and regimen ensures success and safety of N-butyl-2-cyanoacrylate injection for the treatment of gastric fundal varices (with videos). Gastrointest Endosc 2008; 68:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/75\">",
"      Holster IL, Poley JW, Kuipers EJ, Tjwa ET. Controlling gastric variceal bleeding with endoscopically applied hemostatic powder (Hemospray&trade;). J Hepatol 2012; 57:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/76\">",
"      Jutabha R, Jensen DM. Management of upper gastrointestinal bleeding in the patient with chronic liver disease. Med Clin North Am 1996; 80:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/77\">",
"      Chau TN, Patch D, Chan YW, et al. \"Salvage\" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998; 114:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/78\">",
"      Mishra SR, Chander Sharma B, Kumar A, Sarin SK. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. Gut 2010; 59:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/79\">",
"      Hung HH, Chang CJ, Hou MC, et al. Efficacy of non-selective &beta;-blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: a randomized controlled trial. J Hepatol 2012; 56:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/80\">",
"      Cheng LF, Wang ZQ, Li CZ, et al. Low incidence of complications from endoscopic gastric variceal obturation with butyl cyanoacrylate. Clin Gastroenterol Hepatol 2010; 8:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/81\">",
"      Binmoeller KF, Weilert F, Shah JN, Kim J. EUS-guided transesophageal treatment of gastric fundal varices with combined coiling and cyanoacrylate glue injection (with videos). Gastrointest Endosc 2011; 74:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/82\">",
"      Shiha G, El-Sayed SS. Gastric variceal ligation: a new technique. Gastrointest Endosc 1999; 49:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/83\">",
"      Ramesh J, Limdi JK, Sharma V, Makin AJ. The use of thrombin injections in the management of bleeding gastric varices: a single-center experience. Gastrointest Endosc 2008; 68:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/84\">",
"      Przemioslo RT, McNair A, Williams R. Thrombin is effective in arresting bleeding from gastric variceal hemorrhage. Dig Dis Sci 1999; 44:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/85\">",
"      Yang WL, Tripathi D, Therapondos G, et al. Endoscopic use of human thrombin in bleeding gastric varices. Am J Gastroenterol 2002; 97:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/86\">",
"      Lee MS, Cho JY, Cheon YK, et al. Use of detachable snares and elastic bands for endoscopic control of bleeding from large gastric varices. Gastrointest Endosc 2002; 56:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/87\">",
"      Akahoshi T, Hashizume M, Tomikawa M, et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience. J Gastroenterol Hepatol 2008; 23:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/88\">",
"      Cho SK, Shin SW, Lee IH, et al. Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients. AJR Am J Roentgenol 2007; 189:W365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/89\">",
"      Yoshimatsu R, Yamagami T, Tanaka O, et al. Development of thrombus in a systemic vein after balloon-occluded retrograde transvenous obliteration of gastric varices. Korean J Radiol 2012; 13:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/90\">",
"      Bernstein D, Yrizarry J, Reddy KR, et al. Transjugular intrahepatic portosystemic shunt in the treatment of intermittently bleeding stomal varices. Am J Gastroenterol 1996; 91:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/91\">",
"      Allgaier HP, Ochs A, Haag K, et al. [Recurrent bleeding from colonic varices in portal hypertension. The successful prevention of recurrence by the implantation of a transjugular intrahepatic stent-shunt (TIPS)]. Dtsch Med Wochenschr 1995; 120:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/92\">",
"      Sort P, Elizalde I, Llach I, et al. Duodenal variceal bleeding treated with a transjugular intrahepatic portosystemic shunt. Endoscopy 1995; 27:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/93\">",
"      Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 2010; 51:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/61/23514/abstract/94\">",
"      Hashimoto N, Akahoshi T, Yoshida D, et al. The efficacy of balloon-occluded retrograde transvenous obliteration on small intestinal variceal bleeding. Surgery 2010; 148:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1260 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-7C5CD5D856-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23514=[""].join("\n");
var outline_f22_61_23514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROPHYLACTIC ANTIBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTRAVENOUS VASOPRESSIN AND ITS ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Terlipressin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SOMATOSTATIN AND ITS ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Somatostatin versus placebo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Somatostatin versus vasopressin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Somatostatin versus sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Somatostatin plus sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Somatostatin plus endoscopic variceal ligation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ENDOSCOPIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Failure of endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Definition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BALLOON TAMPONADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Balloon placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Rebleeding and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      GASTRIC VARICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Approach to patients with bleeding gastric varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Alternative treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21562738\">",
"      BLEEDING ECTOPIC VARICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      AASLD GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Treatment of esophageal varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment of gastric varices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1260\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1260|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/30/5614\" title=\"algorithm 1\">",
"      Rx acute variceal bleed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1260|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/2/14383\" title=\"diagnostic image 1\">",
"      Esophageal perf sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1260|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/10/3239\" title=\"figure 1\">",
"      Transjugular intrahepatic portosystemic shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1260|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/13/3282\" title=\"picture 1\">",
"      Two varices banded Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14639\" title=\"picture 2\">",
"      Gastric varix Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/5/35935\" title=\"picture 3\">",
"      Portal hypertensive gastropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1260|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/61/27611\" title=\"table 1\">",
"      Somatostatin in variceal bleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/27/21948\" title=\"table 2\">",
"      Sclerotherapy in variceal bleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/41/34459\" title=\"table 3\">",
"      Complications of sclerotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=related_link\">",
"      Endoscopic variceal ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=related_link\">",
"      General principles of the management of variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=related_link\">",
"      Patient information: Screening for esophageal varices (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=related_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=related_link\">",
"      Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_61_23515="Heart in hypothyroidism";
var content_f22_61_23515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypothyroidism and the heart",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vascular resistance",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac output",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systolic",
"       </td>",
"       <td class=\"sublist_other\">",
"        Decreased or normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diastolic",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increased or normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate",
"       </td>",
"       <td>",
"        Decreased or normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac contractility",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac mass",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood volume",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular arrhythmias",
"       </td>",
"       <td>",
"        Can induce or worsen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23515=[""].join("\n");
var outline_f22_61_23515=null;
var title_f22_61_23516="Using powder inhalers 1 PI";
var content_f22_61_23516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Technique for use of various dry powder inhalers - I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Aerolizer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove cover and hold the base of inhaler.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Twist mouthpiece in counter-clockwise direction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove capsule from foil blister immediately before use and place capsule in the base of the inhaler.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the base of the inhaler and turn clockwise to close.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simultaneously press both buttons once to pierce the capsule.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exhale normally - do not exhale into the mouthpiece.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tilt head back slightly, hold device horizontal with the buttons on the left and right, place mouthpiece into the mouth, and close lips around mouthpiece.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove device from mouth and exhale outside device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open chamber and examine capsule; if powder remains, repeat inhalation process.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After use, remove and discard capsule, and cover mouthpiece; store device in cool, dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diskhaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove mouthpiece cover and pull tray out from device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place disk on wheel with numbers facing up.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rotate disk by sliding tray out and in.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lift back of lid until fully upright so that needle pierces both sides of blister.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep device level while inhaling dose with a rapid and steady flow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove device from mouth and exhale outside device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brush off any powder remaining within device once every week; store device in cool, dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diskus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open the device and slide the lever until it clicks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep device level while inhaling dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove device from mouth and exhale outside device; store device in cool, dry place.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23516=[""].join("\n");
var outline_f22_61_23516=null;
var title_f22_61_23517="ACE inhibitor advanced HF";
var content_f22_61_23517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor improves survival in advanced HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 242px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Decreased mortality in patients with advanced NYHA class III or IV heart failure after treatment with enalapril compared to placebo (p = 0.003).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The CONSENSUS Trial Study Group, N Engl J Med 1987; 316:1429.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23517=[""].join("\n");
var outline_f22_61_23517=null;
var title_f22_61_23518="Intracellular signaling in graft rejection";
var content_f22_61_23518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic representation of intracellular signaling in graft rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 466px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Once T cell activation occurs, a chain of intracellular events is triggered under the influence of a variety of growth and differentiation factors, of which the best characterized is IL-2. These events lead to clonal expansion of antigen-specific T cells. Such cells are differentiated into CD8+ cytotoxic T cells (which directly induce donor cell death), and CD4+ helper T cells (which help B cells produce alloantibodies and help macrophages induce delayed type hypersensitivity responses). All of these mechanisms are active in graft rejection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23518=[""].join("\n");
var outline_f22_61_23518=null;
var title_f22_61_23519="Scanning geometry helical CT";
var content_f22_61_23519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Helical CT scanning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the scanning geometry for helical CT.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kalender, WA, Sissler, W, Klotz, E, Vock, P. Radiology 1990; 176:181.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_61_23519=[""].join("\n");
var outline_f22_61_23519=null;
